<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005328.pub3" GROUP_ID="MUSKEL" ID="941700071114102759" MERGED_FROM="" MODIFIED="2015-11-02 12:53:10 -0500" MODIFIED_BY="[Empty name]" REVIEW_NO="A013-R" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.2">
<COVER_SHEET MODIFIED="2015-11-02 12:52:08 -0500" MODIFIED_BY="Jordi Pardo Pardo">
<TITLE MODIFIED="2015-10-08 07:40:27 -0400" MODIFIED_BY="[Empty name]">Intra-articular corticosteroid for knee osteoarthritis</TITLE>
<CONTACT>
<PERSON ID="63946946052527852742120320190755" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Bruno</FIRST_NAME>
<MIDDLE_INITIALS>R</MIDDLE_INITIALS>
<LAST_NAME>da Costa</LAST_NAME>
<SUFFIX/>
<POSITION>Head of Clinical Research, PhD</POSITION>
<EMAIL_1>bruno.dacosta@biham.unibe.ch</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+41 31 911 12 64</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Institute of Primary Health Care (BIHAM)</DEPARTMENT>
<ORGANISATION>University of Bern</ORGANISATION>
<ADDRESS_1>Gesellschaftsstrasse 49</ADDRESS_1>
<ADDRESS_2/>
<CITY>Bern</CITY>
<ZIP>3012</ZIP>
<REGION>Bern</REGION>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1>+41 31 631 58 69</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2015-11-02 12:52:08 -0500" MODIFIED_BY="Jordi Pardo Pardo">
<PERSON ID="10779" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Peter</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Jüni</LAST_NAME>
<SUFFIX/>
<POSITION>Director</POSITION>
<EMAIL_1>peter.juni@biham.unibe.ch</EMAIL_1>
<EMAIL_2/>
<URL>http://www.biham.unibe.ch</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Institute of Primary Health Care (BIHAM)</DEPARTMENT>
<ORGANISATION>University of Bern</ORGANISATION>
<ADDRESS_1>Gesellschaftsstrasse 49</ADDRESS_1>
<ADDRESS_2/>
<CITY>Bern</CITY>
<ZIP>3012</ZIP>
<REGION/>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1>+41 31 631 33 78</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1508311723487280166876233617511" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Roman</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Hari</LAST_NAME>
<SUFFIX/>
<POSITION>Physician</POSITION>
<EMAIL_1>roman.hari@biham.unibe.ch</EMAIL_1>
<EMAIL_2>roman@hari.be</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Institute of Primary Health Care (BIHAM)</DEPARTMENT>
<ORGANISATION>University of Bern</ORGANISATION>
<ADDRESS_1>Gesellschaftsstrasse 49</ADDRESS_1>
<ADDRESS_2/>
<CITY>Bern</CITY>
<ZIP>3012</ZIP>
<REGION/>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1>+41 31 631 57 93</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="55AAB96B82E26AA2000F11BC5E70C1F3" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Anne</FIRST_NAME>
<MIDDLE_INITIALS>WS</MIDDLE_INITIALS>
<LAST_NAME>Rutjes</LAST_NAME>
<SUFFIX/>
<POSITION>Head of Unit</POSITION>
<EMAIL_1>anne.rutjes@ispm.unibe.ch</EMAIL_1>
<EMAIL_2>rutjes@live.it</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Centre for Systematic Reviews</DEPARTMENT>
<ORGANISATION>Fondazione "Università G. D'Annunzio"</ORGANISATION>
<ADDRESS_1>Via dei Vestini 31</ADDRESS_1>
<ADDRESS_2/>
<CITY>Chieti</CITY>
<ZIP>66100</ZIP>
<REGION>Chieti</REGION>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>00393899993650</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1508311724545776677928346151028" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Roland</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Fischer</LAST_NAME>
<SUFFIX/>
<POSITION>Resident physician</POSITION>
<EMAIL_1>roland.fischer@insel.ch</EMAIL_1>
<EMAIL_2>rolando.pescatore@gmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE>+41 79 211 21 49</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Department of General Internal Medicine</DEPARTMENT>
<ORGANISATION>Inselspital Bern</ORGANISATION>
<ADDRESS_1>Freiburgstrasse 4</ADDRESS_1>
<ADDRESS_2/>
<CITY>Bern</CITY>
<ZIP>CH-3010</ZIP>
<REGION/>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1502041550396731232971060796329" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Maria</FIRST_NAME>
<MIDDLE_INITIALS>G</MIDDLE_INITIALS>
<LAST_NAME>Silletta</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Research Fellow</POSITION>
<EMAIL_1>mgsille@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Centre for Systematic Reviews</DEPARTMENT>
<ORGANISATION>Fondazione "Università G. D'Annunzio"</ORGANISATION>
<ADDRESS_1>Via dei Vestini 31</ADDRESS_1>
<ADDRESS_2/>
<CITY>Chieti</CITY>
<ZIP>66100</ZIP>
<REGION>Chieti</REGION>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="BA21A0D082E26AA2016BE8A0E778565A" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Stephan</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Reichenbach</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Research Associate</POSITION>
<EMAIL_1>rbach@ispm.unibe.ch</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department for Rheumatology, Clinical Immunology, and Allergology</DEPARTMENT>
<ORGANISATION>University Hospital</ORGANISATION>
<ADDRESS_1>Inselspital</ADDRESS_1>
<ADDRESS_2/>
<CITY>Bern</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1>+1 617-418-3368</PHONE_1>
<PHONE_2>+41 31 631 33 78</PHONE_2>
<FAX_1>+41 31 631 35 20</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="63946946052527852742120320190755" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Bruno</FIRST_NAME>
<MIDDLE_INITIALS>R</MIDDLE_INITIALS>
<LAST_NAME>da Costa</LAST_NAME>
<SUFFIX/>
<POSITION>Head of Clinical Research, PhD</POSITION>
<EMAIL_1>bruno.dacosta@biham.unibe.ch</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+41 31 911 12 64</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Institute of Primary Health Care (BIHAM)</DEPARTMENT>
<ORGANISATION>University of Bern</ORGANISATION>
<ADDRESS_1>Gesellschaftsstrasse 49</ADDRESS_1>
<ADDRESS_2/>
<CITY>Bern</CITY>
<ZIP>3012</ZIP>
<REGION>Bern</REGION>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1>+41 31 631 58 69</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2015-10-20 03:11:20 -0400" MODIFIED_BY="Bruno da Costa">
<UP_TO_DATE>
<DATE DAY="3" MONTH="2" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="3" MONTH="2" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2005"/>
<LAST_CITATION_ISSUE ISSUE="10" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2015-11-02 11:16:34 -0500" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-11-02 11:11:08 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="2" MONTH="11" YEAR="2015"/>
<DESCRIPTION>
<P>Typo corrected. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-11-02 11:16:34 -0500" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2015-11-02 11:16:34 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="2" MONTH="9" YEAR="2015"/>
<DESCRIPTION>
<P>The review has been updated since last version of 2006.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2015-09-24 04:43:37 -0400" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2015-09-24 04:43:37 -0400" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2015-09-24 04:43:37 -0400" MODIFIED_BY="[Empty name]">
<NAME>NIHR Cochrane Direct Commmission Incentive Award</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>This review was supported by a grant from the NIHR, UK (NIHR Cochrane Direct Commmission Incentive Award)</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-10-20 03:13:08 -0400" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2015-10-19 06:41:35 -0400" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2015-10-08 07:40:27 -0400" MODIFIED_BY="[Empty name]">Joint corticosteroid injection for knee osteoarthritis</TITLE>
<SUMMARY_BODY MODIFIED="2015-10-19 06:41:35 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Review question</B>
</P>
<P>We searched the literature until 3 February 2015 for studies of the effects on pain, function, quality of life, and safety of intra-articular (injected into the joint) corticosteroids compared with sham injection or no treatment in people with knee osteoarthritis.</P>
<P>
<B>Background</B>
</P>
<P>Osteoarthritis is a disease associated with a breakdown of cartilage of the joints, such as the knee. When the joint loses cartilage, the body responds by growing bone abnormally, which can result in the bone becoming misshapen and the joint painful and unstable. This can affect physical function and the ability to use the joint.</P>
<P>Although osteoarthritis is generally thought to be of degenerative rather than inflammatory origin, an inflammatory component may be present at times. Intra-articular corticosteroids are potent anti-inflammatory agents injected inside the knee joint.</P>
<P>
<B>Study characteristics</B>
</P>
<P>After searching for all relevant studies to 3 February 2015, we found 27 randomised controlled trials with a total of 1767 participants, of a duration ranging from two weeks to one year.</P>
<P>
<B>Key results</B>
</P>
<P>
<I>Pain</I>
</P>
<P>&#8226; People who received intra-articular corticosteroids rated improvement in their pain to be about 3 on a scale of 0 (no pain) to 10 (extreme pain) after 1 month.<BR/>&#8226; People who received a placebo rated improvement in their pain to be about 2 on a scale of 0 (no pain) to 10 (extreme pain) after 1 month.</P>
<P>Another way of saying this is:<BR/>&#8226; 44 people out of 100 who receive intra-articular corticosteroids respond to treatment (44%).<BR/>&#8226; 31 people out of 100 who receive a placebo respond to treatment (31%).<BR/>&#8226; 13 more people respond to treatment with intra-articular corticosteroids than with placebo (difference of 13%). </P>
<P>Note that these numbers may considerably overestimate the true benefit due to the low quality of the evidence.</P>
<P>
<I>Physical function</I>
</P>
<P>&#8226; People who received intra-articular corticosteroids rated improvement in their physical function to be about 2 on a scale of 0 (no disability) to 10 (extreme disability) after 1 month.<BR/>&#8226; People who received a placebo rated improvement in their physical function to be about 1 on a scale of 0 (no disability) to 10 (extreme disability) after 1 month.</P>
<P>Another way of saying this is:</P>
<P>&#8226; 36 people out of 100 who received intra-articular corticosteroids respond to treatment (36%).<BR/>&#8226; 26 people out of 100 who received a placebo respond to treatment (26%).<BR/>&#8226; 10 more people respond to treatment with intra-articular corticosteroids than with placebo (difference of 10%).</P>
<P>Note that these numbers may considerably overestimate the true benefit due to the low quality of the evidence.</P>
<P>
<I>Side effects</I>
</P>
<P>&#8226; 13 people out of 100 who used intra-articular corticosteroids experienced side effects (13%).<BR/>&#8226; 15 people out of 100 who used a placebo experienced side effects (15%).<BR/>&#8226; 2 more people experienced side effects with placebo than with intra-articular corticosteroids (difference of 2%).</P>
<P>
<I>Dropouts because of side effects</I>
</P>
<P>&#8226; 6 people out of 1000 who used intra-articular corticosteroids dropped out because of side effects (0.6%).<BR/>&#8226; 17 people out of 1000 who used a placebo dropped out because of side effects (1.7%).<BR/>&#8226; 11 more people dropped out because of side effects with placebo than with intra-articular corticosteroids (difference of 1.1%).</P>
<P>
<I>Side effects resulting in hospitalisation, persistent disability, or death</I>
</P>
<P>&#8226; 3 people out of 1000 who used intra-articular corticosteroids experienced side effects resulting in hospitalisation, persistent disability, or death (0.3%).<BR/>&#8226; 4 people out of 1000 who used a placebo experienced side effects resulting in hospitalisation, persistent disability, or death(0.4%).<BR/>&#8226; 1 more person experienced side effects resulting in hospitalisation, persistent disability, or death with placebo than with intra-articular corticosteroids (difference of 0.1%).</P>
<P>Based on the evidence, intra-articular corticosteroids may cause a moderate improvement in pain and a small improvement in physical function, but the quality of the evidence is low and results are inconclusive. Intra-articular corticosteroids appear to cause as many side effects as a placebo. However, we do not have precise and reliable information about side effects.</P>
<P>
<B>Quality of evidence</B>
</P>
<P>We graded the quality of the evidence as low for all of our findings, which means that we have little confidence in these results. This was because results were generally highly discordant across studies and mainly based on small studies of low quality.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-10-20 03:13:08 -0400" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2015-10-20 03:13:08 -0400" MODIFIED_BY="[Empty name]">
<P>Knee osteoarthritis is a leading cause of chronic pain, disability, and decreased quality of life. Despite the long-standing use of intra-articular corticosteroids, there is an ongoing debate about their benefits and safety. This is an update of a Cochrane review first published in 2005.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2015-10-16 10:50:54 -0400" MODIFIED_BY="[Empty name]">
<P>To determine the benefits and harms of intra-articular corticosteroids compared with sham or no intervention in people with knee osteoarthritis in terms of pain, physical function, quality of life, and safety.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-10-19 09:32:03 -0400" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and EMBASE (from inception to 3 February 2015), checked trial registers, conference proceedings, reference lists, and contacted authors.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2015-10-08 07:40:27 -0400" MODIFIED_BY="[Empty name]">
<P>We included randomised or quasi-randomised controlled trials that compared intra-articular corticosteroids with sham injection or no treatment in people with knee osteoarthritis. We applied no language restrictions.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2015-10-19 10:43:15 -0400" MODIFIED_BY="[Empty name]">
<P>We calculated standardised mean differences (SMDs) and 95% confidence intervals (CI) for pain, function, quality of life, joint space narrowing, and risk ratios (RRs) for safety outcomes. We combined trials using an inverse-variance random-effects meta-analysis.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-10-20 03:11:42 -0400" MODIFIED_BY="[Empty name]">
<P>We identified 27 trials (13 new studies) with 1767 participants in this update. We graded the quality of the evidence as 'low' for all outcomes because treatment effect estimates were inconsistent with great variation across trials, pooled estimates were imprecise and did not rule out relevant or irrelevant clinical effects, and because most trials had a high or unclear risk of bias. Intra-articular corticosteroids appeared to be more beneficial in pain reduction than control interventions (SMD -0.40, 95% CI -0.58 to -0.22), which corresponds to a difference in pain scores of 1.0 cm on a 10-cm visual analogue scale between corticosteroids and sham injection and translates into a number needed to treat for an additional beneficial outcome (NNTB) of 8 (95% CI 6 to 13). An I<SUP>2</SUP> statistic of 68% indicated considerable between-trial heterogeneity. A visual inspection of the funnel plot suggested some asymmetry (asymmetry coefficient -1.21, 95%CI -3.58 to 1.17). When stratifying results according to length of follow-up, benefits were moderate at 1 to 2 weeks after end of treatment (SMD -0.48, 95% CI -0.70 to -0.27), small to moderate at 4 to 6 weeks (SMD -0.41, 95% CI -0.61 to -0.21), small at 13 weeks (SMD -0.22, 95% CI -0.44 to 0.00), and no evidence of an effect at 26 weeks (SMD -0.07, 95% CI -0.25 to 0.11). An I<SUP>2</SUP> statistic of &#8805; 63% indicated a moderate to large degree of between-trial heterogeneity up to 13 weeks after end of treatment (P for heterogeneity&#8804;0.001), and an I<SUP>2</SUP> of 0% indicated low heterogeneity at 26 weeks (P=0.43). There was evidence of lower treatment effects in trials that randomised on average at least 50 participants per group (P=0.05) or at least 100 participants per group (P=0.013), in trials that used concomittant viscosupplementation (P=0.08), and in trials that used concomitant joint lavage (P&#8804;0.001).</P>
<P>Corticosteroids appeared to be more effective in function improvement than control interventions (SMD -0.33, 95% CI -0.56 to -0.09), which corresponds to a difference in functions scores of -0.7 units on standardised Western Ontario and McMaster Universities Arthritis Index (WOMAC) disability scale ranging from 0 to 10 and translates into a NNTB of 10 (95% CI 7 to 33). An I<SUP>2</SUP> statistic of 69% indicated a moderate to large degree of between-trial heterogeneity. A visual inspection of the funnel plot suggested asymmetry (asymmetry coefficient -4.07, 95% CI -8.08 to -0.05). When stratifying results according to length of follow-up, benefits were small to moderate at 1 to 2 weeks after end of treatment (SMD -0.43, 95% CI -0.72 to -0.14), small to moderate at 4 to 6 weeks (SMD -0.36, 95% CI -0.63 to -0.09), and no evidence of an effect at 13 weeks (SMD -0.13, 95% CI -0.37 to 0.10) or at 26 weeks (SMD 0.06, 95% CI -0.16 to 0.28). An I<SUP>2</SUP> statistic of &#8805; 62% indicated a moderate to large degree of between-trial heterogeneity up to 13 weeks after end of treatment (P for heterogeneity&#8804;0.004), and an I<SUP>2</SUP> of 0% indicated low heterogeneity at 26 weeks (P=0.52). We found evidence of lower treatment effects in trials that randomised on average at least 50 participants per group (P=0.023), in unpublished trials (P=0.023), in trials that used non-intervention controls (P=0.031), and in trials that used concomitant viscosupplementation (P=0.06).</P>
<P>Participants on corticosteroids were 11% less likely to experience adverse events, but confidence intervals included the null effect (RR 0.89, 95% CI 0.64 to 1.23, I<SUP>2</SUP>=0%). Participants on corticosteroids were 67% less likely to withdraw because of adverse events, but confidence intervals were wide and included the null effect (RR 0.33, 95% CI 0.05 to 2.07, I<SUP>2</SUP>=0%). Participants on corticosteroids were 27% less likely to experience any serious adverse event, but confidence intervals were wide and included the null effect (RR 0.63, 95% CI 0.15 to 2.67, I<SUP>2</SUP>=0%).</P>
<P>We found no evidence of an effect of corticosteroids on quality of life compared to control (SMD -0.01, 95% CI -0.30 to 0.28, I<SUP>2</SUP>=0%). There was also no evidence of an effect of corticosteroids on joint space narrowing compared to control interventions (SMD -0.02, 95% CI -0.49 to 0.46).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-10-08 07:40:27 -0400" MODIFIED_BY="[Empty name]">
<P>Whether there are clinically important benefits of intra-articular corticosteroids after one to six weeks remains unclear in view of the overall quality of the evidence, considerable heterogeneity between trials, and evidence of small-study effects. A single trial included in this review described adequate measures to minimise biases and did not find any benefit of intra-articular corticosteroids.</P>
<P>In this update of the systematic review and meta-analysis, we found most of the identified trials that compared intra-articular corticosteroids with sham or non-intervention control small and hampered by low methodological quality. An analysis of multiple time points suggested that effects decrease over time, and our analysis provided no evidence that an effect remains six months after a corticosteroid injection.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-10-19 10:25:52 -0400" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2015-10-08 07:40:27 -0400" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2015-10-08 07:40:27 -0400" MODIFIED_BY="[Empty name]">
<P>Knee osteoarthritis is a leading cause of chronic disability in the United States (<LINK REF="REF-Felson-2000" TYPE="REFERENCE">Felson 2000;</LINK> <LINK REF="REF-Felson-2000a" TYPE="REFERENCE">Felson 2000a</LINK>). It results from a multitude of both local and systemic factors. Progression of the disease leads to cartilage degeneration and thinning of the joint surface with subsequent joint pain and stiffness (<LINK REF="REF-Brandt-1996" TYPE="REFERENCE">Brandt 1996</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2015-10-08 07:40:27 -0400" MODIFIED_BY="[Empty name]">
<P>Intra-articular corticosteroid therapy has been used in knee osteoarthritis for over 50 years. The first clinical trial of intra-articular corticosteroids in knee osteoarthritis was performed in 1958 by Miller and colleagues (<LINK REF="STD-Miller-1958" TYPE="STUDY">Miller 1958</LINK>). Corticosteroids are available in both crystalline and non-crystalline forms. The crystalline triamcinolone and the non-crystalline prednisolone and methylprednisolone are used most frequently. Although this review is restricted to osteoarthritis of the knee joint, intra-articular corticosteroids have also been evaluated in osteoarthritis of various other joints (<LINK REF="REF-McColl-2000" TYPE="REFERENCE">McColl 2000</LINK>; <LINK REF="REF-Rozental-2000" TYPE="REFERENCE">Rozental 2000</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2015-10-08 07:40:27 -0400" MODIFIED_BY="[Empty name]">
<P>Although osteoarthritis is generally thought to be of degenerative rather than inflammatory origin, there is evidence that an inflammatory component may be present in at least some phases of the disease (<LINK REF="REF-Creamer-1997" TYPE="REFERENCE">Creamer 1997</LINK>). Corticosteroids are known as potent anti-inflammatory agents that act through a variety of mechanisms on different cellular levels.</P>
</THEORY>
<IMPORTANCE MODIFIED="2015-10-08 07:40:27 -0400" MODIFIED_BY="[Empty name]">
<P>The 2012 American College of Rheumatology (ACR) guidelines recommend the participation in exercise programs as well as weight loss (for overweight patients) as first-line treatments for symptomatic knee osteoarthritis. There is no strong recommendation for any pharmacological treatment other than over-the-counter paracetamol or nonsteroidal anti-inflammatory drugs. However, for people unresponsive to the basic treatment, there is a conditional, weak recommendation for the use of intra-articular corticosteroids (<LINK REF="REF-Hochberg-2012" TYPE="REFERENCE">Hochberg 2012</LINK>). Despite the long-standing use of intra-articular corticosteroids, there is an ongoing debate about their effectiveness and safety. Concerns have been expressed that intra-articular corticosteroids might mask the pain, enabling patients to prematurely mobilise and hereby promoting further destruction of the joint (<LINK REF="REF-Brandt-2001" TYPE="REFERENCE">Brandt 2001</LINK>)</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-10-08 07:40:27 -0400" MODIFIED_BY="[Empty name]">
<P>To determine the benefits and harms of intra-articular corticosteroids compared with sham or no intervention in people with knee osteoarthritis in terms of pain, physical function, quality of life, and safety.</P>
</OBJECTIVES>
<METHODS MODIFIED="2015-10-19 10:25:33 -0400" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2015-10-19 10:25:33 -0400" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2015-01-12 05:41:32 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised or quasi-randomised controlled trials with a control group receiving sham or no intervention.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2015-10-08 07:40:27 -0400" MODIFIED_BY="[Empty name]">
<P>At least 75% of participants with clinically or radiologically confirmed osteoarthritis of the knee. We did not consider trials that included exclusively people with inflammatory arthritis, such as rheumatoid arthritis.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2015-09-18 06:41:22 -0400" MODIFIED_BY="[Empty name]">
<P>The experimental intervention of interest is any type of intra-articular corticosteroid. The control interventions of interest are sham intra-articular corticosteroid and no intervention.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-10-19 10:25:33 -0400" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2015-10-19 07:22:18 -0400" MODIFIED_BY="[Empty name]">
<P>The main outcomes were pain and function, as currently recommended for osteoarthritis trials (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>; <LINK REF="REF-Pham-2004" TYPE="REFERENCE">Pham 2004</LINK>), reported within four and six weeks after end of treatment. If data on more than one pain scale were provided for a trial, we referred to a previously described hierarchy of pain-related outcomes (<LINK REF="REF-J_x00fc_ni-2006" TYPE="REFERENCE">Jüni 2006</LINK>; <LINK REF="REF-Reichenbach-2007" TYPE="REFERENCE">Reichenbach 2007</LINK>), and extracted data on the pain scale that was highest on this list:</P>
<OL>
<LI>global pain;</LI>
<LI>pain on walking;</LI>
<LI>Western Ontario and McMaster Universities Arthritis Index (WOMAC) osteoarthritis index pain subscore;</LI>
<LI>composite pain scores other than WOMAC;</LI>
<LI>pain on activities other than walking;</LI>
<LI>rest pain or pain during the night;</LI>
<LI>WOMAC global algofunctional score;</LI>
<LI>Lequesne osteoarthritis index global score;</LI>
<LI>other algofunctional scale;</LI>
<LI>participant's global assessment;</LI>
<LI>physician's global assessment.</LI>
</OL>
<P>If data on more than one function scale were provided for a trial, we extracted data according to the hierarchy:</P>
<OL>
<LI>global disability score;</LI>
<LI>walking disability;</LI>
<LI>WOMAC disability subscore;</LI>
<LI>composite disability scores other than WOMAC;</LI>
<LI>disability other than walking;</LI>
<LI>WOMAC global scale;</LI>
<LI>Lequesne osteoarthritis index global score;</LI>
<LI>other algofunctional scale;</LI>
<LI>participant's global assessment;</LI>
<LI>physician's global assessment</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2015-10-19 10:25:33 -0400" MODIFIED_BY="[Empty name]">
<P>Secondary outcomes were pain and function assessed at 1 to 2, 4 to 6, 13, and 26 weeks after end of treatment, quality of life assessed at 1 to 2, 4 to 6, 13, and 26 weeks, and the following safety outcomes: joint space narrowing assessed at 1 to 2, 4 to 6, 13, and 26 weeks; the number of participants who experienced any adverse event; withdrew because of adverse events; and experienced any serious adverse events. We defined serious adverse events as events resulting in hospitalisation, prolongation of hospitalisation, persistent or significant disability, congenital abnormality or birth defect of offspring, life-threatening events, or death.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-10-19 08:34:36 -0400" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2015-10-19 08:15:42 -0400" MODIFIED_BY="[Empty name]">
<P>Please see <LINK REF="STD-Bellamy-2006" TYPE="STUDY">Bellamy 2006</LINK> for information on electronic searches applied in the previous version of this review. Here, we developed a new search strategy using the electronic databases the Cochrane Central Register of Controlled Trials (CENTRAL, Issue 1, 2015; <A HREF="http://mrw.interscience.wiley.com/cochrane/">mrw.interscience.wiley.com/cochrane/</A>), MEDLINE, and EMBASE (Ovid SP platform). We did a top-up search in PubMed to capture citations not yet indexed in MEDLINE. We used a combination of text words and controlled terms (MeSH or MeSH-like terms), including truncated variations of preparation names and brand names combined with terms related to osteoarthritis. We applied a validated methodological filter for controlled clinical trials (<LINK REF="REF-Dickersin-1994" TYPE="REFERENCE">Dickersin 1994</LINK>; <LINK REF="REF-Lefebvre-2008" TYPE="REFERENCE">Lefebvre 2008</LINK>). We have displayed the specific search algorithms in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> and <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>. We performed the searches from inception to 3 February 2015.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2015-10-19 08:34:36 -0400" MODIFIED_BY="[Empty name]">
<P>We manually searched the proceedings of the European League Against Rheumatism at <A HREF="http://www.abstracts2view.com/eular/sessionindex.php">http://www.abstracts2view.com/eular/sessionindex.php</A>, the American College of Rheumatology at <A HREF="http://acrannualmeeting.org/abstracts/abstract-archives/">http://acrannualmeeting.org/abstracts/abstract-archives/</A> (we no longer have access to Osteoarthritis Research Society International); used Science Citation Index to retrieve reports citing relevant articles; contacted content experts and trialists; and screened reference lists of all obtained articles. We also retrieved and screened systematic reviews published since January 2004 that evaluated the effects and safety of corticosteroid injections for knee osteoarthritis (<LINK REF="STD-Abdulla-2013" TYPE="STUDY">Abdulla 2013</LINK>; <LINK REF="STD-Arroll-2004" TYPE="STUDY">Arroll 2004</LINK>; <LINK REF="STD-Avouac-2010" TYPE="STUDY">Avouac 2010</LINK>; <LINK REF="STD-Bannuru-2015" TYPE="STUDY">Bannuru 2015</LINK>; <LINK REF="STD-Bellamy-2006" TYPE="STUDY">Bellamy 2006</LINK>; <LINK REF="STD-Bjordal-2007" TYPE="STUDY">Bjordal 2007</LINK>; <LINK REF="STD-Cheng-2012" TYPE="STUDY">Cheng 2012</LINK>; <LINK REF="STD-Garg-2014" TYPE="STUDY">Garg 2014</LINK>; <LINK REF="STD-Godwin-2004" TYPE="STUDY">Godwin 2004</LINK>; <LINK REF="STD-Hepper-2009" TYPE="STUDY">Hepper 2009</LINK>; <LINK REF="STD-Hirsch-2013" TYPE="STUDY">Hirsch 2013</LINK>; <LINK REF="STD-Maricar-2013" TYPE="STUDY">Maricar 2013</LINK>). Finally, we searched the following clinical trial registries: ClinicalTrials.gov, metaRegister of Controlled Trials (<A HREF="http://www.controlled-trials.com/">http://www.controlled-trials.com/</A>), Australian New Zealand Clinical Trials Registry (<A HREF="http://www.anzctr.org.au/TrialSearch.aspx">http://www.anzctr.org.au/TrialSearch.aspx</A>), and UMIN Clinical Trials Registry (<A HREF="http://www.umin.ac.jp/ctr)">http://www.umin.ac.jp/ctr)</A>) to identify ongoing trials. We performed the last update of the search on 26 March 2015.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-10-19 08:39:55 -0400" MODIFIED_BY="[Empty name]">
<P>We used a generic protocol with instructions for data extraction, quality assessment, and statistical analyses, which we also used in our previous Cochrane reviews (<LINK REF="REF-da-Costa-2012" TYPE="REFERENCE">da Costa 2012</LINK>; <LINK REF="REF-da-Costa-2014" TYPE="REFERENCE">da Costa 2014</LINK>; <LINK REF="REF-Reichenbach-2010" TYPE="REFERENCE">Reichenbach 2010</LINK>; <LINK REF="REF-Rutjes-2009" TYPE="REFERENCE">Rutjes 2009</LINK>; <LINK REF="REF-Rutjes-2009a" TYPE="REFERENCE">Rutjes 2009a</LINK>; <LINK REF="REF-Rutjes-2010" TYPE="REFERENCE">Rutjes 2010</LINK>).</P>
<STUDY_SELECTION MODIFIED="2015-10-19 08:36:31 -0400" MODIFIED_BY="[Empty name]">
<P>Please see <LINK REF="STD-Bellamy-2006" TYPE="STUDY">Bellamy 2006</LINK> for information on the selection of studies in the original review. In this review update, two out of three review authors independently evaluated all titles and abstracts for eligibility (MGS, MdN and AR). We resolved disagreements by discussion. We applied no language restrictions. If multiple reports described the same trial, we considered all.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2015-10-08 07:40:27 -0400" MODIFIED_BY="[Empty name]">
<P>Please see <LINK REF="STD-Bellamy-2006" TYPE="STUDY">Bellamy 2006</LINK> for information on data extraction and management in the original review. In this review update, two out of three review authors (BDC, RF, RH) extracted trial information independently and in duplicate using a standardised, piloted extraction form accompanied by a codebook. We resolved disagreements by discussion. We extracted characteristics of the experimental intervention (ultrasound-guided injection, use of local anesthetic, crystalline preparation, and prednisolone equivalance), the type of control used, dosage, frequency, duration of treatment, participant characteristics, types of measures used and pain-, function-, and quality of life-related outcomes, trial design, trial size, duration of follow-up, type and source of financial support, and publication status. When necessary, we approximated means and measures of dispersion from figures in the reports. For cross-over trials, we extracted data from the first period only. Whenever possible, we used results from an intention-to-treat analysis.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-10-08 07:40:27 -0400" MODIFIED_BY="[Empty name]">
<P>Two out of three review authors (BDC, RF, RH) assessed randomisation, blinding, and adequacy of analyses independently and in duplicate (<LINK REF="REF-J_x00fc_ni-2001" TYPE="REFERENCE">Jüni 2001</LINK>). We resolved disagreements by consensus. We assessed two components of randomisation: generation of allocation sequences and concealment of allocation. We considered generation of sequences to be adequate if it resulted in an unpredictable allocation schedule; mechanisms considered adequate included random-number tables, computer-generated random numbers, minimisation, coin tossing, shuffling cards, and drawing lots. We considered trials using an unpredictable allocation sequence to be randomised and trials using potentially predictable allocation mechanisms, such as alternation or the allocation of participants according to date of birth to be quasi-randomised. We considered concealment of allocation to be adequate if participants and investigators responsible for participant selection were unable to suspect before allocation which treatment was next. Methods considered adequate included central randomisation; pharmacy-controlled randomisation using identical, pre-numbered containers; and sequentially numbered, sealed, opaque envelopes. We considered blinding of participants to be adequate if a sham injection was used with a syringe that was identical in appearance to the control intervention, or an attempt was made to hide the participant's view of the injected knee by placing screens, for example. We considered blinding of therapists to be adequate if a credible blinding attempt was described, such as the use of independently prepared, opaque syringes. We considered analyses to be performed according to the intention-to-treat principle if all randomised participants were included in the analysis. We further assessed the reporting of primary outcomes, sample size calculations, and funding source. Finally, we used GRADE to describe the quality of the overall body of evidence (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>; <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>), defined as the extent of confidence into the estimates of treatment benefits and harms.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2015-10-08 07:40:27 -0400" MODIFIED_BY="[Empty name]">
<P>We summarised continuous outcomes using standardised mean differences (SMD) with 95% confidence intervals (CI), with the differences in mean change from baseline values across treatment groups divided by the pooled standard deviation (SD). If differences in mean change were unavailable, we used differences in mean values at the end of the treatment (<LINK REF="REF-da-Costa-2013" TYPE="REFERENCE">da Costa 2013</LINK>). If some of the required data were unavailable, we used approximations, as previously described (<LINK REF="REF-Reichenbach-2007" TYPE="REFERENCE">Reichenbach 2007</LINK>). An SMD of -0.20 SD units can be considered a small difference between the experimental and control groups, an SMD of -0.50 a moderate difference, and -0.80 a large difference (<LINK REF="REF-Cohen-1988" TYPE="REFERENCE">Cohen 1988</LINK>; <LINK REF="REF-J_x00fc_ni-2006" TYPE="REFERENCE">Jüni 2006</LINK>). SMDs can also be interpreted in terms of the percent of overlap of the experimental group's scores with scores of the control group. An SMD of -0.20 indicates an overlap in the distribution of pain or function scores in about 85% of cases, an SMD of -0.50 in about 67%, and an SMD of -0.80 in about 53% of cases (<LINK REF="REF-Cohen-1988" TYPE="REFERENCE">Cohen 1988</LINK>; <LINK REF="REF-J_x00fc_ni-2006" TYPE="REFERENCE">Jüni 2006</LINK>). On the basis of a median pooled SD of 2.5 cm, found in large-scale osteoarthritis trials that assessed pain using a 10-cm visual analogue scale (VAS) (<LINK REF="REF-N_x00fc_esch-2009" TYPE="REFERENCE">Nüesch 2009</LINK>), SMDs of -0.20 correspond to approximate differences in pain scores between experimental and control groups of 0.5 cm on a 10-cm VAS, -0.50 of 1.25 cm, and -0.80 of 2 cm. We back transformed SMDs for function to a standardised WOMAC disability score (<LINK REF="REF-Bellamy-1995" TYPE="REFERENCE">Bellamy 1995</LINK>), ranging from 0 to 10 on the basis of a median pooled SD of 2.1 units observed in large-scale osteoarthritis trials (<LINK REF="REF-N_x00fc_esch-2009" TYPE="REFERENCE">Nüesch 2009</LINK>). We expressed binary outcomes as risk ratios (RR) with 95% CI.</P>
</EFFECT_MEASURES>
<DATA_SYNTHESIS MODIFIED="2015-10-19 08:39:55 -0400" MODIFIED_BY="[Empty name]">
<P>We used a standard inverse-variance random-effects meta-analysis to combine the trials (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>). We quantified heterogeneity between trials using the I<SUP>2</SUP> statistic (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>), which describes the percentage of variation across trials that is attributable to heterogeneity rather than to chance. I<SUP>2</SUP> values of 25% may be interpreted as low, 50% as moderate, and 75% as high between-trial heterogeneity (<LINK REF="REF-da-Costa-2014a" TYPE="REFERENCE">da Costa 2014a</LINK>), although interpretation of I<SUP>2</SUP> depends on the size and number of trials included (<LINK REF="REF-Rucker-2008" TYPE="REFERENCE">Rucker 2008</LINK>). Each trial contributed once to our main effectiveness analyses with the effect estimate closer to our primary time point of interest at four to six weeks. We investigated the association between trial size and treatment effects in contour-enhanced funnel plots (<LINK REF="REF-Peters-2008" TYPE="REFERENCE">Peters 2008</LINK>), plotting effect sizes on the vertical axis against their standard errors on the horizontal axis (<LINK REF="REF-Sterne-2001" TYPE="REFERENCE">Sterne 2001</LINK>; <LINK REF="REF-Sterne-2011" TYPE="REFERENCE">Sterne 2011</LINK>; <LINK REF="REF-Thompson-1999" TYPE="REFERENCE">Thompson 1999</LINK>), accompanied by a regression test for asymmetry (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). We then performed stratified analyses of the primary outcomes, pain and function, accompanied by interaction tests according to the following trial characteristics: concealment of allocation (adequate versus inadequate or unclear), blinding of participants (adequate versus inadequate or unclear), blinding of therapists (adequate versus inadequate or unclear), type of control (placebo versus no intervention), analysis in accordance with the intention-to-treat principle (yes versus no or unclear), trial size, funding (funding independent of industry versus industry or unclear source of funding), publication type (full journal article versus other type or unpublished material), ultrasound-guidance of injections (yes versus no or unclear), use of local anaesthetic (yes versus no or unclear), use of crystalline preparation (yes versus no or unclear), prednisolone equivalence dose (&#8805; 50 mg versus &lt; 50 mg), use of intra-articular viscosupplementation as co-intervention (yes versus no or unclear), and use of joint lavage as co-intervention (yes versus no or unclear). We prespecified a cutoff of 100 allocated participants per trial arm to distinguish between small and large trials. A sample size of 2 x 100 participants will yield more than 80% power to detect a small to moderate SMD of -0.40 at a two-sided P value of 0.05, which corresponds to a difference of 1 cm on a 10-cm VAS between the experimental and control intervention (<LINK REF="REF-N_x00fc_esch-2010" TYPE="REFERENCE">Nüesch 2010</LINK>). Since only one large trial was available, we also used a less stringent cutoff of 50 participants per arm as previously described (<LINK REF="REF-N_x00fc_esch-2013" TYPE="REFERENCE">Nüesch 2013</LINK>). Two arms with 50 participants each will yield more than 80% power to detect a moderate to large SMD of -0.60. We calculated prednisolone equivalence doses, with prednisolone 10 mg considered equivalent to betametasone 1.6 mg, cortivazol 0.8 mg, dexamethasone 1.6 mg, hydrocortisone 40 mg, methylprednisolone 8 mg, and triamcinolone 8 mg. Interaction tests were based on z scores of the difference in effect sizes between strata divided by the corresponding standard error.</P>
<P>We converted SMDs of pain intensity and function to number needed to treat for an additional beneficial outcome on pain or function as compared with placebo (NNTB), and number needed to treat for an additional harmful outcome (NNTH) (<LINK REF="REF-da-Costa-2012a" TYPE="REFERENCE">da Costa 2012a</LINK>). We defined treatment response as a 50% improvement in scores (<LINK REF="REF-Clegg-2006" TYPE="REFERENCE">Clegg 2006</LINK>; <LINK REF="REF-Dworkin-2008" TYPE="REFERENCE">Dworkin 2008</LINK>; <LINK REF="REF-Dworkin-2009" TYPE="REFERENCE">Dworkin 2009</LINK>). With a median standardised pain intensity at baseline of 2.4 SD units, observed in large osteoarthritis trials (<LINK REF="REF-N_x00fc_esch-2009" TYPE="REFERENCE">Nüesch 2009</LINK>), this corresponds to a mean decrease in scores of 1.2 SD units. Based on the median standardised decrease in pain scores of 0.72 SD units (<LINK REF="REF-N_x00fc_esch-2009" TYPE="REFERENCE">Nüesch 2009</LINK>), we calculated that a median of 31% of participants in the placebo group would achieve an improvement of pain scores of 50% or more. We used this percentage as the control group response rate to calculate NNTBs for pain. Based on the median standardised WOMAC function score at baseline of 2.7 SD units and the median standardised decrease in function scores of 0.58 SD units (<LINK REF="REF-N_x00fc_esch-2009" TYPE="REFERENCE">Nüesch 2009</LINK>), 26% of participants in the placebo group would achieve a reduction in function of 50% or more. Again, we used this percentage as the control group response rate to calculate NNTBs for function. We used the median risks of 150 patients with adverse events per 1000 patient-years, four patients with serious adverse events per 1000 patient-years, and 17 dropouts due to adverse events per 1000 patient-years as observed in placebo groups in large osteoarthritis trials to calculate NNTHs for safety outcomes (<LINK REF="REF-N_x00fc_esch-2009" TYPE="REFERENCE">Nüesch 2009</LINK>). All P values were two-sided. We performed analyses using Review Manager 5.3 (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>), and STATA version 14.0 (StataCorp, College Station, Texas).</P>
</DATA_SYNTHESIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-10-19 10:04:39 -0400" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2015-10-19 10:04:39 -0400" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2015-10-08 07:40:28 -0400" MODIFIED_BY="[Empty name]">
<P>We identified 2324 potentially relevant references through our electronic searches and 20 additional references through other sources (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). We excluded 1769 references after screening titles and abstracts and retrieved 154 potentially relevant references for full-text assessment. We included 33 reports on 27 RCTs in the review.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-10-19 10:04:39 -0400" MODIFIED_BY="[Empty name]">
<P>Twenty-six trials reported effectiveness data. We included all 26 trials in the analysis of pain outcomes, 15 trials in the analysis of function outcomes (<LINK REF="STD-Beyaz-2012" TYPE="STUDY">Beyaz 2012</LINK>; <LINK REF="STD-Campos-2013" TYPE="STUDY">Campos 2013</LINK>; <LINK REF="STD-Castro-2007" TYPE="STUDY">Castro 2007</LINK>; <LINK REF="STD-Chao-2010" TYPE="STUDY">Chao 2010</LINK>; <LINK REF="STD-Di-Sante-2012" TYPE="STUDY">Di Sante 2012</LINK>; <LINK REF="STD-Gaffney-1995" TYPE="STUDY">Gaffney 1995</LINK>; <LINK REF="STD-Henriksen-2015" TYPE="STUDY">Henriksen 2015</LINK>; <LINK REF="STD-Lyons-2005" TYPE="STUDY">Lyons 2005</LINK>; <LINK REF="STD-Petrella-2015" TYPE="STUDY">Petrella 2015</LINK>; <LINK REF="STD-Popov-1989" TYPE="STUDY">Popov 1989</LINK>; <LINK REF="STD-Ravaud-1999" TYPE="STUDY">Ravaud 1999</LINK>; <LINK REF="STD-Raynauld-2003" TYPE="STUDY">Raynauld 2003</LINK>; <LINK REF="STD-Smith-2003" TYPE="STUDY">Smith 2003</LINK>; <LINK REF="STD-Yavuz-2012" TYPE="STUDY">Yavuz 2012</LINK>; <LINK REF="STD-Young-2001" TYPE="STUDY">Young 2001</LINK>), and two trials in the analysis of quality-of-life outcomes (<LINK REF="STD-Gaffney-1995" TYPE="STUDY">Gaffney 1995</LINK>; <LINK REF="STD-Henriksen-2015" TYPE="STUDY">Henriksen 2015</LINK>). Of the 26 included trials, 19 compared corticosteroid injection to sham injection (<LINK REF="STD-Beyaz-2012" TYPE="STUDY">Beyaz 2012</LINK>; <LINK REF="STD-Cederlof-1966" TYPE="STUDY">Cederlof 1966</LINK>; <LINK REF="STD-Chao-2010" TYPE="STUDY">Chao 2010</LINK>; <LINK REF="STD-Dieppe-1980" TYPE="STUDY">Dieppe 1980</LINK>; <LINK REF="STD-Friedman-1980" TYPE="STUDY">Friedman 1980</LINK>; <LINK REF="STD-Gaffney-1995" TYPE="STUDY">Gaffney 1995</LINK>; <LINK REF="STD-Henriksen-2015" TYPE="STUDY">Henriksen 2015</LINK>; <LINK REF="STD-Jones-1996" TYPE="STUDY">Jones 1996</LINK>; <LINK REF="STD-NCT00414427" TYPE="STUDY">NCT00414427</LINK>; <LINK REF="STD-Lyons-2005" TYPE="STUDY">Lyons 2005</LINK>; <LINK REF="STD-Miller-1958" TYPE="STUDY">Miller 1958</LINK>; <LINK REF="STD-Popov-1989" TYPE="STUDY">Popov 1989</LINK>; <LINK REF="STD-Ravaud-1999" TYPE="STUDY">Ravaud 1999</LINK>; <LINK REF="STD-Raynauld-2003" TYPE="STUDY">Raynauld 2003</LINK>; <LINK REF="STD-Schue-2011" TYPE="STUDY">Schue 2011</LINK>; <LINK REF="STD-Smith-2003" TYPE="STUDY">Smith 2003</LINK>; <LINK REF="STD-Yavuz-2012" TYPE="STUDY">Yavuz 2012</LINK>; <LINK REF="STD-Young-2001" TYPE="STUDY">Young 2001</LINK>; <LINK REF="STD-Zhilyayev-2012" TYPE="STUDY">Zhilyayev 2012</LINK>), and 7 compared corticosteroid injection to no treatment (<LINK REF="STD-Campos-2013" TYPE="STUDY">Campos 2013</LINK>; <LINK REF="STD-Castro-2007" TYPE="STUDY">Castro 2007</LINK>; <LINK REF="STD-Di-Sante-2012" TYPE="STUDY">Di Sante 2012</LINK>; <LINK REF="STD-Fri_x0301_as-2004" TYPE="STUDY">Fri&#769;as 2004</LINK>; <LINK REF="STD-Grecomoro-1992" TYPE="STUDY">Grecomoro 1992</LINK>; <LINK REF="STD-Ozturk-2006" TYPE="STUDY">Ozturk 2006</LINK>; <LINK REF="STD-Petrella-2015" TYPE="STUDY">Petrella 2015</LINK>).</P>
<P>Triamcinolone was used in 15 trials (<LINK REF="STD-Beyaz-2012" TYPE="STUDY">Beyaz 2012</LINK>; <LINK REF="STD-Campos-2013" TYPE="STUDY">Campos 2013</LINK>; <LINK REF="STD-Castro-2007" TYPE="STUDY">Castro 2007</LINK>; <LINK REF="STD-Chao-2010" TYPE="STUDY">Chao 2010</LINK>; <LINK REF="STD-Dieppe-1980" TYPE="STUDY">Dieppe 1980</LINK>; <LINK REF="STD-Fri_x0301_as-2004" TYPE="STUDY">Fri&#769;as 2004</LINK>; <LINK REF="STD-Friedman-1980" TYPE="STUDY">Friedman 1980</LINK>; <LINK REF="STD-Gaffney-1995" TYPE="STUDY">Gaffney 1995</LINK>; <LINK REF="STD-NCT00414427" TYPE="STUDY">NCT00414427</LINK>; <LINK REF="STD-Ozturk-2006" TYPE="STUDY">Ozturk 2006</LINK>; <LINK REF="STD-Petrella-2015" TYPE="STUDY">Petrella 2015</LINK>; <LINK REF="STD-Popov-1989" TYPE="STUDY">Popov 1989</LINK>; <LINK REF="STD-Raynauld-2003" TYPE="STUDY">Raynauld 2003</LINK>; <LINK REF="STD-Yavuz-2012" TYPE="STUDY">Yavuz 2012</LINK>; <LINK REF="STD-Zhilyayev-2012" TYPE="STUDY">Zhilyayev 2012</LINK>), methylprednisolone in seven trials (<LINK REF="STD-Di-Sante-2012" TYPE="STUDY">Di Sante 2012</LINK>; <LINK REF="STD-Henriksen-2015" TYPE="STUDY">Henriksen 2015</LINK>; <LINK REF="STD-Lyons-2005" TYPE="STUDY">Lyons 2005</LINK>; <LINK REF="STD-Schue-2011" TYPE="STUDY">Schue 2011</LINK>; <LINK REF="STD-Smith-2003" TYPE="STUDY">Smith 2003</LINK>; <LINK REF="STD-Yavuz-2012" TYPE="STUDY">Yavuz 2012</LINK>; <LINK REF="STD-Young-2001" TYPE="STUDY">Young 2001</LINK>), hydrocortisone in two trials (<LINK REF="STD-Miller-1958" TYPE="STUDY">Miller 1958</LINK>; <LINK REF="STD-Popov-1989" TYPE="STUDY">Popov 1989</LINK>), prednisolone in two trials (<LINK REF="STD-Cederlof-1966" TYPE="STUDY">Cederlof 1966</LINK>; <LINK REF="STD-Jones-1996" TYPE="STUDY">Jones 1996</LINK>), dexamethasonephosphate in one trial (<LINK REF="STD-Grecomoro-1992" TYPE="STUDY">Grecomoro 1992</LINK>), betametazone disodium phosphate in one trial (<LINK REF="STD-Yavuz-2012" TYPE="STUDY">Yavuz 2012</LINK>), and cortivazol in one trial (<LINK REF="STD-Ravaud-1999" TYPE="STUDY">Ravaud 1999</LINK>). Four trials used viscosupplementation as a concomitant treatment (<LINK REF="STD-Campos-2013" TYPE="STUDY">Campos 2013</LINK>; <LINK REF="STD-Grecomoro-1992" TYPE="STUDY">Grecomoro 1992</LINK>; <LINK REF="STD-Ozturk-2006" TYPE="STUDY">Ozturk 2006</LINK>; <LINK REF="STD-Petrella-2015" TYPE="STUDY">Petrella 2015</LINK>), and four trials used lavage as a concomitant treatment (<LINK REF="STD-Castro-2007" TYPE="STUDY">Castro 2007</LINK>; <LINK REF="STD-Fri_x0301_as-2004" TYPE="STUDY">Fri&#769;as 2004</LINK>; <LINK REF="STD-Ravaud-1999" TYPE="STUDY">Ravaud 1999</LINK>; <LINK REF="STD-Smith-2003" TYPE="STUDY">Smith 2003</LINK>). Two trials used ultrasound to assure intra-articular delivery of corticosteroid preparation (<LINK REF="STD-Di-Sante-2012" TYPE="STUDY">Di Sante 2012</LINK>; <LINK REF="STD-Henriksen-2015" TYPE="STUDY">Henriksen 2015</LINK>). The median prednisolone equivalence dose across all trials was 50 mg, and the median number of corticosteroid injections was one. Trials randomised a median of 76 participants (range 16 to 205 participants).</P>
<P>One additional trial investigating hydrocortisone only reported safety data, on number of participants experiencing any adverse event (<LINK REF="STD-Wright-1960" TYPE="STUDY">Wright 1960</LINK>).</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2015-10-08 07:40:28 -0400" MODIFIED_BY="[Empty name]">
<P>The <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table displays the reasons for excluding trials in this systematic review. Typical reasons were wrong study design, use of active control interventions, more than 25% of participants with rheumatoid arthritis in the sample, or the use of cross-over designs without providing sufficient information on the first phase.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-10-08 07:40:28 -0400" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> summarises the methodological characteristics and sources of funding of included trials. Two trials (7%) reported both adequate sequence generation and adequate allocation concealment (<LINK REF="STD-Henriksen-2015" TYPE="STUDY">Henriksen 2015</LINK>; <LINK REF="STD-Smith-2003" TYPE="STUDY">Smith 2003</LINK>), and six trials reported only adequate sequence generation (<LINK REF="STD-Campos-2013" TYPE="STUDY">Campos 2013</LINK>; <LINK REF="STD-Cederlof-1966" TYPE="STUDY">Cederlof 1966</LINK>; <LINK REF="STD-Di-Sante-2012" TYPE="STUDY">Di Sante 2012</LINK>; <LINK REF="STD-Ozturk-2006" TYPE="STUDY">Ozturk 2006</LINK>; <LINK REF="STD-Petrella-2015" TYPE="STUDY">Petrella 2015</LINK>; <LINK REF="STD-Raynauld-2003" TYPE="STUDY">Raynauld 2003</LINK>). In the remaining 18 trials, low quality of reporting hampered any judgement regarding sequence generation and concealment of allocation. Six trials reported the use of indistinguishable interventions to blind participants, and three trials reported the use of indistinguishable interventions to blind therapists. Nine and five trials conducted analysis of pain and function outcomes according to the intention-to-treat principle, respectively. Eleven trials received financial support from a nonprofit organisation, and no trial was explicitly supported by a commercial organisation. Twenty-three trials used parallel-group randomisation, and two were cross-over trials (<LINK REF="STD-Dieppe-1980" TYPE="STUDY">Dieppe 1980</LINK>; <LINK REF="STD-Jones-1996" TYPE="STUDY">Jones 1996</LINK>).<BR/>
</P>
<P>For the effectiveness outcomes pain and function, we classified the quality of the evidence as low in view of the high risk of bias in the included trials and the high heterogeneity between trials (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>) (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>).</P>
<P>For adverse event, dropouts due to adverse events, and serious adverse event outcomes, we classified the quality of the evidence as low because of the small number of trials reporting the outcomes and the small number of overall events, which resulted in imprecise estimates, and because we considered 50% or more of these trials to be at high risk of bias (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>) (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-10-19 08:42:52 -0400" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Knee pain</HEADING>
<P>
<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> presents results of the overall analysis of knee pain reported closest to four to six weeks after end of treatment. Corticosteroids were more effective in pain reduction than control interventions (SMD -0.40, 95% CI -0.58 to -0.22), which corresponds to a difference in pain scores of 1.0 cm on a 10-cm VAS between corticosteroids and sham injection. This corresponds to a difference in improvement of 17% (95% CI 10% to 25%) between corticosteroids and sham injection (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>), which translates into a NNTB to cause one additional treatment response on pain of 8 (95% CI 6 to 13) (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). An I<SUP>2</SUP> statistic of 68% indicated a moderate to large degree of between-trial heterogeneity (P for heterogeneity &lt; 0.001). A visual inspection of the funnel plot suggested some asymmetry (asymmetry coefficient -1.21, 95% CI -3.58 to 1.17), but the corresponding regression test for asymmetry indicated no evidence for asymmetry (P = 0.30) (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>).</P>
<P>
<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK> presents results stratified according to length of follow-up. Benefits were moderate at 1 to 2 weeks after end of treatment (SMD -0.48, 95% CI -0.70 to -0.27), small to moderate at 4 to 6 weeks (SMD -0.41, 95% CI -0.61 to -0.21), small at 13 weeks (SMD -0.22, 95% CI -0.44 to 0.00), and no effect at 26 weeks (SMD -0.07, 95% CI -0.25 to 0.11). An I<SUP>2</SUP> statistic of &#8805; 63% indicated a moderate to large degree of between-trial heterogeneity up to 13 weeks after end of treatment (P for heterogeneity &#8804; 0.001), and an I<SUP>2</SUP> of 0% indicated low heterogeneity at 26 weeks (P = 0.43).</P>
<P>
<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> presents the results of stratified analyses. We found little or no evidence for an association of SMDs with corticosteroid dosages, ultrasound guidance, local anesthetic, crystalline preparation, type of control intervention, financial support, publication type, concealment of allocation, adequate blinding of participants or therapists, or intention-to-treat analysis (P &#8805; 0.10). There was some evidence of lower treatment effects in trials that randomised on average at least 50 participants per group (P = 0.05), or in trials that used viscosupplementation as a co-intervention (P = 0.08). There was strong evidence of lower treatment effects in trials that randomised on average at least 100 participants per group (P = 0.013), or in trials that used joint lavage as a co-intervention (P &#8804; 0.001).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Knee function</HEADING>
<P>
<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK> presents results of the overall analysis of knee function reported closest to four to six weeks after end of treatment. Corticosteroids were more effective in function improvement than control interventions (SMD -0.33, 95% CI -0.56 to -0.09), which corresponds to a difference in functions scores of -0.7 units on standardised WOMAC disability scale ranging from 0 to 10. This corresponds to a difference in improvement of 13% (95% CI 4% to 22%) between corticosteroids and sham injection (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>), which translates into a NNTB to cause one additional treatment response on function of 10 (95% CI 7 to 33) (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). An I<SUP>2</SUP> statistic of 69% indicated a moderate to large degree of between-trial heterogeneity (P for heterogeneity &lt; 0.001). A visual inspection of the funnel plot suggested asymmetry (asymmetry coefficient -4.07, 95% CI -8.08 to -0.05), and the test for asymmetry showed evidence for asymmetry (P = 0.047) (<LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>).</P>
<P>
<LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK> presents results stratified according to length of follow-up. Benefits were small to moderate at 1 to 2 weeks after end of treatment (SMD -0.43, 95% CI -0.72 to -0.14), small at 4 to 6 weeks (SMD -0.36, 95% CI -0.63 to -0.09), no effect at 13 weeks (SMD -0.13, 95% CI -0.37 to 0.10), and no effect at 26 weeks (SMD 0.06, 95% CI -0.16 to 0.28). An I<SUP>2</SUP> statistic of &#8805; 62% indicated a moderate to large degree of between-trial heterogeneity up to 13 weeks after end of treatment (P for heterogeneity &#8804; 0.004), and an I<SUP>2</SUP> of 0% indicated low heterogeneity at 26 weeks (P = 0.52).</P>
<P>
<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> presents the results of stratified analyses. We found little or no evidence for an association of SMDs with corticosteroid dosages, ultrasound guidance, local anaesthetic, crystalline preparation, joint lavage as a co-intervention, financial support, concealment of allocation, adequate blinding of participants or therapists, or intention-to-treat analysis (P &#8805; 0.10). There was some evidence of lower treatment effects in trials that randomised on average at least 50 participants per group (P = 0.023), in unpublished trials (P = 0.023), in trials that used no intervention as control (P = 0.031), or in trials that used intra-articular viscosupplementation as a co-intervention (P = 0.06).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<P>
<LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK> presents results of the overall analysis on quality of life reported closest to four to six weeks after end of treatment. Corticosteroids had no effect on quality of life compared to control interventions (SMD -0.01, 95% CI -0.30 to 0.28). An I<SUP>2</SUP> statistic of 0% indicated a low degree of between-trial heterogeneity (P for heterogeneity = 0.96). <LINK REF="FIG-10" TYPE="FIGURE">Figure 10</LINK> presents results of the overall analysis on joint space narrowing reported closest to four to six weeks after end of treatment. Corticosteroids had no effect in joint space narowing compared to control interventions (SMD -0.02, 95% CI -0.49 to 0.46). An I<SUP>2</SUP> statistic was not estimable because only one trial was included in this analysis. There was not enough data to report results according to the pre-specified time points neither for quality of life nor joint space narrowing outcomes.</P>
<P>
<LINK REF="FIG-11" TYPE="FIGURE">Figure 11</LINK> presents results of the overall analysis on number of participants experiencing any type of adverse event. We included 2 trials with a total of 84 participants and 46 events in this analysis. Participants on corticosteroids were 11% less likely to experience adverse events, but confidence intervals included the null effect (RR 0.89, 95% CI 0.64 to 1.23). An I<SUP>2</SUP> statistic of 0% indicated a low degree of between-trial heterogeneity (P for heterogeneity = 0.44). Due to the imprecision in results, we were not able to calculate meaningful NNTHs.</P>
<P>
<LINK REF="FIG-12" TYPE="FIGURE">Figure 12</LINK> presents results of the overall analysis on number of participants who withdraw because of adverse events. We included 2 trials with a total of 204 participants and 5 events in this analysis. Participants on corticosteroids were 67% less likely to withdraw because of adverse events, but confidence intervals were wide and included the null effect (RR 0.33, 95% CI 0.05 to 2.07). An I<SUP>2</SUP> statistic of 0% indicated a low degree of between-trial heterogeneity (P for heterogeneity = 1.00). Due to the imprecision in results, we were not able to calculate meaningful NNTHs.</P>
<P>
<LINK REF="FIG-13" TYPE="FIGURE">Figure 13</LINK> presents results of the overall analysis on number of participants experiencing serious adverse events. We included 5 trials with a total of 331 participants and 8 events in this analysis. Participants on corticosteroids were 27% less likely to withdraw because of adverse events, but confidence intervals were wide and included the null effect (RR 0.63, 95% CI 0.15 to 2.67). An I<SUP>2</SUP> statistic of 0% indicated a low degree of between-trial heterogeneity (P for heterogeneity = 0.46). Due to the imprecision in results, we were not able to calculate meaningful NNTHs.</P>
<SUBSECTION>
<HEADING LEVEL="4">Quality of the evidence (GRADE)</HEADING>
<P>We graded the quality of the evidence as 'low' for all outcomes because treatment effect estimates were inconsistent with great variation across trials, pooled estimates were imprecise and did not rule out relevant or irrelevant clinical effects, and because most trials had a high or unclear risk of bias.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-10-19 10:25:52 -0400" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2015-10-19 08:43:02 -0400" MODIFIED_BY="[Empty name]">
<P>In this update of the systematic review and meta-analysis by Bellamy (<LINK REF="STD-Bellamy-2006" TYPE="STUDY">Bellamy 2006</LINK>), we found most of the identified trials that compared intra-articular corticosteroids with sham or non-intervention control to be small and hampered by low methodological quality, and graded the quality of evidence for the major outcomes as 'low'. Only one trial was considered large according to our prespecified criteria (<LINK REF="STD-Fri_x0301_as-2004" TYPE="STUDY">Fri&#769;as 2004</LINK>), with an average sample size of 100 participants or more per group, but this trial did not report adequate randomisation, participant blinding, or an intention-to-treat analysis. Conversely, only one trial reported adequate randomisation, participant blinding, and an intention-to-treat analysis (<LINK REF="STD-Henriksen-2015" TYPE="STUDY">Henriksen 2015</LINK>), but it was of moderate size only. An analysis of multiple time points suggested that effects decrease over time (P &#8804; 0.011), and our analysis provides no evidence that an effect remains six months after a corticosteroid injection. Whether there are clinically important benefits after one to six weeks remains unclear in view of the overall quality of the evidence. A single trial included in this review described adequate measures to consistently minimise biases (<LINK REF="STD-Henriksen-2015" TYPE="STUDY">Henriksen 2015</LINK>); this trial did not find any benefit of intra-articular corticosteroids (SMD 0.04, 95% CI -0.43 to 0.35).</P>
</SUMMARY_OF_RESULTS>
<QUALITY_OF_EVIDENCE MODIFIED="2015-10-19 10:25:52 -0400" MODIFIED_BY="[Empty name]">
<P>The overall analyses of pain and function were difficult to interpret in view of the large extent of heterogeneity between trials. Stratified analyses suggested an association of estimates of treatment effects with sample size (P &#8804; 0.05), and funnel plots appeared asymmetrical, even though the accompanying asymmetry test was positive only for function (P = 0.047). Stratified analyses according to components of methodological quality showed negative interaction tests. Conversely, trials with protocol-mandated concomitant lavage or viscosupplementation treatment in both experimental and control groups appeared to show smaller benefits of corticosteroids as compared with control.</P>
<P>The largest trial used joint lavage as concomitant treatment in all participants (<LINK REF="STD-Fri_x0301_as-2004" TYPE="STUDY">Fri&#769;as 2004</LINK>). It therefore ultimately remains unclear whether the lack of treatment effect in this trial is a function of study size in the presence of small-study effects (<LINK REF="REF-N_x00fc_esch-2010" TYPE="REFERENCE">Nüesch 2010</LINK>), or a function of the concomitant use of joint lavage, which may act as an effect modifier even in the absence of a specific therapeutic effect (<LINK REF="REF-Reichenbach-2010" TYPE="REFERENCE">Reichenbach 2010</LINK>). However, among the three largest trials, which included at least 50 participants per group, only one used lavage (<LINK REF="STD-Fri_x0301_as-2004" TYPE="STUDY">Fri&#769;as 2004</LINK>), another used viscosupplementation as concomitant treatment (<LINK REF="STD-Campos-2013" TYPE="STUDY">Campos 2013</LINK>), and the third used neither (<LINK REF="STD-Henriksen-2015" TYPE="STUDY">Henriksen 2015</LINK>). When pooling these moderate-to-large trials, we found only a small, clinically irrelevant, and statistically non-significant effect on pain and function with a low degree of heterogeneity.</P>
<P>For other clinical characteristics including the use of ultrasound to guide injections, crystalline preparations, and prednisone equivalent doses, we did not find a treatment by subgroup interaction. Only two trials used ultrasound guidance to ensure proper placement of needles (<LINK REF="STD-Di-Sante-2012" TYPE="STUDY">Di Sante 2012</LINK>, <LINK REF="STD-Henriksen-2015" TYPE="STUDY">Henriksen 2015</LINK>), however contradictory results and insufficient data are available to determine whether ultrasound guidance is associated with larger treatment effects.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2015-10-08 07:40:28 -0400" MODIFIED_BY="[Empty name]">
<P>We based our review on an extensive literature search, and so it seems unlikely that we missed relevant trials, provided that they were published as full-text articles or accessible in conference proceedings or trial registries (<LINK REF="REF-Egger-2003" TYPE="REFERENCE">Egger 2003</LINK>). Two review authors independently performed selection of trials and data extraction in order to reduce bias and transcription errors (<LINK REF="REF-Egger-2001" TYPE="REFERENCE">Egger 2001</LINK>; <LINK REF="REF-G_x00f8_tzsche-2007" TYPE="REFERENCE">Gøtzsche 2007</LINK>). We are therefore confident that potential biases during the review process were minimised.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2015-10-08 07:40:28 -0400" MODIFIED_BY="[Empty name]">
<P>Our update of the previous systematic review and meta-analysis by Bellamy identified 14 new trials that compared intra-articular corticosteroids with sham or non-intervention control (<LINK REF="STD-Bellamy-2006" TYPE="STUDY">Bellamy 2006</LINK>). In view of the overall body of evidence, we are as confident as Bellamy et al that no effect of intra-articular corticosteroids remains after six months, but are less confident than Bellamy that there is a clinically relevant short-term effect in view of large heterogeneity and possible small-study effects.</P>
<P>The most recent systematic review and network meta-analysis on intra-articular corticosteroids in knee osteoarthritis (<LINK REF="STD-Bannuru-2015" TYPE="STUDY">Bannuru 2015</LINK>), carried out in August 2014, identified seven trials comparing intra-articular corticosteroids to intra-articular placebo, all of which we included in our analysis. Again, we are less confident than these authors that there is a clinically relevant short-term effect of intra-articular corticosteroids considering the issues described above.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-10-08 07:40:28 -0400" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2015-10-08 07:40:28 -0400" MODIFIED_BY="[Empty name]">
<P>It remains unclear whether there are clinically important benefits one to six weeks after corticosteroid injection in view of the low quality of the included trials, the large amount of heterogeneity, and the likely presence of small-study effects (<LINK REF="REF-N_x00fc_esch-2010" TYPE="REFERENCE">Nüesch 2010</LINK>). Intra-articular corticosteroids should therefore be considered experimental in knee osteoarthritis and not be routinely used until adequately powered and properly designed trials clearly indicate a short- to mid-term benefit.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-10-08 07:40:28 -0400" MODIFIED_BY="[Empty name]">
<P>An adequately designed, multicentre, randomised, double-blind, sham-controlled, parallel-group trial is required to confirm or refute clinically relevant short- to mid-term benefits of intra-articular corticosteroids in knee osteoarthritis. A sample size of 100 participants per group would yield 80% power to detect a clinically meaningful moderate effect size of 0.4 standard deviation units in terms of pain reduction. The trial should use ultrasound guidance to ensure intra-articular needle placement as recently described by Henriksen et al (<LINK REF="STD-Henriksen-2015" TYPE="STUDY">Henriksen 2015</LINK>).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-10-08 07:40:28 -0400" MODIFIED_BY="[Empty name]">
<P>We acknowledge Dr. med. Marcello Di Nisio for his contribution with reference screening. We are grateful to Dr. Janne Estill and Elena Jüni for their translation of the <LINK REF="STD-Popov-1989" TYPE="STUDY">Popov 1989</LINK> trial. We would also like to acknowledge the authors of the original version of this review: Nicholas Bellamy, Jane Campbell, Vivian Welch, Travis L Gee, Robert Bourne, and George A Wells.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2015-10-08 07:40:28 -0400" MODIFIED_BY="[Empty name]">
<P>Peter Jüni: none<BR/>Roman Hari: none<BR/>Anne WS Rutjes: none<BR/>Roland Fischer: none<BR/>Maria G Silletta: none<BR/>Stephan Reichenbach: none<BR/>Bruno R da Costa: none<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-10-08 07:40:28 -0400" MODIFIED_BY="[Empty name]">
<P>Protocol completion: Jüni, Rutjes, Reichenbach, da Costa.<BR/>Acquisition of data: Hari, Rutjes, Fischer, Silletta, da Costa.<BR/>Analysis and interpretation of data: Jüni, Hari, Reichenbach, da Costa.<BR/>Manuscript preparation: Jüni, Hari, da Costa.<BR/>Statistical analysis: Jüni, da Costa.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2015-10-08 07:40:28 -0400" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Types of studies</HEADING>
<P>In the previous version of this Cochrane Review, only RCTs were eligible for inclusion, while in the present review update both RCTs and quasi-RCTs were eligible.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Types of interventions</HEADING>
<P>In the previous review version, control interventions were both sham intra-articular corticosteroid and active interventions (joint lavage, intra-articular hyaluronan/hylan, and other intra-articular corticosteroids). In the present review update, the prespecified control interventions were sham intra-articular corticosteroid and no intervention.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Types of outcome measures</HEADING>
<P>In the previous review version there were eight outcomes: pain, physical function, patient global assessment, joint imaging, adverse reaction caused by procedure, adverse reaction caused by corticosteroid, adverse reaction caused by toxicity-related withdrawals, total number of withdrawals and dropouts. In the review update, there were two prespecified primary outcomes and six prespecified secondary outcomes. Primary outcomes were pain and physical function, and secondary outcomes were quality of life, joint imaging, and the number of participants who experienced any adverse event, withdrew because of adverse events, and experienced any serious adverse events.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Search methods for identification of studies</HEADING>
<P>In the previous review version, the following four databases were searched: Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (including PreMEDLINE), EMBASE, and Current Contents. The electronic searches were supplemented by handsearches of bibliographic references and abstracts published in conference proceedings or in special issues of specialised journals, and industry representatives were contacted to request additional studies of their product that could meet eligibility criteria. In the present review update, we searched the following three databases: Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE Ovid and PubMed platforms, and EMBASE. The electronic searches were supplemented by handsearches of bibliographic references, abstracts published in conference proceedings, and search of clinical trial registers to identify ongoing or recently concluded trials.</P>
</SUBSECTION>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-10-19 10:24:14 -0400" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2015-10-19 10:24:14 -0400" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2015-10-19 10:17:30 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Beyaz-2012" MODIFIED="2015-10-08 01:39:05 -0400" MODIFIED_BY="[Empty name]" NAME="Beyaz 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-10-08 01:39:05 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Beyaz S G</AU>
<TI>Comparison of efficacy of intra-articular morphine and steroid in patients with knee osteoarthritis</TI>
<SO>Journal of Anaesthesiology Clinical Pharmacology</SO>
<YR>2012</YR>
<VL>28</VL>
<NO>4</NO>
<PG>496-500</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Campos-2013" MODIFIED="2015-10-08 01:44:55 -0400" MODIFIED_BY="[Empty name]" NAME="Campos 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-08-19 02:27:37 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Campos G C, Rezende M U, Fruchi R, Pasqualin T, Hissadomi M I</AU>
<TI>Adding triamcinolone to viscosupplementation: One year outcome of randomized trial</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2014</YR>
<VL>22</VL>
<PG>S198</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-10-08 01:44:55 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Campos G C, Rezende M U, Pailo A F, Frucchi R, Camargo O P</AU>
<TI>Adding triamcinolone improves viscosupplementation: A randomized clinical trial</TI>
<SO>Clinical Orthopaedics and Related Research</SO>
<YR>2013</YR>
<VL>471</VL>
<NO>2</NO>
<PG>613-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-08-19 02:27:37 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Campos G C, Rezende M U, Pailo A F, Frucchi R, Pasqualin T</AU>
<TI>Evaluation of the effect of adding corticosteroid to viscosupplementation: A prospective and randomized study</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2012</YR>
<VL>20</VL>
<PG>S169-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-08-19 02:27:37 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Campos G C</AU>
<TI>Evaluation of the effect of adding corticosteroid to viscosupplementation: A prospective and randomized study</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2011</YR>
<VL>19</VL>
<PG>S236</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Castro-2007" MODIFIED="2015-10-08 01:40:57 -0400" MODIFIED_BY="[Empty name]" NAME="Castro 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-10-08 01:40:57 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Castro M, Font P, Escudero A, Frias G, Mun&#771;oz E, Collantes E</AU>
<TI>Evaluation of effectiveness of five modalities of intraarticular treatment in patients with osteoarthritis of the knee</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2007</YR>
<VL>66(Suppl II)</VL>
<PG>515</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cederlof-1966" MODIFIED="2015-09-25 10:18:41 -0400" MODIFIED_BY="[Empty name]" NAME="Cederlof 1966" YEAR="1966">
<REFERENCE MODIFIED="2015-08-25 04:10:46 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cederlof S, Jonson G</AU>
<TI>Intraarticular prednisolone injection for osteoarthritis of the knee. A double blind test with placebo</TI>
<SO>Acta Chirurgica Scandinavica</SO>
<YR>1966</YR>
<VL>132(5)</VL>
<PG>532-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chao-2010" MODIFIED="2015-10-08 01:42:00 -0400" MODIFIED_BY="[Empty name]" NAME="Chao 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-10-08 01:42:00 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chao J, Wu C, Sun B, Hose M K, Quan A, Hughes T H, et al</AU>
<TI>Inflammatory characteristics on ultrasound predict poorer long-term response to intraarticular corticosteroid injections in knee osteoarthritis</TI>
<SO>Journal of Rheumatology</SO>
<YR>2010</YR>
<VL>37</VL>
<NO>3</NO>
<PG>650-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-08-19 02:28:45 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chao J, Wu C, Sun B, Hose M, Quan A, May S, et al</AU>
<TI>Inflammatory characteristics on ultrasound predict poorer long-term response to intraarticular corticosteroid injections in knee osteoarthritis</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2009</YR>
<VL>17</VL>
<PG>S153</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dieppe-1980" MODIFIED="2015-08-19 01:39:20 -0400" MODIFIED_BY="[Empty name]" NAME="Dieppe 1980" YEAR="1980">
<REFERENCE MODIFIED="2015-08-19 01:39:20 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dieppe P A, Sathapatayavongs B, Jones H E</AU>
<TI>Intra-articular steroids in osteoarthritis</TI>
<SO>Rheumatology and Rehabilitation</SO>
<YR>1980</YR>
<VL>19</VL>
<NO>4</NO>
<PG>212-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Di-Sante-2012" MODIFIED="2015-10-08 01:46:33 -0400" MODIFIED_BY="[Empty name]" NAME="Di Sante 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-10-08 01:46:33 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Di Sante L, Paoloni M, Dimaggio M, Colella L, Cerino A, Bernetti A, et al</AU>
<TI>Ultrasound-guided aspiration and corticosteroid injection compared to horizontal therapy for treatment of knee osteoarthritis complicated with Baker's cyst: a randomized controlled trial</TI>
<SO>European Journal of Physical &amp; Rehabilitation Medicine</SO>
<YR>2012</YR>
<VL>48</VL>
<NO>4</NO>
<PG>561-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fri_x0301_as-2004" MODIFIED="2015-10-08 01:48:20 -0400" MODIFIED_BY="[Empty name]" NAME="Fri&#769;as 2004" YEAR="2004">
<REFERENCE MODIFIED="2015-10-08 01:48:20 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fri&#769;as G, Caracuel M A, Escudero A, Rumbao J, Pe&#769;rez-Gujo V, Carmen Castro M, et al</AU>
<TI>Assessment of the efficacy of joint lavage versus joint lavage plus corticoids in patients with osteoarthritis of the knee</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>2004</YR>
<VL>20</VL>
<NO>6</NO>
<PG>861-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Friedman-1980" MODIFIED="2015-08-19 01:39:33 -0400" MODIFIED_BY="[Empty name]" NAME="Friedman 1980" YEAR="1980">
<REFERENCE MODIFIED="2015-08-19 01:39:33 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Friedman D M, Moore M E</AU>
<TI>The efficacy of intraarticular steroids in osteoarthritis: A double-blind study</TI>
<SO>Journal of Rheumatology</SO>
<YR>1980</YR>
<VL>7</VL>
<NO>6</NO>
<PG>850-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gaffney-1995" MODIFIED="2015-08-19 01:39:39 -0400" MODIFIED_BY="[Empty name]" NAME="Gaffney 1995" YEAR="1995">
<REFERENCE MODIFIED="2015-08-19 01:39:39 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gaffney K, Ledingham J, Perry J D</AU>
<TI>Intra-articular triamcinolone hexacetonide in knee osteoarthritis: Factors influencing the clinical response</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>1995</YR>
<VL>54</VL>
<NO>5</NO>
<PG>379-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grecomoro-1992" MODIFIED="2015-08-19 01:39:47 -0400" MODIFIED_BY="[Empty name]" NAME="Grecomoro 1992" YEAR="1992">
<REFERENCE MODIFIED="2015-08-19 01:39:47 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Grecomoro G, Piccione F, Letizia G</AU>
<TI>Therapeutic synergism between hyaluronic acid and dexamethasone in the intra-articular treatment of osteoarthritis of the knee: a preliminary open study</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>1992</YR>
<VL>13</VL>
<NO>1</NO>
<PG>49-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Henriksen-2015" MODIFIED="2015-10-08 01:51:43 -0400" MODIFIED_BY="[Empty name]" NAME="Henriksen 2015" YEAR="2015">
<REFERENCE MODIFIED="2015-10-08 01:51:43 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Henriksen M, Christensen R, Klokker L, Bartholdy C, Bandak E, Ellegaard K, et al</AU>
<TI>Evaluation of the benefit of corticosteroid injection before exercise therapy in patients with osteoarthritis of the knee. A randomized clinical trial</TI>
<SO>JAMA Internal Medicine</SO>
<YR>2015</YR>
<VL>175</VL>
<NO>6</NO>
<PG>923-30</PG>
<IDENTIFIERS MODIFIED="2015-10-08 01:51:25 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-10-08 01:51:25 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1001/jamainternmed.2015.0461"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jones-1996" MODIFIED="2015-08-19 01:40:53 -0400" MODIFIED_BY="[Empty name]" NAME="Jones 1996" YEAR="1996">
<REFERENCE MODIFIED="2015-08-19 01:40:53 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jones A, Doherty M</AU>
<TI>Intra-articular corticosteroids are effective in osteoarthritis but there are no clinical predictors of response</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>1996</YR>
<VL>55</VL>
<NO>11</NO>
<PG>829-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lyons-2005" MODIFIED="2015-10-19 10:11:06 -0400" MODIFIED_BY="[Empty name]" NAME="Lyons 2005" YEAR="2005">
<REFERENCE MODIFIED="2015-10-19 10:11:06 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lyons C, Majeed A, Banarsee R</AU>
<TI>Effectiveness of high volume intra-articular injection of cortisone and lignocaine in osteoarthritis of the knee. Pilot study</TI>
<SO>North &amp; West London journal of general practice: NWLJGP</SO>
<YR>2005</YR>
<VL>11(1)</VL>
<PG>23-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-1958" MODIFIED="2015-10-08 02:00:57 -0400" MODIFIED_BY="[Empty name]" NAME="Miller 1958" YEAR="1958">
<REFERENCE MODIFIED="2015-09-24 05:00:22 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Miller J H, White J, Norton T H</AU>
<TI>The value of intra-articular injections in osteoarthritis of the knee</TI>
<SO>Journal of Bone &amp; Joint Surgery - British Volume</SO>
<YR>1958</YR>
<VL>40-B</VL>
<NO>4</NO>
<PG>636-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00414427" MODIFIED="2015-10-19 10:04:39 -0400" MODIFIED_BY="[Empty name]" NAME="NCT00414427" YEAR="2010">
<REFERENCE MODIFIED="2015-10-19 10:04:17 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>NCT00414427</AU>
<TI>Using ultrasound to predict response to intraarticular corticosteroids in knee osteoarthritis</TI>
<SO>ClinicalTrials.gov</SO>
<YR>(acessed 19 October 2015)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ozturk-2006" MODIFIED="2015-10-08 02:02:33 -0400" MODIFIED_BY="[Empty name]" NAME="Ozturk 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-10-08 02:02:33 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ozturk C, Atamaz F, Hepguler S, Argin M, Arkun R</AU>
<TI>The safety and efficacy of intraarticular hyaluronan with/without corticosteroid in knee osteoarthritis: 1-year, single-blind, randomized study</TI>
<SO>Rheumatology International</SO>
<YR>2006</YR>
<VL>26</VL>
<NO>4</NO>
<PG>314-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Petrella-2015" MODIFIED="2015-10-08 02:03:13 -0400" MODIFIED_BY="[Empty name]" NAME="Petrella 2015" YEAR="2015">
<REFERENCE MODIFIED="2015-08-20 06:34:09 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Petrella R J, Eamans P, Alleyne J, Maroney M</AU>
<TI>A prospective, multi-center, randomized, double-blind feasibility study to evaluate the safety and performance of hydros joint therapy and hydros-ta joint therapy for management of pain associated with osteoarthritis in the knee</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2012</YR>
<VL>20</VL>
<PG>S172-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-10-08 02:03:13 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Petrella R J, Emans P J, Alleyne J, Dellaert F, Gill D P, Maroney M</AU>
<TI>Safety and performance of Hydros and Hydros-TA for knee osteoarthritis. A prospective, multicenter, randomized, double-blind feasibility trial</TI>
<SO>BMC Musculoskeletal Disorders</SO>
<YR>2015</YR>
<VL>16:57</VL>
<PG>1-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Popov-1989" MODIFIED="2015-10-08 02:05:56 -0400" MODIFIED_BY="[Empty name]" NAME="Popov 1989" YEAR="1989">
<REFERENCE MODIFIED="2015-10-08 02:05:56 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Popov V V, Bunchuk N V, Apenysheva N P</AU>
<TI>Treatment of patients with gonarthrosis by intra-articular administration of drugs</TI>
<SO>Klinicheskaia Meditsina (Moskva)</SO>
<YR>1989</YR>
<VL>67</VL>
<NO>4</NO>
<PG>104-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ravaud-1999" MODIFIED="2015-10-08 02:06:57 -0400" MODIFIED_BY="[Empty name]" NAME="Ravaud 1999" YEAR="1999">
<REFERENCE MODIFIED="2015-10-08 02:06:57 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ravaud P, Moulinier L, Giraudeau B, Ayral X, Guerin C, Noel E, et al</AU>
<TI>Effects of joint lavage and steroid injection in patients with osteoarthritis of the knee: results of a multicenter, randomized, controlled trial</TI>
<SO>Arthritis &amp; Rheumatology</SO>
<YR>1999</YR>
<VL>42</VL>
<NO>3</NO>
<PG>475-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raynauld-2003" MODIFIED="2015-10-08 02:07:32 -0400" MODIFIED_BY="[Empty name]" NAME="Raynauld 2003" YEAR="2003">
<REFERENCE MODIFIED="2015-10-08 02:07:32 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Raynauld J P, Buckland-Wright C, Ward R, Choquette D, Haraoui B, Martel-Pelletier J, et al</AU>
<TI>Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial. [Erratum appears in Arthritis &amp; Rheumatology 2003 Nov;48(11):3300]</TI>
<SO>Arthritis &amp; Rheumatology</SO>
<YR>2003</YR>
<VL>48</VL>
<NO>2</NO>
<PG>370-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schue-2011" MODIFIED="2015-10-19 10:17:30 -0400" MODIFIED_BY="[Empty name]" NAME="Schue 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-10-19 10:17:30 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Schue J R</AU>
<TI>Treatment of knee osteoarthritis with intraarticular infliximab may improve knee function and reduce synovial infiltration by macrophages: Proceedings of the ACR 2011 Conference</TI>
<SO>American College of Theumatology</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-2003" MODIFIED="2015-10-08 02:11:20 -0400" MODIFIED_BY="[Empty name]" NAME="Smith 2003" YEAR="2003">
<REFERENCE MODIFIED="2015-10-08 02:10:12 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Smith M D, Wetherall M, Darby T, Esterman A, Slavotinek J, Roberts-Thomson P, et al</AU>
<TI>A randomized placebo-controlled trial of artroscopic lavage versus lavage plus intra-articular corticosteroids in the management of symptomatic osteoarthritis of the knee</TI>
<SO>Rheumatology</SO>
<YR>2003</YR>
<VL>42</VL>
<NO>12</NO>
<PG>1477-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-10-08 02:11:20 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith M, Wetherall M, Roberts-Thomson P, Ahem M</AU>
<TI>Is intra-articular depot corticosteroid treatment effective in symptomatic osteoarthritis of the knee joint? [abstract]</TI>
<SO>Australian and New Zealand Journal of Medicine</SO>
<YR>2000</YR>
<VL>30</VL>
<NO>4</NO>
<PG>527</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wright-1960" MODIFIED="2015-09-24 04:54:05 -0400" MODIFIED_BY="[Empty name]" NAME="Wright 1960" YEAR="1960">
<REFERENCE MODIFIED="2015-09-24 04:54:05 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Relevant outcomes, data not extractable though .&lt;/p&gt;" NOTES_MODIFIED="2015-09-24 04:54:05 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wright V, Chandler G N, Morison R A, Hartfall S J</AU>
<TI>Intra-articular therapy in osteo-arthritis; comparison of hydrocortisone acetate and hydrocortisone tertiary-butylacetate</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>1960</YR>
<VL>19</VL>
<PG>257-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yavuz-2012" MODIFIED="2015-08-19 01:47:15 -0400" MODIFIED_BY="[Empty name]" NAME="Yavuz 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-08-19 01:47:15 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Yavuz U, Sokucu S, Albayrak A, Ozturk K</AU>
<TI>Efficacy comparisons of the intraarticular steroidal agents in the patients with knee osteoarthritis</TI>
<SO>Rheumatology International</SO>
<YR>2012</YR>
<VL>32</VL>
<NO>11</NO>
<PG>3391-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Young-2001" MODIFIED="2015-08-19 01:47:21 -0400" MODIFIED_BY="[Empty name]" NAME="Young 2001" YEAR="2001">
<REFERENCE MODIFIED="2015-08-19 01:47:21 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Young L, Katrib A, Cuello C, Vollmer-Conna U, Bertouch J V, Roberts-Thomson P J, et al</AU>
<TI>Effects of intraarticular glucocorticoids on macrophage infiltration and mediators of joint damage in osteoarthritis synovial membranes: findings in a double-blind, placebo-controlled study</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2001</YR>
<VL>44</VL>
<NO>2</NO>
<PG>343-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhilyayev-2012" MODIFIED="2015-08-19 01:47:29 -0400" MODIFIED_BY="[Empty name]" NAME="Zhilyayev 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-08-19 01:47:29 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zhilyayev E, Zagrebneva A, Glazunov A, Glazunov P, Alkhimenko T</AU>
<TI>Efficacy of intraarticular and periarticular glucocorticoid injections in patients with knee osteoarthritis: A randomized double-blind study</TI>
<SO>International Journal of Rheumatic Diseases</SO>
<YR>2012</YR>
<VL>15</VL>
<PG>95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-10-19 10:24:14 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Abdulla-2013" MODIFIED="2015-07-17 12:45:52 -0400" MODIFIED_BY="[Empty name]" NAME="Abdulla 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-07-17 12:45:52 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Systematic review on the topic published in or after 2004.&lt;/p&gt;" NOTES_MODIFIED="2015-07-17 12:45:52 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abdulla A, Adams N, Bone M, Elliott A M, Gaffin J, Jones D, et al</AU>
<TI>Guidance on the management of pain in older people</TI>
<SO>Age and Ageing</SO>
<YR>2013</YR>
<VL>42 Suppl 1</VL>
<PG>i1-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-1978" MODIFIED="2015-07-17 12:46:51 -0400" MODIFIED_BY="[Empty name]" NAME="Anonymous 1978" YEAR="1978">
<REFERENCE MODIFIED="2015-07-17 12:46:51 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong study design.&lt;/p&gt;" NOTES_MODIFIED="2015-07-17 12:46:51 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Intra-articular steroids</TI>
<SO>British Medical Journal</SO>
<YR>1978</YR>
<VL>1</VL>
<PG>600-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-2011" MODIFIED="2015-10-08 02:19:57 -0400" MODIFIED_BY="[Empty name]" NAME="Anonymous 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-10-08 02:19:57 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong study design.&lt;/p&gt;" NOTES_MODIFIED="2015-10-08 02:19:57 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Knee osteoarthritis. [Original report in American Family Physician. 2011 Jun 1;83(11):1287-92; PMID: 21661710]</TI>
<SO>American Family Physician</SO>
<YR>2011</YR>
<VL>83</VL>
<PG>1294</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arroll-2004" MODIFIED="2015-07-17 12:47:08 -0400" MODIFIED_BY="[Empty name]" NAME="Arroll 2004" YEAR="2004">
<REFERENCE MODIFIED="2015-07-17 12:47:08 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Systematic review on the topic published in or after 2004.&lt;/p&gt;" NOTES_MODIFIED="2015-07-17 12:47:08 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arroll B, Goodyear-Smith F</AU>
<TI>Corticosteroid injections for osteoarthritis of the knee: meta-analysis</TI>
<SO>BMJ</SO>
<YR>2004</YR>
<VL>328</VL>
<PG>869</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arroll-2005" MODIFIED="2015-07-17 12:47:13 -0400" MODIFIED_BY="[Empty name]" NAME="Arroll 2005" YEAR="2005">
<REFERENCE MODIFIED="2015-07-17 12:47:13 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong study design.&lt;/p&gt;" NOTES_MODIFIED="2015-07-17 12:47:13 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arroll B, Goodyear-Smith F, Shoor S</AU>
<TI>Review: Intra-articular corticosteroid injections are better than placebo for improving symptoms of knee osteoarthritis</TI>
<SO>Evidence-Based Medicine</SO>
<YR>2005</YR>
<VL>10</VL>
<PG>23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Avouac-2010" MODIFIED="2015-07-17 12:47:17 -0400" MODIFIED_BY="[Empty name]" NAME="Avouac 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-07-17 12:47:17 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Systematic review on the topic published in or after 2004.&lt;/p&gt;" NOTES_MODIFIED="2015-07-17 12:47:17 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Avouac J, Vicaut E, Bardin T, Richette P</AU>
<TI>Efficacy of joint lavage in knee osteoarthritis: Meta-analysis of randomized controlled studies</TI>
<SO>Rheumatology</SO>
<YR>2010</YR>
<VL>49</VL>
<PG>334-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baker-1969" MODIFIED="2015-07-17 12:47:21 -0400" MODIFIED_BY="[Empty name]" NAME="Baker 1969" YEAR="1969">
<REFERENCE MODIFIED="2015-07-17 12:47:21 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Active comparator.&lt;/p&gt;" NOTES_MODIFIED="2015-07-17 12:47:21 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baker D M, Burland W L</AU>
<TI>Intra-articular injection of corticosteroid for degenerative arthritis</TI>
<SO>Practitioner</SO>
<YR>1969</YR>
<VL>202</VL>
<PG>431-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bannuru-2013" MODIFIED="2015-07-17 12:47:26 -0400" MODIFIED_BY="[Empty name]" NAME="Bannuru 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-07-17 12:47:26 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Abstract to relevant SR, no references listed.&lt;/p&gt;" NOTES_MODIFIED="2015-07-17 12:47:26 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bannuru R R, McAlindon T E, Wong J B, Kent D, Schmid C</AU>
<TI>Comparative effectiveness of pharmacological interventions for knee osteoarthritis: A network meta-analysis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2013</YR>
<VL>65</VL>
<PG>S915-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bannuru-2014" MODIFIED="2015-07-17 12:47:32 -0400" MODIFIED_BY="[Empty name]" NAME="Bannuru 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-07-17 12:47:32 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Abstract to relevant SR, no references listed.&lt;/p&gt;" NOTES_MODIFIED="2015-07-17 12:47:32 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bannuru R R, Schmid C H, Sullivan M C, Kent D M, Wong J B, McAlindon T E</AU>
<TI>Differential response of placebo treatments in osteoarthritis trials: A systematic review and network meta-analysis</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2014</YR>
<VL>22</VL>
<PG>S24-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bannuru-2015" MODIFIED="2015-10-08 02:30:27 -0400" MODIFIED_BY="[Empty name]" NAME="Bannuru 2015" YEAR="2015">
<REFERENCE MODIFIED="2015-10-08 02:30:27 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Systematic review on the topic published in or after 2004.&lt;/p&gt;" NOTES_MODIFIED="2015-10-08 02:30:27 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bannuru R R, Schmid C H, Kent D M, Vaysbrot E E, Wong J B, McAlindon T E</AU>
<TI>Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: A systematic review and network meta-analysis</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2015</YR>
<VL>162</VL>
<PG>46-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baratham-2010" MODIFIED="2015-07-17 12:47:41 -0400" MODIFIED_BY="[Empty name]" NAME="Baratham 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-07-17 12:47:41 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong outcomes.&lt;/p&gt;" NOTES_MODIFIED="2015-07-17 12:47:41 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baratham A, Lukert B P, Lindsley H B</AU>
<TI>Effects of intraarticular (IA) corticosteroid injections on bone markers and endogenous cortisol in patients with knee osteoarthritis (OA), a pilot study</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2010</YR>
<VL>62</VL>
<PG>943</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bellamy-2005" MODIFIED="2015-10-08 02:35:54 -0400" MODIFIED_BY="[Empty name]" NAME="Bellamy 2005" YEAR="2005">
<REFERENCE MODIFIED="2015-10-08 02:35:54 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Systematic review on the topic published in or after 2004.&lt;/p&gt;" NOTES_MODIFIED="2015-10-08 02:35:54 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="COCHRANE_REVIEW">
<AU>Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G</AU>
<TI>Intraarticular corticosteroid for treatment of osteoarthritis of the knee</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2015-10-08 02:33:54 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-10-08 02:33:54 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005328.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bellamy-2006" MODIFIED="2015-10-19 10:19:59 -0400" MODIFIED_BY="[Empty name]" NAME="Bellamy 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-10-19 10:19:59 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Systematic review on the topic published in or after 2004.&lt;/p&gt;" NOTES_MODIFIED="2015-10-19 10:19:59 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="COCHRANE_REVIEW">
<AU>Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G</AU>
<TI>Intraarticular corticosteroid for treatment of osteoarthritis of the knee</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<VL>19</VL>
<NO>2</NO>
<PG>CD005328</PG>
<IDENTIFIERS MODIFIED="2015-10-19 10:19:59 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-10-19 10:19:53 -0400" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="DOI: 10.1002/14651858.CD005328.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bennell-2012" MODIFIED="2015-09-24 05:03:27 -0400" MODIFIED_BY="[Empty name]" NAME="Bennell 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-09-24 05:03:27 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong study design.&lt;/p&gt;" NOTES_MODIFIED="2015-09-24 05:03:27 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bennell K L, Hunter D J, Hinman R S</AU>
<TI>Management of osteoarthritis of the knee</TI>
<SO>BMJ (Online)</SO>
<YR>2012</YR>
<VL>345</VL>
<PG>1-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bjordal-2007" MODIFIED="2015-07-17 12:48:32 -0400" MODIFIED_BY="[Empty name]" NAME="Bjordal 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-07-17 12:48:32 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Systematic review on the topic published in or after 2004.&lt;/p&gt;" NOTES_MODIFIED="2015-07-17 12:48:32 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bjordal J M, Klovning A, Ljunggren A E, Slordal L</AU>
<TI>Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: A meta-analysis of randomised placebo-controlled trials</TI>
<SO>European Journal of Pain</SO>
<YR>2007</YR>
<VL>11</VL>
<PG>125-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blanke-2008" MODIFIED="2015-10-08 02:41:05 -0400" MODIFIED_BY="[Empty name]" NAME="Blanke 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-10-08 02:41:05 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong study design.&lt;/p&gt;" NOTES_MODIFIED="2015-10-08 02:41:05 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blanke M, Gusinde J, Dobre A, Brem M H</AU>
<TI>Treatment of knee osteoarthritis</TI>
<SO>MMW Fortschritte der Medizin</SO>
<YR>2008</YR>
<VL>150</VL>
<PG>26-9; quiz 30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bourne-1985" MODIFIED="2015-07-17 12:48:42 -0400" MODIFIED_BY="[Empty name]" NAME="Bourne 1985" YEAR="1985">
<REFERENCE MODIFIED="2015-07-17 12:48:42 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong study design.&lt;/p&gt;" NOTES_MODIFIED="2015-07-17 12:48:42 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bourne I H</AU>
<TI>Injecting painful knees with triamcinolone</TI>
<SO>Practitioner</SO>
<YR>1985</YR>
<VL>229</VL>
<PG>33-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brys-2004" MODIFIED="2015-07-17 12:48:46 -0400" MODIFIED_BY="[Empty name]" NAME="Brys 2004" YEAR="2004">
<REFERENCE MODIFIED="2015-07-17 12:48:46 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong study design.&lt;/p&gt;" NOTES_MODIFIED="2015-07-17 12:48:46 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brys D A</AU>
<TI>Corticosteroid compared with hyaluronic acid injections for the treatment of osteoarthritis of the knee</TI>
<SO>Journal of Bone &amp; Joint Surgery - American Volume</SO>
<YR>2004</YR>
<VL>86-A</VL>
<PG>874; author reply 874-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Canillas-2011" MODIFIED="2015-07-17 12:49:09 -0400" MODIFIED_BY="[Empty name]" NAME="Canillas 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-07-17 12:49:09 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong study design.&lt;/p&gt;" NOTES_MODIFIED="2015-07-17 12:49:09 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Canillas M, Kandavanam R, Reilly K</AU>
<TI>Do intra-articular (IA) steroid injections relieve pain and improve outcomes beyond two weeks for patients with osteoarthritis (OA) of the knee</TI>
<SO>Journal - Oklahoma State Medical Association</SO>
<YR>2011</YR>
<VL>104</VL>
<PG>262-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cats-1979b" MODIFIED="2015-10-08 02:43:06 -0400" MODIFIED_BY="[Empty name]" NAME="Cats 1979b" YEAR="1979">
<REFERENCE MODIFIED="2015-10-08 02:43:06 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong patient population.&lt;/p&gt;" NOTES_MODIFIED="2015-10-08 02:43:06 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cats A, JA I J, Davinova Y, Werthauer-Rodrigues Pereira M, Blakemore C B, Steiner F J</AU>
<TI>The efficacy of intra-articularly administered MYC 2095, triamcinolone hexacetonide and placebo in gonarthritis. A combined double-blind clinical trial</TI>
<SO>Scandinavian Journal of Rheumatology</SO>
<YR>1979</YR>
<VL>8</VL>
<PG>199-203</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Charalambous-2004" MODIFIED="2015-07-17 12:49:20 -0400" MODIFIED_BY="[Empty name]" NAME="Charalambous 2004" YEAR="2004">
<REFERENCE MODIFIED="2015-07-17 12:49:20 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong study design.&lt;/p&gt;" NOTES_MODIFIED="2015-07-17 12:49:20 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Charalambous C P</AU>
<TI>Corticosteroid compared with hyaluronic acid injections for the treatment of osteoarthritis of the knee</TI>
<SO>Journal of Bone &amp; Joint Surgery - American Volume</SO>
<YR>2004</YR>
<VL>86-A</VL>
<PG>874; author reply 874</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cheng-2012" MODIFIED="2015-10-08 02:43:58 -0400" MODIFIED_BY="[Empty name]" NAME="Cheng 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-10-08 02:43:58 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Systematic review on the topic published in or after 2004.&lt;/p&gt;" NOTES_MODIFIED="2015-10-08 02:43:58 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheng O T, Souzdalnitski D, Vrooman B, Cheng J</AU>
<TI>Evidence-based knee injections for the management of arthritis</TI>
<SO>Pain Medicine (United States)</SO>
<YR>2012</YR>
<VL>13</VL>
<PG>740-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Courtney-2009" MODIFIED="2015-07-17 12:51:57 -0400" MODIFIED_BY="[Empty name]" NAME="Courtney 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-07-17 12:51:57 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong study design.&lt;/p&gt;" NOTES_MODIFIED="2015-07-17 12:51:57 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Courtney P, Doherty M</AU>
<TI>Editorial: Intra-articular corticosteroid injection for osteoarthritis</TI>
<SO>International Journal of Clinical Rheumatology</SO>
<YR>2009</YR>
<VL>4</VL>
<PG>621-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Douglas-2012" MODIFIED="2015-07-17 12:50:30 -0400" MODIFIED_BY="[Empty name]" NAME="Douglas 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-07-17 12:50:30 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong study design.&lt;/p&gt;" NOTES_MODIFIED="2015-07-17 12:50:30 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Douglas R J</AU>
<TI>Corticosteroid injection into the osteoarthritic knee: drug selection, dose, and injection frequency</TI>
<SO>International Journal of Clinical Practice</SO>
<YR>2012</YR>
<VL>66</VL>
<PG>699-704</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gait-2014" MODIFIED="2015-07-17 12:50:09 -0400" MODIFIED_BY="[Empty name]" NAME="Gait 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-07-17 12:50:09 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong study design.&lt;/p&gt;" NOTES_MODIFIED="2015-07-17 12:50:09 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gait A D, Hodgson R, Cootes T F, Marjanovic E J, Parkes M, O'Neill T W, et al</AU>
<TI>Late synovial enhancement detects effects of intraarticular steroids on synovitis better than synovial volume</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2014</YR>
<VL>22</VL>
<PG>S240-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garg-2013" MODIFIED="2015-09-24 05:23:25 -0400" MODIFIED_BY="[Empty name]" NAME="Garg 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-09-24 05:23:25 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Abstract to relevant SR, no references listed.&lt;/p&gt;" NOTES_MODIFIED="2015-09-24 05:23:25 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garg N, Deodhar A</AU>
<TI>A systematic review of comparative efficacy of various corticosteroid preparations for intra-articular and soft tissue injections</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2013</YR>
<VL>72</VL>
<PG>A720</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garg-2014" MODIFIED="2015-10-19 08:27:37 -0400" MODIFIED_BY="[Empty name]" NAME="Garg 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-10-19 08:27:37 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garg N, Perry L, Deodhar A</AU>
<TI>Intra-articular and soft tissue injections, a systematic review of relative efficacy of various corticosteroids.</TI>
<SO>Clinical Rheumatology</SO>
<YR>2014</YR>
<VL>33</VL>
<PG>1695-706</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gerlag-2008a" MODIFIED="2015-10-08 02:47:22 -0400" MODIFIED_BY="[Empty name]" NAME="Gerlag 2008a" YEAR="2008">
<REFERENCE MODIFIED="2015-10-08 02:47:22 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong study design.&lt;/p&gt;" NOTES_MODIFIED="2015-10-08 02:47:22 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gerlag D M, Tak P P</AU>
<TI>Prolonged effect of intra-articularly administered corticosteroids in combination with arthroscopic lavage in patients with an inflammatory arthritis of the knee</TI>
<TO>Verlenging van het effect van intra-articulair toegediende corticosteroiden door combinatie hiervan met artroscopische lavage bij patienten met een inflammatoire artritis van de knie</TO>
<SO>Nederlands Tijdschrift Voor Geneeskunde</SO>
<YR>2008</YR>
<VL>152</VL>
<PG>1953-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Godwin-2004" MODIFIED="2015-07-17 12:51:21 -0400" MODIFIED_BY="[Empty name]" NAME="Godwin 2004" YEAR="2004">
<REFERENCE MODIFIED="2015-07-17 12:51:21 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Systematic review on the topic published in or after 2004.&lt;/p&gt;" NOTES_MODIFIED="2015-07-17 12:51:21 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Godwin M, Dawes M</AU>
<TI>Intra-articular steroid injections for painful knees. Systematic review with meta-analysis</TI>
<SO>Canadian Family Physician</SO>
<YR>2004</YR>
<VL>50</VL>
<PG>241-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Habib-2009" MODIFIED="2015-07-17 12:51:07 -0400" MODIFIED_BY="[Empty name]" NAME="Habib 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-07-17 12:51:07 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong study design.&lt;/p&gt;" NOTES_MODIFIED="2015-07-17 12:51:07 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Habib G S</AU>
<TI>Systemic effects of intra-articular corticosteroids</TI>
<SO>Clinical Rheumatology</SO>
<YR>2009</YR>
<VL>28</VL>
<PG>749-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Habib-2010" MODIFIED="2015-07-17 12:51:16 -0400" MODIFIED_BY="[Empty name]" NAME="Habib 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-07-17 12:51:16 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong study design.&lt;/p&gt;" NOTES_MODIFIED="2015-07-17 12:51:16 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Habib G S, Saliba W, Nashashibi M</AU>
<TI>Local effects of intra-articular corticosteroids</TI>
<SO>Clinical Rheumatology</SO>
<YR>2010</YR>
<VL>29</VL>
<PG>347-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hepper-2009" MODIFIED="2015-10-19 08:31:02 -0400" MODIFIED_BY="[Empty name]" NAME="Hepper 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-10-19 08:31:00 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hepper C T, Halvorson J J, Duncan S T, Gregory A J M, Dunn W R, Spindler K P</AU>
<TI>The efficacy and duration of intra-articular corticosteroid injection for knee osteoarthritis: A systematic review of level I studies</TI>
<SO>Journal of the American Academy of Orthopaedic Surgeons</SO>
<YR>2009</YR>
<VL>17</VL>
<PG>638-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hirsch-2013" MODIFIED="2015-10-19 08:34:11 -0400" MODIFIED_BY="[Empty name]" NAME="Hirsch 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-10-19 08:33:50 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hirsch G, Kitas G, Klocke R</AU>
<TI>Intra-articular corticosteroid injection in osteoarthritis of the knee and hip: factors predicting pain relief--a systematic review</TI>
<SO>Seminars in Arthritis &amp; Rheumatism</SO>
<YR>2013</YR>
<VL>42</VL>
<PG>451-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ivanov-1981" MODIFIED="2015-10-08 02:48:38 -0400" MODIFIED_BY="[Empty name]" NAME="Ivanov 1981" YEAR="1981">
<REFERENCE MODIFIED="2015-10-08 02:48:38 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong comparator.&lt;/p&gt;" NOTES_MODIFIED="2015-10-08 02:48:38 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ivanov B A, Koliago S A</AU>
<TI>Use of hydrocortisone in treating arthrosis deformans of the extremities</TI>
<SO>Voenno-Meditsinskii Zhurnal</SO>
<YR>1981</YR>
<NO>6</NO>
<PG>56-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jarner-1992" MODIFIED="2015-10-08 02:49:00 -0400" MODIFIED_BY="[Empty name]" NAME="Jarner 1992" YEAR="1992">
<REFERENCE MODIFIED="2015-10-08 02:49:00 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Active comparator.&lt;/p&gt;" NOTES_MODIFIED="2015-10-08 02:49:00 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jarner D, Aaboe T, Andersen L A</AU>
<TI>Intra-articular indomethacin versus triamcinolone hexacetonide injections in osteoarthritis and hydrarthrosis</TI>
<SO>Scandinavian Journal of Rheumatology. Supplement</SO>
<YR>1992</YR>
<VL>93</VL>
<PG>67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jones-1993" MODIFIED="2015-07-17 12:51:35 -0400" MODIFIED_BY="[Empty name]" NAME="Jones 1993" YEAR="1993">
<REFERENCE MODIFIED="2015-07-17 12:51:35 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong study design.&lt;/p&gt;" NOTES_MODIFIED="2015-07-17 12:51:35 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jones A, Regan M, Ledingham J, Pattrick M, Manhire A, Doherty M</AU>
<TI>Importance of placement of intra-articular steroid injections</TI>
<SO>BMJ</SO>
<YR>1993</YR>
<VL>307</VL>
<PG>1329-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jones-2014" MODIFIED="2015-07-17 12:51:38 -0400" MODIFIED_BY="[Empty name]" NAME="Jones 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-07-17 12:51:38 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong study design.&lt;/p&gt;" NOTES_MODIFIED="2015-07-17 12:51:38 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jones T, Kelsberg G, Safranek S</AU>
<TI>FPIN's clinical inquiries: Intra-articular corticosteroid injections for osteoarthritis of the knee</TI>
<SO>American Family Physician</SO>
<YR>2014</YR>
<VL>90</VL>
<PG>115-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Keagy-1967" MODIFIED="2015-07-17 12:52:52 -0400" MODIFIED_BY="[Empty name]" NAME="Keagy 1967" YEAR="1967">
<REFERENCE MODIFIED="2015-07-17 12:52:52 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong study design.&lt;/p&gt;" NOTES_MODIFIED="2015-07-17 12:52:52 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keagy R D, Keim H A</AU>
<TI>Intra-articular steroid therapy: repeated use in patients with chronic arthritis</TI>
<SO>American Journal of the Medical Sciences</SO>
<YR>1967</YR>
<VL>253</VL>
<PG>45-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Khitrov-1997" MODIFIED="2015-10-08 02:50:21 -0400" MODIFIED_BY="[Empty name]" NAME="Khitrov 1997" YEAR="1997">
<REFERENCE MODIFIED="2015-10-08 02:50:21 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Active comparator.&lt;/p&gt;" NOTES_MODIFIED="2015-10-08 02:50:21 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khitrov N A, Sil'vestrov V P, Tsurko V V</AU>
<TI>A comparative evaluation of local therapy methods in treating osteoarthrosis deformans</TI>
<SO>Terapevticheskii Arkhiv</SO>
<YR>1997</YR>
<VL>69</VL>
<PG>53-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kizilkaya-2004" MODIFIED="2015-07-17 12:52:44 -0400" MODIFIED_BY="[Empty name]" NAME="Kizilkaya 2004" YEAR="2004">
<REFERENCE MODIFIED="2015-07-17 12:52:44 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kizilkaya M, Yildirim O S, Dogan N, Kursad H, Okur A</AU>
<TI>Analgesic effects of intraarticular sufentanil and sufentanil plus methylprednisolone after arthroscopic knee surgery</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>2004</YR>
<VL>98</VL>
<NO>4</NO>
<PG>1062-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kizilkaya-2005" MODIFIED="2015-07-17 12:52:41 -0400" MODIFIED_BY="[Empty name]" NAME="Kizilkaya 2005" YEAR="2005">
<REFERENCE MODIFIED="2015-07-17 12:52:41 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kizilkaya M, Yildirim O S, Ezirmik N, Kursad H, Karsan O</AU>
<TI>Comparisons of analgesic effects of different doses of morphine and morphine plus methylprednisolone after knee surgery</TI>
<SO>European Journal of Anaesthesiology</SO>
<YR>2005</YR>
<VL>22</VL>
<NO>8</NO>
<PG>603-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koyonos-2009" MODIFIED="2015-07-17 12:52:32 -0400" MODIFIED_BY="[Empty name]" NAME="Koyonos 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-07-17 12:52:32 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koyonos L, Yanke A B, McNickle A G, Kirk S S, Kang R W, Lewis P B, et al</AU>
<TI>A randomized, prospective, double-blind study to investigate the effectiveness of adding DepoMedrol to a local anesthetic injection in postmeniscectomy patients with osteoarthritis of the knee</TI>
<SO>American Journal of Sports Medicine</SO>
<YR>2009</YR>
<VL>37</VL>
<NO>6</NO>
<PG>1077-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krause-1971" MODIFIED="2015-10-08 02:51:47 -0400" MODIFIED_BY="[Empty name]" NAME="Krause 1971" YEAR="1971">
<REFERENCE MODIFIED="2015-10-08 02:51:47 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong study design.&lt;/p&gt;" NOTES_MODIFIED="2015-10-08 02:51:47 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krause W</AU>
<TI>Intra-articular steroid therapy in knee joint diseases</TI>
<SO>Medizinische Welt</SO>
<YR>1971</YR>
<VL>46</VL>
<PG>1841-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Legre_x002d_Boyer-2015" MODIFIED="2015-10-19 10:23:21 -0400" MODIFIED_BY="[Empty name]" NAME="Legre-Boyer 2015" YEAR="2015">
<REFERENCE MODIFIED="2015-10-19 10:23:21 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong study design.&lt;/p&gt;" NOTES_MODIFIED="2015-10-19 10:23:21 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Legre-Boyer V</AU>
<TI>Viscosupplementation: Techniques, indications, results.</TI>
<SO>Orthop Traumatol Surg Res</SO>
<YR>2015</YR>
<VL>9</VL>
<PG>S101-108</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lequesne-1970" MODIFIED="2015-07-17 12:52:25 -0400" MODIFIED_BY="[Empty name]" NAME="Lequesne 1970" YEAR="1970">
<REFERENCE MODIFIED="2015-07-17 12:52:25 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong study design.&lt;/p&gt;" NOTES_MODIFIED="2015-07-17 12:52:25 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lequesne M, Bensasson M, Kemmer C, Amouroux J</AU>
<TI>Painful juxtameniscal areas in certain arthropathies of the knee and their treatment by juxtameniscal cortisone infiltration</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>1970</YR>
<VL>29</VL>
<PG>689</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maricar-2013" MODIFIED="2015-07-17 12:52:18 -0400" MODIFIED_BY="[Empty name]" NAME="Maricar 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-07-17 12:52:18 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Abstract to relevant SR, no references listed.&lt;/p&gt;" NOTES_MODIFIED="2015-07-17 12:52:18 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maricar N, Parkes M J, Callaghan M J, Felson D T, O'Neill T W</AU>
<TI>A systematic review of where and how to inject in the knee?</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2013</YR>
<VL>21</VL>
<PG>S300</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maricar-2013c" MODIFIED="2015-07-17 12:52:10 -0400" MODIFIED_BY="[Empty name]" NAME="Maricar 2013c" YEAR="2013">
<REFERENCE MODIFIED="2015-07-17 12:52:10 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Systematic review on the topic published in or after 2004.&lt;/p&gt;" NOTES_MODIFIED="2015-07-17 12:52:10 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maricar N, Callaghan M J, Felson D T, O'Neill T W</AU>
<TI>Predictors of response to intra-articular steroid injections in knee osteoarthritis-a systematic review</TI>
<SO>Rheumatology (United Kingdom)</SO>
<YR>2013</YR>
<VL>52</VL>
<PG>1022-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maricar-2014" MODIFIED="2015-07-17 12:52:06 -0400" MODIFIED_BY="[Empty name]" NAME="Maricar 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-07-17 12:52:06 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong study design.&lt;/p&gt;" NOTES_MODIFIED="2015-07-17 12:52:06 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maricar N, Parkes M J, Forsythe L M, Felson D T, O'Neill T W</AU>
<TI>Do psychological factors predict response to intraarticular steroid therapy in knee osteoarthritis?</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2014</YR>
<VL>22</VL>
<PG>S381</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McAlindon-2014" MODIFIED="2015-07-17 12:52:02 -0400" MODIFIED_BY="[Empty name]" NAME="McAlindon 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-07-17 12:52:02 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong study design.&lt;/p&gt;" NOTES_MODIFIED="2015-07-17 12:52:02 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McAlindon T E, Bannuru R R, Sullivan M C, Arden N K, Berenbaum F, Bierma-Zeinstra S M, et al</AU>
<TI>OARSI guidelines for the non-surgical management of knee osteoarthritis</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2014</YR>
<VL>22</VL>
<PG>363-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Murdoch-1959" MODIFIED="2015-07-17 12:55:35 -0400" MODIFIED_BY="[Empty name]" NAME="Murdoch 1959" YEAR="1959">
<REFERENCE MODIFIED="2015-07-17 12:55:35 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong study design.&lt;/p&gt;" NOTES_MODIFIED="2015-07-17 12:55:35 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Murdoch W R, Will G</AU>
<TI>Prednisolone trimethylacetate in intra-articular therapy</TI>
<SO>British Medical Journal</SO>
<YR>1959</YR>
<VL>1</VL>
<PG>1267-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Murdoch-1959a" MODIFIED="2015-07-17 12:54:24 -0400" MODIFIED_BY="[Empty name]" NAME="Murdoch 1959a" YEAR="1959">
<REFERENCE MODIFIED="2015-07-17 12:54:24 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong study design.&lt;/p&gt;" NOTES_MODIFIED="2015-07-17 12:54:24 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Murdoch W R, Will G</AU>
<TI>Synovial fluid changes in intra-articular therapy: effect of prednisolone trimethylacetate</TI>
<SO>British Medical Journal</SO>
<YR>1959</YR>
<VL>1</VL>
<PG>1271-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neame-2003" MODIFIED="2015-07-17 12:55:31 -0400" MODIFIED_BY="[Empty name]" NAME="Neame 2003" YEAR="2003">
<REFERENCE MODIFIED="2015-07-17 12:55:31 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong study design.&lt;/p&gt;" NOTES_MODIFIED="2015-07-17 12:55:31 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neame R L, Doherty M</AU>
<TI>Managing osteoarthritis</TI>
<SO>Practitioner</SO>
<YR>2003</YR>
<VL>247</VL>
<PG>768-70, 773, 775</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nicol-1972" MODIFIED="2015-07-17 12:54:03 -0400" MODIFIED_BY="[Empty name]" NAME="Nicol 1972" YEAR="1972">
<REFERENCE MODIFIED="2015-07-17 12:54:03 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong study design.&lt;/p&gt;" NOTES_MODIFIED="2015-07-17 12:54:03 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nicol W J, Sarkin T L</AU>
<TI>Indications for intra-articular steroid in osteo-arthritis of the knee</TI>
<SO>South African Medical Journal. Suid-Afrikaanse Tydskrif Vir Geneeskunde</SO>
<YR>1972</YR>
<VL>46</VL>
<PG>379</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-No-named-author" MODIFIED="2015-09-17 12:06:19 -0400" MODIFIED_BY="[Empty name]" NAME="No named author" YEAR="2004">
<REFERENCE MODIFIED="2015-09-17 12:00:03 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong study design.&lt;/p&gt;" NOTES_MODIFIED="2015-09-17 12:00:03 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<TI>Steroid injections effective for knee osteoarthritis</TI>
<SO>Journal of Family Practice</SO>
<YR>2004</YR>
<VL>53</VL>
<PG>606</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-No-named-author-a" MODIFIED="2015-10-08 03:03:15 -0400" MODIFIED_BY="[Empty name]" NAME="No named author a" YEAR="2006">
<REFERENCE MODIFIED="2015-10-08 03:03:15 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong study design.&lt;/p&gt;" NOTES_MODIFIED="2015-10-08 03:03:15 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<TI>Intraarticular injections in gonarthrosis</TI>
<TO>Intraartikulare injektionen bei gonarthrose</TO>
<SO>Pharma-Kritik</SO>
<YR>2006</YR>
<VL>28</VL>
<PG>1-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-No-named-author-b" MODIFIED="2015-09-17 12:07:10 -0400" MODIFIED_BY="[Empty name]" NAME="No named author b" YEAR="2006">
<REFERENCE MODIFIED="2015-07-17 12:54:07 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong study design.&lt;/p&gt;" NOTES_MODIFIED="2015-07-17 12:54:07 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<TI>Intra-articular injections for osteoarthritis of the knee</TI>
<SO>Medical Letter on Drugs and Therapeutics</SO>
<YR>2006</YR>
<VL>48</VL>
<PG>25-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-No-named-author-c" MODIFIED="2015-09-24 05:11:59 -0400" MODIFIED_BY="[Empty name]" NAME="No named author c" YEAR="2004">
<REFERENCE MODIFIED="2015-09-24 05:11:59 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong study design.&lt;/p&gt;" NOTES_MODIFIED="2015-09-24 05:11:59 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<TI>Corticosteroids for knee OA</TI>
<SO>Pharmaceutical Journal</SO>
<YR>2004</YR>
<VL>272</VL>
<PG>465</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Parmigiani-2010" MODIFIED="2015-07-17 12:53:56 -0400" MODIFIED_BY="[Empty name]" NAME="Parmigiani 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-07-17 12:53:56 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Duplicate Reference.&lt;/p&gt;" NOTES_MODIFIED="2015-07-17 12:53:56 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Parmigiani L, Furtado R N V, Lopes R V, Ribeiro L H C, Natour J</AU>
<TI>Joint lavage associated with triamcinolone hexacetonide injection in knee osteoarthritis: A randomized double-blind controlled study</TI>
<SO>Clinical Rheumatology</SO>
<YR>2010</YR>
<VL>29</VL>
<PG>1311-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pendleton-2008" MODIFIED="2015-07-17 12:53:48 -0400" MODIFIED_BY="[Empty name]" NAME="Pendleton 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-07-17 12:53:48 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong study design.&lt;/p&gt;" NOTES_MODIFIED="2015-07-17 12:53:48 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pendleton A, Millar A, O'Kane D, Wright G D, Taggart A J</AU>
<TI>Can sonography be used to predict the response to intra-articular corticosteroid injection in primary osteoarthritis of the knee?</TI>
<SO>Scandinavian Journal of Rheumatology</SO>
<YR>2008</YR>
<VL>37</VL>
<PG>395-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Punzi-2001" MODIFIED="2015-07-17 12:53:40 -0400" MODIFIED_BY="[Empty name]" NAME="Punzi 2001" YEAR="2001">
<REFERENCE MODIFIED="2015-07-17 12:53:40 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong intervention.&lt;/p&gt;" NOTES_MODIFIED="2015-07-17 12:53:40 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Punzi L</AU>
<TI>Intra-articular sodium hyaluronate reduces pain and improves function in osteoarthritis of knee</TI>
<SO>Clinical and Experimental Rheumatology</SO>
<YR>2001</YR>
<VL>19</VL>
<PG>9-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rasmussen-1998" MODIFIED="2015-10-08 03:08:35 -0400" MODIFIED_BY="[Empty name]" NAME="Rasmussen 1998" YEAR="1998">
<REFERENCE MODIFIED="2015-10-08 03:08:35 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rasmussen S, Larsen A S, Thomsen S T, Kehlet H</AU>
<TI>Intraarticular glucocorticoid reduces pain, inflammatory response and convalescence after arthroscopic meniscectomy [abstract]</TI>
<SO>Acta Orthopaedica Scandinavica</SO>
<YR>1998</YR>
<VL>69</VL>
<NO>Suppl 282</NO>
<PG>53-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rasmussen-1998a" MODIFIED="2015-10-08 03:09:58 -0400" MODIFIED_BY="[Empty name]" NAME="Rasmussen 1998a" YEAR="1998">
<REFERENCE MODIFIED="2015-10-08 03:09:58 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rasmussen S, Larsen A S, Thomsen S T, Kehlet H</AU>
<TI>Intraarticular glucocorticoid, morphine and bupivacaine reduces pain, inflammatory response and convalescence after arthroscopic meniscectomy [abstract]</TI>
<SO>Acta Orthopaedica Scandinavica</SO>
<YR>1998</YR>
<VL>69</VL>
<NO>Suppl 280</NO>
<PG>45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rasmussen-1998b" MODIFIED="2015-10-08 03:10:52 -0400" MODIFIED_BY="[Empty name]" NAME="Rasmussen 1998b" YEAR="1998">
<REFERENCE MODIFIED="2015-10-08 03:10:52 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rasmussen S, Larsen A S, Thomsen S T, Kehlet H</AU>
<TI>Intra-articular glucocorticoid, bupivacaine and morphine reduces pain, inflammatory response and convalescence after arthroscopic meniscectomy [abstract]</TI>
<SO>Pain</SO>
<YR>1998</YR>
<VL>78</VL>
<PG>131-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reshetov-2000" MODIFIED="2015-10-08 03:12:51 -0400" MODIFIED_BY="[Empty name]" NAME="Reshetov 2000" YEAR="2000">
<REFERENCE MODIFIED="2015-10-08 03:12:51 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reshetov P P, Tverdokhleb I P, Bezmenov V A</AU>
<TI>The use of hydrocortisone combined with ultrasound with gonarthrosis patients</TI>
<SO>Voprosy Kurortologii, Fizioterapii, i Lechebnoi Fizicheskoi Kultury</SO>
<YR>2000</YR>
<NO>4</NO>
<PG>47-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ronchetti-2001" MODIFIED="2015-10-08 03:13:39 -0400" MODIFIED_BY="[Empty name]" NAME="Ronchetti 2001" YEAR="2001">
<REFERENCE MODIFIED="2015-10-08 03:13:39 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Active comparator.&lt;/p&gt;" NOTES_MODIFIED="2015-10-08 03:13:39 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ronchetti I P, Guerra D, Taparelli F, Boraldi F, Bergamini G, Mori G, et al</AU>
<TI>Morphological analysis of knee synovial membrane biopsies from a randomized controlled clinical study comparing the effects of sodium hyaluronate (Hyalgan) and methylprednisolone acetate (Depomedrol) in osteoarthritis</TI>
<SO>Rheumatology</SO>
<YR>2001</YR>
<VL>40</VL>
<PG>158-69</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roskos-2005" MODIFIED="2015-07-17 12:52:58 -0400" MODIFIED_BY="[Empty name]" NAME="Roskos 2005" YEAR="2005">
<REFERENCE MODIFIED="2015-07-17 12:52:58 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong study design.&lt;/p&gt;" NOTES_MODIFIED="2015-07-17 12:52:58 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roskos S E</AU>
<TI>Intra-articular corticosteroid for treating osteoarthritis of the knee</TI>
<SO>American Family Physician</SO>
<YR>2005</YR>
<VL>72</VL>
<PG>1222-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saito-1971" MODIFIED="2015-10-08 03:14:02 -0400" MODIFIED_BY="[Empty name]" NAME="Saito 1971" YEAR="1971">
<REFERENCE MODIFIED="2015-10-08 03:14:02 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong study design.&lt;/p&gt;" NOTES_MODIFIED="2015-10-08 03:14:02 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saito H, Asai H, Nakamura R</AU>
<TI>Effect of intra-articular injection of steroid in deforming arthrosis of the knee</TI>
<SO>Seikei Geka - Orthopedic Surgery</SO>
<YR>1971</YR>
<VL>22</VL>
<PG>612-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shah-1967" MODIFIED="2015-07-17 12:54:59 -0400" MODIFIED_BY="[Empty name]" NAME="Shah 1967" YEAR="1967">
<REFERENCE MODIFIED="2015-07-17 12:54:59 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong comparator.&lt;/p&gt;" NOTES_MODIFIED="2015-07-17 12:54:59 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shah K D, Wright V</AU>
<TI>Intra-articular hydrocortisone in osteo-arthrosis</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>1967</YR>
<VL>26</VL>
<PG>316-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sheldon-1973" MODIFIED="2015-10-08 03:14:33 -0400" MODIFIED_BY="[Empty name]" NAME="Sheldon 1973" YEAR="1973">
<REFERENCE MODIFIED="2015-10-08 03:14:33 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong patient population.&lt;/p&gt;" NOTES_MODIFIED="2015-10-08 03:14:33 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sheldon P, Beer T C</AU>
<TI>Synovitis of the knee treated by intra-articular hydrocortisone acetate, hydrocortisone acetate plus saline, or saline alone. A double-blind trial</TI>
<SO>Rheumatology and Rehabilitation</SO>
<YR>1973</YR>
<VL>12</VL>
<PG>37-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stein-1996" MODIFIED="2015-10-08 03:15:34 -0400" MODIFIED_BY="[Empty name]" NAME="Stein 1996" YEAR="1996">
<REFERENCE MODIFIED="2015-10-08 03:15:34 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Active comparator.&lt;/p&gt;" NOTES_MODIFIED="2015-10-08 03:15:34 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stein A, Helmke K, Szopko C, Stein C, Yassouridis A</AU>
<TI>Intraarticular morphine versus steroid application in gonarthrosis and arthritis in case of acute painful joint</TI>
<TO>Intraartikulare morphin - versus steroidapplikation bei gonarthrose und arthritis im akut schmerzhaften gelenk</TO>
<SO>Deutsche Medizinische Wochenschrift</SO>
<YR>1996</YR>
<VL>121</VL>
<PG>255</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stitik-2006" MODIFIED="2015-07-17 12:55:24 -0400" MODIFIED_BY="[Empty name]" NAME="Stitik 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-07-17 12:55:24 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong study design.&lt;/p&gt;" NOTES_MODIFIED="2015-07-17 12:55:24 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stitik T P, Kumar A, Foye P M</AU>
<TI>Corticosteroid injections for osteoarthritis</TI>
<SO>American Journal of Physical Medicine &amp; Rehabilitation</SO>
<YR>2006</YR>
<VL>85</VL>
<PG>S51-65; quiz S66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stojanovic-1969" MODIFIED="2015-10-08 03:16:16 -0400" MODIFIED_BY="[Empty name]" NAME="Stojanovic 1969" YEAR="1969">
<REFERENCE MODIFIED="2015-10-08 03:16:16 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong study design.&lt;/p&gt;" NOTES_MODIFIED="2015-10-08 03:16:16 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stojanovic I, Spasojevic L, Koturovic L, Josipovic D</AU>
<TI>Our results in treatment of gonarthrosis</TI>
<SO>Reumatizam</SO>
<YR>1969</YR>
<VL>16</VL>
<PG>65-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Talke-1986" MODIFIED="2015-10-08 03:16:29 -0400" MODIFIED_BY="[Empty name]" NAME="Talke 1986" YEAR="1986">
<REFERENCE MODIFIED="2015-10-08 03:16:29 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong study design.&lt;/p&gt;" NOTES_MODIFIED="2015-10-08 03:16:29 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Talke M</AU>
<TI>Intra-articular corticoid therapy with triamcinolone hexacetonide</TI>
<SO>Fortschritte der Medizin</SO>
<YR>1986</YR>
<VL>104</VL>
<PG>742-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Middelkoop-2013" MODIFIED="2015-10-08 03:20:12 -0400" MODIFIED_BY="[Empty name]" NAME="Van Middelkoop 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-10-08 03:20:12 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Abstract to relevant SR, no references listed.&lt;/p&gt;" NOTES_MODIFIED="2015-10-08 03:20:12 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Middelkoop M, Dziedzic K S, Doherty M, Zhang W, Bijlsma J W, McAlindon T E, et al</AU>
<TI>Individual patient data meta-analysis of trials investigating the effectiveness of intra-articular glucocorticoid injections in patients with knee or hip osteoarthritis: an OA Trial Bank protocol for a systematic review</TI>
<SO>Systems Review</SO>
<YR>2013</YR>
<VL>2</VL>
<PG>54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Middelkoop-2013a" MODIFIED="2015-10-08 03:19:50 -0400" MODIFIED_BY="[Empty name]" NAME="Van Middelkoop 2013a" YEAR="2013">
<REFERENCE MODIFIED="2015-09-24 05:26:49 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Abstract to relevant SR, no references listed.&lt;/p&gt;" NOTES_MODIFIED="2015-09-24 05:26:49 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Van Middelkoop M, Dziedzic K, Doherty M, Zhang W, Bijlsma J W, McAlindon T, et al</AU>
<TI>The OA trial bank: Individual patient data meta-analysis of trials investigating the effectiveness of intra-articular corticosteroid injections in patients with knee or hip oa</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2013</YR>
<VL>72</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Middelkoop-2013b" MODIFIED="2015-10-08 03:22:48 -0400" MODIFIED_BY="[Empty name]" NAME="Van Middelkoop 2013b" YEAR="2013">
<REFERENCE MODIFIED="2015-10-08 03:22:48 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong study design.&lt;/p&gt;" NOTES_MODIFIED="2015-10-08 03:22:48 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Middelkoop M, Dziedzic K, Doherty M, Zhang W, Bijlsma J, McAlindon T, et al</AU>
<TI>The oa trial bank: Individual patient data meta-analysis of trials investigating the effectiveness of intra-articular corticosteroid injections in patients with knee or hip oa</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2013</YR>
<VL>21</VL>
<PG>S259</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Middelkoop-2014" MODIFIED="2015-09-24 05:25:03 -0400" MODIFIED_BY="[Empty name]" NAME="Van Middelkoop 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-09-24 05:25:03 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Abstract to relevant SR, no references listed.&lt;/p&gt;" NOTES_MODIFIED="2015-09-24 05:25:03 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Middelkoop M, Arden N, Atchia I, Birrell F, Chao J, Lambert R, et al</AU>
<TI>The OA trial bank: Meta-analysis of individual patient data show that patients with severe pain or with inflammatory signs detected by ultrasound especially benefit from intra-articular glucocorticoids for knee or hip OA</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2014</YR>
<VL>73</VL>
<PG>749</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Middelkoop-2014a" MODIFIED="2015-07-17 12:56:22 -0400" MODIFIED_BY="[Empty name]" NAME="Van Middelkoop 2014a" YEAR="2014">
<REFERENCE MODIFIED="2015-07-17 12:56:22 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Abstract to relevant SR, no references listed.&lt;/p&gt;" NOTES_MODIFIED="2015-07-17 12:56:22 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Middelkoop M, Arden N, Atchia I, Birrell F, Chao J, Lambert R G, et al</AU>
<TI>The OA trial bank: Meta-analysis of individual patient data show that patients with severe pain or with inflammatory signs detected by ultrasound especially benefit from intra-articular glucocorticoids for knee or hip OA</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2014</YR>
<VL>22</VL>
<PG>S474-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-1998" MODIFIED="2015-07-17 12:56:18 -0400" MODIFIED_BY="[Empty name]" NAME="Wang 1998" YEAR="1998">
<REFERENCE MODIFIED="2015-07-17 12:56:18 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang J J, Ho S T, Lee S C, Tang J J S, Liaw W J</AU>
<TI>Intraarticular triamcinolone acetonide for pain control after arthroscopic knee surgery</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>1998</YR>
<VL>87</VL>
<NO>5</NO>
<PG>1113-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2015" MODIFIED="2015-10-08 03:25:03 -0400" MODIFIED_BY="[Empty name]" NAME="Wang 2015" YEAR="2015">
<REFERENCE MODIFIED="2015-10-08 03:25:03 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong study design.&lt;/p&gt;" NOTES_MODIFIED="2015-10-08 03:25:03 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang F, He X</AU>
<TI>Intra-articular hyaluronic acid and corticosteroids in the treatment of knee osteoarthritis: A meta-analysis</TI>
<SO>Experimental and Therapeutic Medicine</SO>
<YR>2015</YR>
<VL>9</VL>
<PG>493-500</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wramner-1959" MODIFIED="2015-07-17 12:56:12 -0400" MODIFIED_BY="[Empty name]" NAME="Wramner 1959" YEAR="1959">
<REFERENCE MODIFIED="2015-07-17 12:56:12 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong study design.&lt;/p&gt;" NOTES_MODIFIED="2015-07-17 12:56:12 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wramner T</AU>
<TI>The effect of intra-articular hydrocortisone therapy upon the joint temperature in osteoarthritis and rheumatoid arthritis</TI>
<SO>Acta Rheumatologica Scandinavica</SO>
<YR>1959</YR>
<VL>5</VL>
<PG>59-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yamamoto-1970" MODIFIED="2015-10-08 03:25:29 -0400" MODIFIED_BY="[Empty name]" NAME="Yamamoto 1970" YEAR="1970">
<REFERENCE MODIFIED="2015-10-08 03:25:29 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong study design.&lt;/p&gt;" NOTES_MODIFIED="2015-10-08 03:25:29 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yamamoto M, Fukuma H</AU>
<TI>Intra-articular injection of adrenocortical steroid hormone in osteoarthritis of the knee</TI>
<SO>Seikei Geka - Orthopedic Surgery</SO>
<YR>1970</YR>
<VL>21</VL>
<PG>103-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2008" MODIFIED="2015-07-17 12:56:15 -0400" MODIFIED_BY="[Empty name]" NAME="Zhang 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-07-17 12:56:15 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong study design.&lt;/p&gt;" NOTES_MODIFIED="2015-07-17 12:56:15 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang W, Moskowitz R W, Nuki G, Abramson S, Altman R D, Arden N, et al</AU>
<TI>OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2008</YR>
<VL>16</VL>
<PG>137-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2010" MODIFIED="2015-07-17 12:55:58 -0400" MODIFIED_BY="[Empty name]" NAME="Zhang 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-07-17 12:55:58 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Wrong study design.&lt;/p&gt;" NOTES_MODIFIED="2015-07-17 12:55:58 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang W, Nuki G, Moskowitz R W, Abramson S, Altman R D, Arden N K, et al</AU>
<TI>OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009</TI>
<SO>Osteoarthritis Cartilage</SO>
<YR>2010</YR>
<VL>18</VL>
<PG>476-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zuckner-1958" MODIFIED="2015-10-08 03:27:35 -0400" MODIFIED_BY="[Empty name]" NAME="Zuckner 1958" YEAR="1958">
<REFERENCE MODIFIED="2015-10-08 03:27:35 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Active comparator.&lt;/p&gt;" NOTES_MODIFIED="2015-10-08 03:27:35 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zuckner J, Machek O</AU>
<TI>Intra-articular injections of hydrocortisone, prednisolone, and their tertiary-butylacetate derivatives in patients with rheumatoid arthritis and osteoarthritis</TI>
<SO>Journal of Chronic Diseases</SO>
<YR>1958</YR>
<VL>8</VL>
<PG>637-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2015-10-08 03:31:46 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Ellis-2011" MODIFIED="2015-10-08 03:28:04 -0400" MODIFIED_BY="[Empty name]" NAME="Ellis 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-10-08 03:28:04 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Relevant outcomes, data not extractable though .&lt;/p&gt;" NOTES_MODIFIED="2015-10-08 03:28:04 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ellis M E, Lun V M Y, Preston Wiley J</AU>
<TI>Combination treatment for knee osteoarthritis</TI>
<SO>Clinical Journal of Sport Medicine</SO>
<YR>2011</YR>
<VL>21</VL>
<NO>4</NO>
<PG>374-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Friedman-1978" MODIFIED="2015-09-23 08:02:10 -0400" MODIFIED_BY="[Empty name]" NAME="Friedman 1978" YEAR="1978">
<REFERENCE MODIFIED="2015-09-23 08:02:10 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Relevant outcomes, data not extractable though .&lt;/p&gt;" NOTES_MODIFIED="2015-09-23 08:02:10 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Friedman D M, Moore M F</AU>
<TI>The efficacy of intraarticular corticosteroid for osteoarthritis of the knee</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1978</YR>
<VL>21</VL>
<PG>556</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hall-2013" MODIFIED="2015-09-24 05:31:32 -0400" MODIFIED_BY="[Empty name]" NAME="Hall 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-09-24 05:31:32 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Relevant outcomes, data not extractable though .&lt;/p&gt;" NOTES_MODIFIED="2015-09-24 05:31:32 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hall M, Courtney P, Doherty S, Latief K, Zhang W, Doherty M</AU>
<TI>Ultrasound response following intra-articular corticosteroid and a placebo injection in symptomatic osteoarthritic knees: A pilot study</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2013</YR>
<VL>72</VL>
<PG>54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hall-2014" MODIFIED="2015-09-23 08:02:36 -0400" MODIFIED_BY="[Empty name]" NAME="Hall 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-09-23 08:02:36 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Relevant outcomes, data not extractable though .&lt;/p&gt;" NOTES_MODIFIED="2015-09-23 08:02:36 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hall M, Doherty S, Courtney P, Latief K, Zhang W, Doherty M</AU>
<TI>Ultrasound detected synovial change and pain response following intra-articular injection of corticosteroid and a placebo in symptomatic osteoarthritic knees: A pilot study</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2014</YR>
<VL>73</VL>
<PG>1590-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Motyl-2013" MODIFIED="2015-10-08 03:29:03 -0400" MODIFIED_BY="[Empty name]" NAME="Motyl 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-10-08 03:29:03 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Relevant outcomes, data not extractable though .&lt;/p&gt;" NOTES_MODIFIED="2015-10-08 03:29:03 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Motyl J M, Driban J B, McAdams E, McAlindon T E</AU>
<TI>Reliability and sensitivity of the 20-meter walk test among patients with knee osteoarthritis</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2013</YR>
<VL>21</VL>
<PG>S137</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Motyl-2013a" MODIFIED="2015-10-08 03:29:34 -0400" MODIFIED_BY="[Empty name]" NAME="Motyl 2013a" YEAR="2013">
<REFERENCE MODIFIED="2015-10-08 03:29:34 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Relevant outcomes, data not extractable though .&lt;/p&gt;" NOTES_MODIFIED="2015-10-08 03:29:34 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Motyl J M, Driban J B, McAdams E, Price L L, McAlindon T E</AU>
<TI>Test-retest reliability and sensitivity of the 20-meter walk test among patients with knee osteoarthritis</TI>
<SO>BMC Musculoskeletal Disorders</SO>
<YR>2013</YR>
<VL>14</VL>
<PG>166</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Neill-2014" MODIFIED="2015-10-08 03:30:04 -0400" MODIFIED_BY="[Empty name]" NAME="O'Neill 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-10-08 03:30:04 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Relevant outcomes, data not extractable though .&lt;/p&gt;" NOTES_MODIFIED="2015-10-08 03:30:04 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Neill T W, Parkes M J, Maricar N, Gait A D, Cootes T F, Marjanovic E J, et al</AU>
<TI>Bone marrow lesions may not respond to anti-inflammatory treatments in knee osteoarthritis (OA)</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2014</YR>
<VL>22</VL>
<PG>S475</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raynauld-1999" MODIFIED="2015-09-23 08:03:32 -0400" MODIFIED_BY="[Empty name]" NAME="Raynauld 1999" YEAR="1999">
<REFERENCE MODIFIED="2015-09-23 08:03:32 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Relevant outcomes, data not extractable though .&lt;/p&gt;" NOTES_MODIFIED="2015-09-23 08:03:32 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raynauld J P</AU>
<TI>Clinical trials: Impact of intraarticular steroid injections on the progression of knee osteoarthritis</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>1999</YR>
<VL>7</VL>
<PG>348-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rezende-2012" MODIFIED="2015-09-23 08:03:44 -0400" MODIFIED_BY="[Empty name]" NAME="Rezende 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-09-23 08:03:44 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Relevant outcomes, data not extractable though .&lt;/p&gt;" NOTES_MODIFIED="2015-09-23 08:03:44 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rezende M U, Campos G C, Pailo A F, Frucchi R, Pasqualim T</AU>
<TI>Evaluation of the effect of adding corticosteroid to viscosupplementation: A prospective and randomized study</TI>
<SO>Osteoporosis International</SO>
<YR>2012</YR>
<VL>23</VL>
<PG>S132-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Singh-1996" MODIFIED="2015-10-08 03:31:46 -0400" MODIFIED_BY="[Empty name]" NAME="Singh 1996" YEAR="1996">
<REFERENCE MODIFIED="2015-10-08 03:31:46 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exclusion reason: Relevant outcomes, data not extractable though .&lt;/p&gt;" NOTES_MODIFIED="2015-10-08 03:31:46 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Singh G K, Jain S, Das S K, Sharma V</AU>
<TI>Conservative treatment of osteoarthritis (OA) of the knee vs add on intra-articular (IA) steroid injection [abstract]</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1996</YR>
<VL>49 Suppl 1</VL>
<PG>8s</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-10-08 04:22:38 -0400" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2015-10-08 04:22:38 -0400" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Altman-1996" MODIFIED="2015-08-31 11:57:49 -0400" MODIFIED_BY="[Empty name]" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman R, Brandt K, Hochberg M, Moskowitz R, Bellamy N, Bloch DA, et al</AU>
<TI>Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society. Results from a workshop</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>1996</YR>
<VL>4</VL>
<NO>4</NO>
<PG>217-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bellamy-1995" MODIFIED="2015-08-31 11:57:49 -0400" MODIFIED_BY="[Empty name]" NAME="Bellamy 1995" TYPE="JOURNAL_ARTICLE">
<AU>Bellamy N</AU>
<TI>Outcome measurement in osteoarthritis clinical trials</TI>
<SO>The Journal of Rheumatology. Supplement</SO>
<YR>1995</YR>
<VL>43</VL>
<PG>49-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brandt-1996" MODIFIED="2015-10-08 03:40:53 -0400" MODIFIED_BY="[Empty name]" NAME="Brandt 1996" TYPE="BOOK">
<AU>Brandt KD</AU>
<SO>Diagnosis and Nonsurgical Management of Osteoarthritis</SO>
<YR>1996</YR>
<EN>1st</EN>
<PB>Professional Communications, Inc.</PB>
<CY>Caddo, OK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brandt-2001" MODIFIED="2015-10-08 03:41:24 -0400" MODIFIED_BY="[Empty name]" NAME="Brandt 2001" TYPE="BOOK_SECTION">
<AU>Brandt K D</AU>
<TI>Management of osteoarthritis</TI>
<SO>Kelley&#8217;s Textbook of Rheumatology</SO>
<YR>2001</YR>
<PG>1419&#8211;32</PG>
<EN>6th</EN>
<ED>Ruddy S, Harris E D Jr, Sledge C B</ED>
<PB>W. B. Saunders Company</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clegg-2006" MODIFIED="2015-10-08 03:42:09 -0400" MODIFIED_BY="[Empty name]" NAME="Clegg 2006" TYPE="JOURNAL_ARTICLE">
<AU>Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, et al</AU>
<TI>Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis</TI>
<SO>The New England Journal of Medicine</SO>
<YR>2006</YR>
<VL>354</VL>
<NO>8</NO>
<PG>795-808</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cohen-1988" MODIFIED="2015-10-08 03:42:31 -0400" MODIFIED_BY="[Empty name]" NAME="Cohen 1988" TYPE="BOOK">
<AU>Cohen J</AU>
<SO>Statistical Power Analysis for the Behavioral Sciences</SO>
<YR>1988</YR>
<EN>2nd</EN>
<PB>Lawrence Earlbaum Associates</PB>
<CY>Hillsdale, NJ</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Creamer-1997" MODIFIED="2015-10-08 03:43:14 -0400" MODIFIED_BY="[Empty name]" NAME="Creamer 1997" TYPE="JOURNAL_ARTICLE">
<AU>Creamer P</AU>
<TI>Intra-articular corticosteroid injections in osteoarthritis: do they work and if so, how?</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>1997</YR>
<VL>56</VL>
<NO>11</NO>
<PG>634&#8211;6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-da-Costa-2012" MODIFIED="2015-10-08 03:45:47 -0400" MODIFIED_BY="[Empty name]" NAME="da Costa 2012" TYPE="COCHRANE_REVIEW">
<AU>da Costa B R, Nüesch E, Reichenbach S, Jüni P, Rutjes A W S</AU>
<TI>Doxycycline for osteoarthritis of the knee or hip</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>11</NO>
<IDENTIFIERS MODIFIED="2015-10-08 03:45:42 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-10-08 03:45:42 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD007323.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-da-Costa-2012a" MODIFIED="2015-10-08 03:46:19 -0400" MODIFIED_BY="[Empty name]" NAME="da Costa 2012a" TYPE="JOURNAL_ARTICLE">
<AU>da Costa BR, Rutjes AWS, Johnston BC, Reichenbach S, Nüesch E, Tonia T, et al</AU>
<TI>Methods to convert continuous outcomes into odds ratios of treatment response and numbers needed to treat: meta-epidemiological study</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2012</YR>
<VL>41</VL>
<NO>5</NO>
<PG>1445-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-da-Costa-2013" MODIFIED="2015-10-08 03:46:44 -0400" MODIFIED_BY="[Empty name]" NAME="da Costa 2013" TYPE="JOURNAL_ARTICLE">
<AU>da Costa BR, Nüesch E, Rutjes AW, Johnston BC, Reichenbach S, Trelle S, et al</AU>
<TI>Combining follow-up and change data is valid in meta-analyses of continuous outcomes: a meta-epidemiological study</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2013</YR>
<VL>66</VL>
<NO>8</NO>
<PG>847-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-da-Costa-2014" MODIFIED="2015-10-08 03:48:34 -0400" MODIFIED_BY="[Empty name]" NAME="da Costa 2014" TYPE="COCHRANE_REVIEW">
<AU>da Costa BR, Nüesch E, Kasteler R, Husni E, Welch V, Rutjes AW, et al</AU>
<TI>Oral or transdermal opioids for osteoarthritis of the knee or hip</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2014</YR>
<NO>9</NO>
<IDENTIFIERS MODIFIED="2015-10-08 03:48:11 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-10-08 03:48:11 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003115.pub4"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-da-Costa-2014a" MODIFIED="2015-09-23 16:56:33 -0400" MODIFIED_BY="[Empty name]" NAME="da Costa 2014a" TYPE="JOURNAL_ARTICLE">
<AU>da Costa BR, Jüni P</AU>
<TI>Systematic reviews and meta-analyses of randomized trials: principles and pitfalls</TI>
<SO>European Heart Journal</SO>
<YR>2014</YR>
<VL>35</VL>
<PG>3336-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" MODIFIED="2015-08-31 11:57:49 -0400" MODIFIED_BY="[Empty name]" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<NO>3</NO>
<PG>177-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1994" MODIFIED="2015-08-31 11:57:49 -0400" MODIFIED_BY="[Empty name]" NAME="Dickersin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K, Scherer R, Lefebvre C</AU>
<TI>Identifying relevant studies for systematic reviews</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<NO>6964</NO>
<PG>1286-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dworkin-2008" MODIFIED="2015-10-08 03:50:12 -0400" MODIFIED_BY="[Empty name]" NAME="Dworkin 2008" TYPE="JOURNAL_ARTICLE">
<AU>Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al</AU>
<TI>Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations</TI>
<SO>Journal of Pain</SO>
<YR>2008</YR>
<VL>9</VL>
<PG>105-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dworkin-2009" MODIFIED="2015-10-08 03:59:55 -0400" MODIFIED_BY="[Empty name]" NAME="Dworkin 2009" TYPE="JOURNAL_ARTICLE">
<AU>Dworkin RH, Turk DC, McDermott MP, Peirce-Sandner S, Burke LB, Cowan P, et al</AU>
<TI>Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations</TI>
<SO>Pain</SO>
<YR>2009</YR>
<VL>146</VL>
<PG>238-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2015-10-08 04:01:40 -0400" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7109</NO>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-2001" MODIFIED="2015-08-31 11:57:49 -0400" MODIFIED_BY="[Empty name]" NAME="Egger 2001" TYPE="BOOK_SECTION">
<AU>Egger M, Smith GD</AU>
<TI>Principles of and procedures for systematic reviews</TI>
<SO>Systematic Reviews in Health Care: Meta-Analysis in Context</SO>
<YR>2001</YR>
<PG>23-42</PG>
<ED>Egger M, Smith GD, Altman DG</ED>
<PB>BMJ Books</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-2003" MODIFIED="2015-10-08 04:04:46 -0400" MODIFIED_BY="[Empty name]" NAME="Egger 2003" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Jüni P, Bartlett C, Holenstein F, Sterne J</AU>
<TI>How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study</TI>
<SO>Health Technology Assessment (Winchester, England)</SO>
<YR>2003</YR>
<VL>7</VL>
<NO>1</NO>
<PG>1-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Felson-2000" MODIFIED="2015-10-08 04:03:07 -0400" MODIFIED_BY="[Empty name]" NAME="Felson 2000" TYPE="JOURNAL_ARTICLE">
<AU>Felson DT, Lawrence RC, Dieppe PA, Hirsch R, Helmick CG, Jordan JA, et al</AU>
<TI>Osteoarthritis: New insights. Part 1: The disease and its risk factors (NIH Conference)</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2000</YR>
<VL>133</VL>
<NO>8</NO>
<PG>635&#8211;46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Felson-2000a" MODIFIED="2015-10-08 04:03:43 -0400" MODIFIED_BY="[Empty name]" NAME="Felson 2000a" TYPE="JOURNAL_ARTICLE">
<AU>Felson DT, Lawrence RC, Hochberg MC, McAlindon T, Minor MA, Blair SN, et al</AU>
<TI>Osteoarthritis: New insights. Part 2: Treatment approaches (NIH Conference)</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2000</YR>
<VL>133</VL>
<NO>9</NO>
<PG>726&#8211;37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2008" MODIFIED="2015-08-31 11:57:49 -0400" MODIFIED_BY="[Empty name]" NAME="Guyatt 2008" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt G, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al</AU>
<TI>GRADE: an emerging consensus on rating quality of evidence and strength of recommendations</TI>
<SO>BMJ</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7650</NO>
<PG>924-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-G_x00f8_tzsche-2007" MODIFIED="2015-08-31 11:57:49 -0400" MODIFIED_BY="[Empty name]" NAME="Gøtzsche 2007" TYPE="JOURNAL_ARTICLE">
<AU>Gøtzsche PC, Hróbjartsson A, Maric K, Tendal B</AU>
<TI>Data extraction errors in meta-analyses that use standardized mean differences</TI>
<SO>JAMA</SO>
<YR>2007</YR>
<VL>298</VL>
<NO>4</NO>
<PG>430-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2015-08-31 11:57:49 -0400" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2015-10-08 04:06:03 -0400" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al</AU>
<TI>The Cochrane Collaboration's tool for assessing risk of bias in randomised trials</TI>
<SO>BMJ</SO>
<YR>2011</YR>
<VL>343</VL>
<PG>1-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hochberg-2012" MODIFIED="2015-08-31 12:13:27 -0400" MODIFIED_BY="[Empty name]" NAME="Hochberg 2012" TYPE="JOURNAL_ARTICLE">
<AU>Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, et al</AU>
<TI>American College of Rheumatology 2012 Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee</TI>
<SO>Arthritis Care and Research</SO>
<YR>2012</YR>
<VL>64</VL>
<NO>4</NO>
<PG>465-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-J_x00fc_ni-2001" MODIFIED="2015-10-08 04:07:04 -0400" MODIFIED_BY="[Empty name]" NAME="Jüni 2001" TYPE="JOURNAL_ARTICLE">
<AU>Jüni P, Altman DG, Egger M</AU>
<TI>Systematic reviews in health care: Assessing the quality of controlled clinical trials</TI>
<SO>BMJ</SO>
<YR>2001</YR>
<VL>323</VL>
<NO>7303</NO>
<PG>42-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-J_x00fc_ni-2006" MODIFIED="2015-10-08 04:07:32 -0400" MODIFIED_BY="[Empty name]" NAME="Jüni 2006" TYPE="JOURNAL_ARTICLE">
<AU>Jüni P, Reichenbach S, Dieppe P</AU>
<TI>Osteoarthritis: rational approach to treating the individual</TI>
<SO>Best Practice &amp; Research. Clinical Rheumatology</SO>
<YR>2006</YR>
<VL>20</VL>
<NO>4</NO>
<PG>721-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2008" MODIFIED="2015-09-24 05:41:41 -0400" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2008" TYPE="JOURNAL_ARTICLE">
<AU>Lefebvre C, Eisinga A, McDonald S, Paul N</AU>
<TI>Enhancing access to reports of randomized trials published world-wide--the contribution of EMBASE records to the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library</TI>
<SO>Emerging Themes in Epidemiology</SO>
<YR>2008</YR>
<VL>5</VL>
<NO>13</NO>
<PG>1-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McColl-2000" MODIFIED="2015-10-08 04:08:31 -0400" MODIFIED_BY="[Empty name]" NAME="McColl 2000" TYPE="JOURNAL_ARTICLE">
<AU>McColl GJ, Dolezal H, Eizenberg N</AU>
<TI>Common corticosteroid injections. An anatomical and evidence based review</TI>
<SO>Australian Family Physician</SO>
<YR>2000</YR>
<VL>29</VL>
<PG>922-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-N_x00fc_esch-2009" MODIFIED="2015-10-08 04:09:41 -0400" MODIFIED_BY="[Empty name]" NAME="Nüesch 2009" TYPE="JOURNAL_ARTICLE">
<AU>Nüesch E, Trelle S, Reichenbach S, Rutjes AWS, Bürgi E, Scherer M, et al</AU>
<TI>The effects of the exclusion of patients from the analysis in randomised controlled trials: meta-epidemiological study</TI>
<SO>BMJ</SO>
<YR>2009</YR>
<VL>339</VL>
<PG>b3244</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-N_x00fc_esch-2010" MODIFIED="2015-10-08 04:10:07 -0400" MODIFIED_BY="[Empty name]" NAME="Nüesch 2010" TYPE="JOURNAL_ARTICLE">
<AU>Nüesch E, Trelle S, Reichenbach S, Rutjes AW, Tschannen B, Altman DG, et al</AU>
<TI>Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study</TI>
<SO>BMJ</SO>
<YR>2010</YR>
<VL>341</VL>
<PG>c3515</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-N_x00fc_esch-2013" MODIFIED="2015-08-31 14:56:02 -0400" MODIFIED_BY="[Empty name]" NAME="Nüesch 2013" TYPE="JOURNAL_ARTICLE">
<AU>Nüesch E, Häuser W, Bernardy K, Barth J, Jüni P</AU>
<TI>Comparative efficacy of pharmacological and non-pharmacological interventions in fibromyalgia syndrome: network meta-analysis</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2013</YR>
<VL>72</VL>
<NO>6</NO>
<PG>955-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Peters-2008" MODIFIED="2015-08-31 14:48:27 -0400" MODIFIED_BY="[Empty name]" NAME="Peters 2008" TYPE="JOURNAL_ARTICLE">
<AU>Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L</AU>
<TI>Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2008</YR>
<VL>61</VL>
<NO>10</NO>
<PG>991-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pham-2004" MODIFIED="2015-10-08 04:12:13 -0400" MODIFIED_BY="[Empty name]" NAME="Pham 2004" TYPE="JOURNAL_ARTICLE">
<AU>Pham T, van der Heijde D, Altman RD, Anderson JJ, Bellamy N, Hochberg M, et al</AU>
<TI>OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2004</YR>
<VL>12</VL>
<NO>5</NO>
<PG>389-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reichenbach-2007" MODIFIED="2015-08-31 11:57:49 -0400" MODIFIED_BY="[Empty name]" NAME="Reichenbach 2007" TYPE="JOURNAL_ARTICLE">
<AU>Reichenbach S, Sterchi R, Scherer M, Trelle S, Burgi E, Burgi U, et al</AU>
<TI>Meta-analysis: chondroitin for osteoarthritis of the knee or hip</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2007</YR>
<VL>146</VL>
<NO>8</NO>
<PG>580-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reichenbach-2010" MODIFIED="2015-10-08 04:14:29 -0400" MODIFIED_BY="[Empty name]" NAME="Reichenbach 2010" TYPE="COCHRANE_REVIEW">
<AU>Reichenbach S, Rutjes AW, Nüesch E, Trelle S, Jüni P</AU>
<TI>Joint lavage for osteoarthritis of the knee</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>5</NO>
<IDENTIFIERS MODIFIED="2015-10-08 04:14:23 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-10-08 04:14:23 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD007320.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2015-10-08 04:14:56 -0400" MODIFIED_BY="[Empty name]" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rozental-2000" MODIFIED="2015-10-08 04:15:12 -0400" MODIFIED_BY="[Empty name]" NAME="Rozental 2000" TYPE="JOURNAL_ARTICLE">
<AU>Rozental TD, Sculco TP</AU>
<TI>Intra-articular corticosteroids: an updated overview</TI>
<SO>American Journal of Orthopedics</SO>
<YR>2000</YR>
<VL>29</VL>
<NO>1</NO>
<PG>18-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rucker-2008" MODIFIED="2015-08-31 11:57:49 -0400" MODIFIED_BY="[Empty name]" NAME="Rucker 2008" TYPE="JOURNAL_ARTICLE">
<AU>Rucker G, Schwarzer G, Carpenter JR, Schumacher M</AU>
<TI>Undue reliance on I(2) in assessing heterogeneity may mislead</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2008</YR>
<VL>8</VL>
<NO>1</NO>
<PG>79</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rutjes-2009" MODIFIED="2015-10-08 04:16:50 -0400" MODIFIED_BY="[Empty name]" NAME="Rutjes 2009" TYPE="COCHRANE_REVIEW">
<AU>Rutjes AW, Nüesch E, Sterchi R, Kalichman L, Hendriks E, Osiri M, et al</AU>
<TI>Transcutaneous electrostimulation for osteoarthritis of the knee</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2015-10-08 04:16:44 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-10-08 04:16:44 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002823.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rutjes-2009a" MODIFIED="2015-10-08 04:19:23 -0400" MODIFIED_BY="[Empty name]" NAME="Rutjes 2009a" TYPE="COCHRANE_REVIEW">
<AU>Rutjes AW, Nuesch E, Reichenbach S, Jüni P</AU>
<TI>S-Adenosylmethionine for osteoarthritis of the knee or hip</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2015-10-08 04:19:17 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-10-08 04:19:17 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD007321.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rutjes-2010" MODIFIED="2015-10-08 04:21:26 -0400" MODIFIED_BY="[Empty name]" NAME="Rutjes 2010" TYPE="COCHRANE_REVIEW">
<AU>Rutjes AW, Nuesch E, Sterchi R, Jüni P</AU>
<TI>Therapeutic ultrasound for osteoarthritis of the knee or hip</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2015-10-08 04:21:17 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-10-08 04:21:17 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003132.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2001" MODIFIED="2015-08-31 11:57:49 -0400" MODIFIED_BY="[Empty name]" NAME="Sterne 2001" TYPE="JOURNAL_ARTICLE">
<AU>Sterne JA, Egger M</AU>
<TI>Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2001</YR>
<VL>54</VL>
<NO>10</NO>
<PG>1046-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2011" MODIFIED="2015-10-08 04:22:38 -0400" MODIFIED_BY="[Empty name]" NAME="Sterne 2011" TYPE="JOURNAL_ARTICLE">
<AU>Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al</AU>
<TI>Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials</TI>
<SO>BMJ</SO>
<YR>2011</YR>
<VL>343</VL>
<PG>d4002</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thompson-1999" MODIFIED="2015-08-31 11:57:49 -0400" MODIFIED_BY="[Empty name]" NAME="Thompson 1999" TYPE="JOURNAL_ARTICLE">
<AU>Thompson SG, Sharp SJ</AU>
<TI>Explaining heterogeneity in meta-analysis: a comparison of methods</TI>
<SO>Statistics in Medicine</SO>
<YR>1999</YR>
<VL>18</VL>
<NO>20</NO>
<PG>2693-708</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES MODIFIED="2015-08-19 01:54:45 -0400" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-10-20 03:45:11 -0400" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-10-20 03:45:11 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2015-10-08 07:40:28 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Beyaz-2012">
<CHAR_METHODS MODIFIED="2015-10-08 07:40:28 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>3-arm parallel-group design</P>
<P>Trial duration: 12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-08-20 06:14:17 -0400" MODIFIED_BY="[Empty name]">
<P>82 participants with knee osteoarthritis were randomised</P>
<P>73 participants were reported at baseline</P>
<P>Number of females: 59 of 73 (81%)</P>
<P>Mean age: 69.1 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-08 07:40:28 -0400" MODIFIED_BY="[Empty name]">
<P>
<I>Experimental intervention</I>
</P>
<P>40 mg triamcinolone acetonide (1 ml) plus 20 mg bupivacaine (4 ml), single intra-articular injection</P>
<P>
<I>Control intervention</I>
</P>
<P>1 ml saline plus 20 mg bupivacaine (4 ml), single intra-articular injection</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-08-12 05:31:48 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: WOMAC pain</P>
<P>Extracted function outcome: WOMAC function</P>
<P>Maximum follow-up: 12 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-08-25 04:22:55 -0400" MODIFIED_BY="[Empty name]">
<P>Funding: Boztepe State Hospital, Ordu, Republic of Turkey</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-08 07:40:28 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Campos-2013">
<CHAR_METHODS MODIFIED="2015-10-08 07:40:28 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>2-arm parallel-group design</P>
<P>Trial duration: 24 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-08-20 06:15:33 -0400" MODIFIED_BY="[Empty name]">
<P>104 participants with knee osteoarthritis were randomised</P>
<P>104 participants were reported at baseline</P>
<P>Number of females: 79 out of 104 (76%)</P>
<P>Mean age: 63.0 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-08 07:40:28 -0400" MODIFIED_BY="[Empty name]">
<P>
<I>Experimental intervention</I>
</P>
<P>20 mg triamcinolone hexacetonide (1 ml) plus 6 ml hylan GF-20, single intra-articular injection</P>
<P>
<I>Control intervention</I>
</P>
<P>6 ml hylan GF-20 intra-articularly, single intra-articular injection</P>
<P>Quote: "Patients with bilateral disease had both knees treated with the same drug, but only one knee (reported by the patient as the worst) was included in the study"</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-10-08 07:40:28 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: WOMAC Pain</P>
<P>Extracted function outcome: WOMAC Global</P>
<P>Maximum follow-up: 24 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-08-25 04:23:09 -0400" MODIFIED_BY="[Empty name]">
<P>Funding: São Paulo Research Foundation (FAPESP) (Sao Paulo, Brazil)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-08 07:40:28 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Castro-2007">
<CHAR_METHODS MODIFIED="2015-10-08 07:40:28 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>5-arm parallel-group design</P>
<P>Trial duration: 12.9 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-10-08 07:40:28 -0400" MODIFIED_BY="[Empty name]">
<P>150 participants with knee osteoarthritis were randomised</P>
<P>Unclear number of participants with knee osteoarthritis reported at baseline</P>
<P>Number of females: 115</P>
<P>Mean age: 65.4</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-08-19 03:04:25 -0400" MODIFIED_BY="[Empty name]">
<P>
<I>Experimental intervention</I>
</P>
<P>Triamcinolone acetonide (no dosage or unit specified) + joint lavage, single intra-articular application</P>
<P>
<I>Control intervention</I>
</P>
<P>Joint lavage, single intra-articular application</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-08-20 06:27:05 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: WOMAC Pain</P>
<P>Extracted function outcome: WOMAC Function</P>
<P>Maximum follow-up: 12.9 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-08-12 05:31:48 -0400" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-08 07:40:29 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cederlof-1966">
<CHAR_METHODS MODIFIED="2015-10-08 07:40:29 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>2-arm parallel-group design</P>
<P>Trial duration: 8 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-08-25 04:17:28 -0400" MODIFIED_BY="[Empty name]">
<P>51 injections in 44 knees belonging to 44 participants with knee osteoarthritis were randomised</P>
<P>Unclear number of participants reported at baseline</P>
<P>Number of females: 41 of 44 (93.2%)</P>
<P>Mean age: Not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-08 07:40:29 -0400" MODIFIED_BY="[Empty name]">
<P>
<I>Experimental intervention</I>
</P>
<P>50 mg prednisolone acetate (2 ml), single intra-articular injection</P>
<P>
<I>Control intervention</I>
</P>
<P>2 ml physiologic saline, single intra-articular injection</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-08-25 04:20:13 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: Patient global assessment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-10-08 07:40:29 -0400" MODIFIED_BY="[Empty name]">
<P>Funding: Aktiebolaget Ferrosan, Malmö, Sweden</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-08 07:40:29 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chao-2010">
<CHAR_METHODS MODIFIED="2015-10-08 07:40:29 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>2-arm parallel-group design</P>
<P>Trial duration: 12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-10-08 07:40:29 -0400" MODIFIED_BY="[Empty name]">
<P>79 participants with knee osteoarthritis were randomised</P>
<P>79 participants were reported at baseline</P>
<P>Number of females: 2 of 79 (2.5%)</P>
<P>Mean age: 64.3 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-08 07:40:29 -0400" MODIFIED_BY="[Empty name]">
<P>
<I>Experimental intervention</I>
</P>
<P>40 mg triamcinolone acetonide (1 ml), single intra-articular injection</P>
<P>
<I>Control intervention</I>
</P>
<P>1 ml 0.9% saline, single intra-articular injection</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-08-12 05:31:48 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: WOMAC Pain</P>
<P>Extracted function outcome: WOMAC Global</P>
<P>Maximum follow-up: 12 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-10-08 07:40:29 -0400" MODIFIED_BY="[Empty name]">
<P>Funding: National Skeletal Muscle Research Center, NIH Grant HD050837</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-08 07:40:29 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Di-Sante-2012">
<CHAR_METHODS MODIFIED="2015-10-08 07:40:29 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>3-arm parallel-group design</P>
<P>Trial duration: 4 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-08-20 06:15:41 -0400" MODIFIED_BY="[Empty name]">
<P>60 participants with knee osteoarthritis were randomised</P>
<P>60 participants were reported at baseline</P>
<P>Mean age: 70.6</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-08 07:40:29 -0400" MODIFIED_BY="[Empty name]">
<P>
<I>Experimental interventions</I>
</P>
<P>40 mg methylprednisolone acetate and lidocaine hydrochloride, single intra-articular injection + Horizontal therapy* locally (10 times over 2 weeks, each lasting 30 minutes)</P>
<P>
<I>Control intervention</I>
</P>
<P>Horizontal therapy* locally (10 times over 2 weeks, each lasting 30 minutes)</P>
<P>Treatment duration: 4 weeks</P>
<P>*Horizontal therapy was described as (quote): "Placement of 4 cutaneous electrodal pads (8 x 13 cm), one in center of the popliteal, one on the patella and two others at the posterior proximal site of the thighs, with a stimulation frequency oscillating at 100 Hz between 4400 and 12346 Hz for 30 minutes"</P>
<P>Maximum follow-up: 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-08-25 04:22:38 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: Pain overall</P>
<P>Extracted function outcome: WOMAC Function</P>
<P>Maximum follow-up: 4 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-08-19 10:30:18 -0400" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-08 07:40:29 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dieppe-1980">
<CHAR_METHODS MODIFIED="2015-08-12 05:31:48 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>2-arm cross-over design</P>
<P>Trial duration: 2 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-08-20 06:15:54 -0400" MODIFIED_BY="[Empty name]">
<P>24 knees belonging to 16 participants with knee osteoarthritis were randomised</P>
<P>24 knees belonging to 16 participants were reported at baseline</P>
<P>Mean age: 65</P>
<P>Number of females: 13 out of 16 (81%)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-08 07:40:29 -0400" MODIFIED_BY="[Empty name]">
<P>
<I>Experimental intervention</I>
</P>
<P>20 mg triamcinalone hexacetonide (1 ml), single intra-articular injection</P>
<P>
<I>Control intervention</I>
</P>
<P>1 ml of saline, single intra-articular injection</P>
<P>Cross-over after 1 week. Every participant received 1 injection (experimental and control) each</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-08-19 10:37:08 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: Pain overall</P>
<P>Maximum follow-up: 1 week</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-10-08 07:40:29 -0400" MODIFIED_BY="[Empty name]">
<P>2 trials were reported in the same paper. Trial A did not report pain outcomes seperately for treatment and intervention and was excluded. Trial B was included in the analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-08 07:40:29 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Friedman-1980">
<CHAR_METHODS MODIFIED="2015-10-08 07:40:29 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>2-arm parallel-group design</P>
<P>Trial duration: 8 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-08-20 06:16:15 -0400" MODIFIED_BY="[Empty name]">
<P>34 participants with knee osteoarthritis were randomised</P>
<P>34 participants were reported at baseline</P>
<P>Number of females: Not reported</P>
<P>Mean age: 60.0 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-08 07:40:29 -0400" MODIFIED_BY="[Empty name]">
<P>
<I>Experimental intervention</I>
</P>
<P>20 mg triamcinolone hexacetonide, single intra-articular injection</P>
<P>
<I>Control intervention</I>
</P>
<P>"Polysorbate, sorbitol solution, benzyl alcohol and water", single intra-articular injection</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-08-12 05:31:48 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: Pain overall</P>
<P>Maximum follow-up: 8 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-10-08 07:40:29 -0400" MODIFIED_BY="[Empty name]">
<P>Funding: Grant from the Eastern Pennsylvania Chapter of the Arthritis Foundation and by the Philadelphia Foundation</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-19 08:48:38 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fri_x0301_as-2004">
<CHAR_METHODS MODIFIED="2015-10-08 07:40:39 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>2-arm parallel-group design</P>
<P>Trial duration: 12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-10-19 08:48:38 -0400" MODIFIED_BY="[Empty name]">
<P>299 knees belonging to 205 participants with knee osteoarthritis were randomised</P>
<P>299 knees belonging to 205 participants were reported at baseline</P>
<P>Number of females: 234 (78%) of 299 knees belonged to female participants</P>
<P>Mean age: 67.0 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-08 07:40:39 -0400" MODIFIED_BY="[Empty name]">
<P>
<I>Experimental intervention</I>
</P>
<P>40 mg triamcinolone acetonide plus lavage (3 L of cold (8°C) saline), single intra-articular application</P>
<P>
<I>Control intervention</I>
</P>
<P>Lavage (3 L of cold (8°C) saline), single intra-articular application</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-10-08 07:40:39 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: Pain overall</P>
<P>Maximum follow-up: 12 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-08-20 05:03:22 -0400" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-08 07:40:39 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gaffney-1995">
<CHAR_METHODS MODIFIED="2015-10-08 07:40:39 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>2-arm parallel-group design</P>
<P>Trial duration: 6 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-08-20 06:16:24 -0400" MODIFIED_BY="[Empty name]">
<P>84 participants with knee osteoarthritis were randomised</P>
<P>84 participants were reported at baseline</P>
<P>Number of females: 60 out of 84 (71%)</P>
<P>Mean age: 67.0 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-08 07:40:39 -0400" MODIFIED_BY="[Empty name]">
<P>
<I>Experimental intervention</I>
</P>
<P>20 mg triamcinolone hexacetonide (1 ml), single intra-articular injection</P>
<P>
<I>Control intervention</I>
</P>
<P>1 ml of 0.9% normal saline, single intra-articular injection</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-08-12 05:31:48 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: Pain overall</P>
<P>Extracted function outcome: Other function composite</P>
<P>Maximum follow-up: 6 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-08-12 05:31:48 -0400" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-08 07:40:39 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Grecomoro-1992">
<CHAR_METHODS MODIFIED="2015-10-08 07:40:39 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>2-arm cross-over design</P>
<P>Trial duration: 8.6 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-10-08 07:40:39 -0400" MODIFIED_BY="[Empty name]">
<P>40 participants with knee osteoarthritis were randomised</P>
<P>40 participants were reported at baseline</P>
<P>Number of females: 27 out of 40 (67.5%)</P>
<P>Mean age: 42.3 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-08 07:40:39 -0400" MODIFIED_BY="[Empty name]">
<P>
<I>Experimental intervention</I>
</P>
<P>0.4 mg dexamethasonephosphate plus 20 mg sodium hyaluronate in 2 ml phosphate buffer, 5 intra-articular injections, 1 weekly for 5 weeks</P>
<P>
<I>Control intervention</I>
</P>
<P>20 mg sodium hyaluronate in 2 ml phosphate buffer, 5 intra-articular injections, 1 weekly for 5 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-08-25 04:09:04 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: Pain on activities other than walking</P>
<P>Maximum follow-up: 8.6 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-08-12 05:31:48 -0400" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-08 07:40:39 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Henriksen-2015">
<CHAR_METHODS MODIFIED="2015-10-08 07:40:39 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>2-arm parallel-group design</P>
<P>Trial duration: 26 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-08-20 06:16:43 -0400" MODIFIED_BY="[Empty name]">
<P>100 participants with knee osteoarthritis were randomised</P>
<P>100 participants were reported at baseline</P>
<P>Number of females: 61 out of 100 (61%)</P>
<P>Mean age: 63.4 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-08 07:40:39 -0400" MODIFIED_BY="[Empty name]">
<P>
<I>Experimental intervention</I>
</P>
<P>40 mg methylprednisolone acetate (1 ml) dissolved in 4 ml of lidocaine hydrochloride, single intra-articular injection + 12-week exercise program</P>
<P>
<I>Control intervention</I>
</P>
<P>1 ml isotonic saline mixed with 4 ml of lidocaine hydrochloride, single intra-articular injection + 12-week exercise program</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-08-19 04:16:09 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: Other pain composite</P>
<P>Extracted pain function: Other function composite</P>
<P>Maximum follow-up: 26 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-08-25 04:23:27 -0400" MODIFIED_BY="[Empty name]">
<P>Funding: Grants by: 10-093704 from the Danish Council for Independent Research Medical Science, Oak Foundation, Association of Danish Physiotherapists, Lundbeck Foundation, Capital Region of Denmark</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-08 07:40:40 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jones-1996">
<CHAR_METHODS MODIFIED="2015-10-08 07:40:40 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>2-arm cross-over design</P>
<P>Trial duration: 16 weeks<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-08-20 06:16:51 -0400" MODIFIED_BY="[Empty name]">
<P>59 participants with knee osteoarthritis were randomised</P>
<P>59 participants were reported at baseline</P>
<P>Number of females: 37 out of 59 (63%)</P>
<P>Mean age: 70.6 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-08 07:40:40 -0400" MODIFIED_BY="[Empty name]">
<P>
<I>Experimental intervention</I>
</P>
<P>40 mg methyl prednisolone acetate (1 ml), single intra-articular injection</P>
<P>
<I>Control intervention</I>
</P>
<P>1 ml 0.9% saline, single intra-articular injection</P>
<P>Cross-over after 8 weeks. Every participant received 1 injection (experimental and control) each</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-08-12 05:31:48 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: Pain on activities other than walking</P>
<P>Maximum follow-up: 8 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-08-12 05:31:48 -0400" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-08 07:40:40 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lyons-2005">
<CHAR_METHODS MODIFIED="2015-10-08 07:40:40 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>2-arm parallel-group design</P>
<P>Trial duration: 8.6 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-10-08 07:40:40 -0400" MODIFIED_BY="[Empty name]">
<P>20 participants with knee osteoarthritis were randomised</P>
<P>Unclear number of participants with knee osteoarthritis reported at baseline</P>
<P>Number of females: 11</P>
<P>Mean age: 59.7</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-08 07:40:40 -0400" MODIFIED_BY="[Empty name]">
<P>
<I>Experimental intervention</I>
</P>
<P>80 mg methylprednisolone (2 ml) + 5 ml 1% lignocaine, single intra-articular injection</P>
<P>
<I>Control intervention</I>
</P>
<P>10 ml of 1% lignocaine, single intra-articular injection</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-08-20 06:29:03 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: Pain overall</P>
<P>Extracted function outcome: Global disability score</P>
<P>Maximum follow-up: 8.6 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-08-25 04:23:40 -0400" MODIFIED_BY="[Empty name]">
<P>Funding: West London Research Network, Primary Care Scientist Award funded by the Department of Health</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-08 07:40:40 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Miller-1958">
<CHAR_METHODS MODIFIED="2015-10-08 07:40:40 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>5-arm parallel-group design</P>
<P>Trial duration: 33.8 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-10-08 07:40:40 -0400" MODIFIED_BY="[Empty name]">
<P>202 participants with knee osteoarthritis were randomised</P>
<P>Unclear number of participants reported at baseline</P>
<P>Number of females: 122</P>
<P>Mean age: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-08 07:40:40 -0400" MODIFIED_BY="[Empty name]">
<P>
<I>Experimental intervention</I>
</P>
<P>50 mg of hydrocortisone (2 ml) + 8 ml of physiological normal saline, 5 intra-articular injections, interval of 2 weeks</P>
<P>
<I>Control intervention</I>
</P>
<P>Physiological normal saline solution (no dosage), 5 intra-articular injections, interval of 2 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-10-08 07:40:40 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: Patients' global assessment</P>
<P>Maximum follow-up: 25.8 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-08-12 05:31:48 -0400" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-08 07:40:40 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00414427">
<CHAR_METHODS MODIFIED="2015-10-08 07:40:40 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>2-arm parallel-group design</P>
<P>Trial duration: 12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-10-08 07:40:40 -0400" MODIFIED_BY="[Empty name]">
<P>79 participants with knee osteoarthritis were randomised</P>
<P>79 participants were reported at baseline</P>
<P>Number of females: 3 out of 79 (4%)</P>
<P>Mean age: 63.0 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-08 07:40:40 -0400" MODIFIED_BY="[Empty name]">
<P>
<I>Experimental intervention</I>
</P>
<P>40 mg triamcinolone acetonide, single intra-articular injection</P>
<P>
<I>Control intervention</I>
</P>
<P>0.9% saline (no dosage), single intra-articular injection</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-08-19 04:19:23 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: WOMAC Pain</P>
<P>Maximum follow-up: 12 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-08-25 04:23:32 -0400" MODIFIED_BY="[Empty name]">
<P>Funding: University of California, San Diego</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-08 07:40:40 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ozturk-2006">
<CHAR_METHODS MODIFIED="2015-10-08 07:40:40 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>2-arm parallel-group design</P>
<P>Trial duration: 52 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-08-20 06:18:04 -0400" MODIFIED_BY="[Empty name]">
<P>47 participants with knee osteoarthritis were randomised</P>
<P>40 participants were reported at baseline</P>
<P>Number of females: 39 out of 47 (83%)</P>
<P>Mean age: 58.0 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-08 07:40:40 -0400" MODIFIED_BY="[Empty name]">
<P>
<I>Experimental intervention</I>
</P>
<P>40 mg triamcinolone acetonide (1 ml) plus 2 ml sodium hyaluronate. Sodium hyaluronate was administered in 3 intra-articular injections in the first month and 3 intra-articular injections during the sixth month, triamcinolone acid was added prior to the first and fourth application.</P>
<P>
<I>Control intervention</I>
</P>
<P>2 ml sodium hyaluronate, 3 intra-articular injections in the first month, and 3 intra-articular injections during the sixth month</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-08-25 03:50:07 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: WOMAC Pain</P>
<P>Maximum follow-up: 25.9 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-08-19 11:17:32 -0400" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-08 07:40:40 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Petrella-2015">
<CHAR_METHODS MODIFIED="2015-10-08 07:40:40 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>2-arm parallel-group design</P>
<P>Trial duration: 26 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-08-20 06:18:40 -0400" MODIFIED_BY="[Empty name]">
<P>98 participants with knee osteoarthritis were randomised</P>
<P>98 participants were reported at baseline</P>
<P>Number of females: 56 out of 98 (57%)</P>
<P>Mean age: 59.7 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-08 07:40:40 -0400" MODIFIED_BY="[Empty name]">
<P>
<I>Experimental intervention</I>
</P>
<P>10 mg triamcinolone acetonide + hyaluronan solution (no dosage stated), 6 ml total, single intra-articular injection</P>
<P>
<I>Control intervention</I>
</P>
<P>Hyaluronan solution (no dosage stated), single intra-articular injection</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-10-08 07:40:40 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: WOMAC Pain</P>
<P>Extracted function outcome: WOMAC Function</P>
<P>Maximum follow-up: 26 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-08-25 04:23:50 -0400" MODIFIED_BY="[Empty name]">
<P>Funding: Carbylan Therapeutics</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-19 08:50:58 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Popov-1989">
<CHAR_METHODS MODIFIED="2015-10-08 07:40:40 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>5-arm parallel-group design</P>
<P>Trial duration: 2.7 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-10-08 07:40:40 -0400" MODIFIED_BY="[Empty name]">
<P>48 participants with knee osteoarthritis were randomised</P>
<P>Unclear number of participants with knee osteoarthritis reported at baseline</P>
<P>Number of females: 38</P>
<P>Mean age: 55 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-08 07:40:40 -0400" MODIFIED_BY="[Empty name]">
<P>
<I>Experimental interventions</I>
</P>
<P>Intervention (A): 40 mg triamcinolone, 3 intra-articular injections, interval 1 week</P>
<P>Intervention (B): 50 mg hydrocortisone, 3 intra-articular injections, interval 1 week</P>
<P>
<I>Control intervention</I>
</P>
<P>Saline solution (no dosage stated), 2 intra-articular injections, interval 1 week</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-10-19 08:50:58 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: (A)-(B): other algofunctional</P>
<P>Extracted function outcome: (A)-(B): other algofunctional</P>
<P>Maximum follow-up: 0.7 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-08-12 05:31:48 -0400" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-08 07:41:18 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ravaud-1999">
<CHAR_METHODS MODIFIED="2015-10-08 07:41:18 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>2 x 2 factorial design</P>
<P>Trial duration: 24 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-08-20 06:19:28 -0400" MODIFIED_BY="[Empty name]">
<P>98 participants with knee osteoarthritis were randomised</P>
<P>98 participants were reported at baseline</P>
<P>Number of females: 66 out of 98 (67%)</P>
<P>Mean age: 65.4</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-08 07:41:18 -0400" MODIFIED_BY="[Empty name]">
<P>
<I>Experimental interventions</I>
</P>
<P>Intervention (A): 3.75 mg cortivazol (1.5 ml), single intra-articular injection</P>
<P>Intervention (B): Lavage, single intra-articular application + 3.75 mg cortivazol (1.5 ml), single intra-articular injection</P>
<P>
<I>Control intervention</I>
</P>
<P>Intervention (A): 1.5 ml 0.9% normal saline, single intra-articular injection</P>
<P>Intervention (B): Lavage, single intra-articular application</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-10-08 07:41:18 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: Pain overall</P>
<P>Extracted function outcome: Lequesne index</P>
<P>Maximum follow-up: 24 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-08-25 04:24:00 -0400" MODIFIED_BY="[Empty name]">
<P>Funding: Société Française de Rhumatologie and the Direction de la Recherche Clinique (Assistance Publique - Hôpitaux de Paris)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-08 07:41:18 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Raynauld-2003">
<CHAR_METHODS MODIFIED="2015-10-08 07:41:18 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>2-arm parallel-group design</P>
<P>Trial duration: 54 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-08-20 06:19:39 -0400" MODIFIED_BY="[Empty name]">
<P>68 participants with knee osteoarthritis were randomised</P>
<P>68 participants were reported at baseline</P>
<P>Number of females: 42 out of 68 (68%)</P>
<P>Mean age: 63.2 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-08 07:41:18 -0400" MODIFIED_BY="[Empty name]">
<P>
<I>Experimental intervention</I>
</P>
<P>40 mg triamcinolone acetonide (1 ml), 8 intra-articular injections, interval 3 months, over 21 months</P>
<P>
<I>Control intervention</I>
</P>
<P>1 ml saline intra-articularly, 8 intra-articular injections, interval 3 months, over 21 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-08-20 06:31:33 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: WOMAC Pain. After end of treatment (during follow-up)</P>
<P>Extracted function outcome: WOMAC Function. After end of treatment (during follow-up)</P>
<P>Maximum follow-up: 12.9 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-08-25 04:24:05 -0400" MODIFIED_BY="[Empty name]">
<P>Funding: Fonds de la recherche en santé du Québec</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-08 07:41:19 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schue-2011">
<CHAR_METHODS MODIFIED="2015-10-08 07:41:18 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>3-arm parallel-group design</P>
<P>Trial duration: 8 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-08-20 06:19:56 -0400" MODIFIED_BY="[Empty name]">
<P>16 participants with knee osteoarthritis were randomised</P>
<P>Unclear number of participants with knee osteoarthritis reported at baseline</P>
<P>Number of females: not reported</P>
<P>Mean age: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-08 07:41:19 -0400" MODIFIED_BY="[Empty name]">
<P>
<I>Experimental intervention</I>
</P>
<P>80 mg methylprednisolone, single intra-articular injection</P>
<P>
<I>Control intervention</I>
</P>
<P>Saline (no dosage specified), single intra-articular injection</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-08-20 06:31:50 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: WOMAC Global</P>
<P>Maximum follow-up: 8 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-08-12 05:31:48 -0400" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-08 07:41:19 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Smith-2003">
<CHAR_METHODS MODIFIED="2015-10-08 07:41:19 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>2-arm parallel-group design</P>
<P>Trial duration: 24 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-08-20 06:20:10 -0400" MODIFIED_BY="[Empty name]">
<P>77 participants with knee osteoarthritis were randomised</P>
<P>71 participants were reported at baseline</P>
<P>Number of females: 27 out of 77 (35%)</P>
<P>Mean age: 66.8 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-08 07:41:19 -0400" MODIFIED_BY="[Empty name]">
<P>
<I>Experimental intervention</I>
</P>
<P>120 mg methylprednisolone acetate following joint lavage, single intra-articular injection</P>
<P>
<I>Control intervention</I>
</P>
<P>Treatment duration: 1 day</P>
<P>Normal saline (no dosage) following joint lavage, single intra-articular injection</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-08-12 05:31:48 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: WOMAC Pain</P>
<P>Extracted function outcome: WOMAC Function</P>
<P>Maximum follow-up: 24 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-10-08 07:41:19 -0400" MODIFIED_BY="[Empty name]">
<P>Funding: National Health and Medical Research Council (Australia) Arthritis Foundation of Australia</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-08 07:41:19 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wright-1960">
<CHAR_METHODS MODIFIED="2015-10-08 07:41:19 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>3-arm parallel-group design</P>
<P>Trial duration: 20 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-10-08 07:41:19 -0400" MODIFIED_BY="[Empty name]">
<P>38 knees belonging to 25 participants with knee osteoarthritis were randomised</P>
<P>Unclear number of participants with knee osteoarthritis reported at baseline</P>
<P>Number of females: not stated</P>
<P>Mean age: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-08 07:41:19 -0400" MODIFIED_BY="[Empty name]">
<P>
<I>Experimental intervention</I>
</P>
<P>Intervention (A): 25 mg hydrocortisone acetate (1 ml), 4 intra-articular injections, interval 2 weeks over 6 weeks</P>
<P>Intervention (B): 25 mg hydrocortisone tertiary-butylacetate (1 ml), 4 intra-articular injections, interval 2 weeks over 6 weeks</P>
<P>
<I>Control intervention</I>
</P>
<P>1 ml of placebo, 4 intra-articular injections, interval 2 weeks over 6 weeks</P>
<P>Cross-over design, every participant received 3 x 4 injections</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-08-29 06:42:51 -0400" MODIFIED_BY="[Empty name]">
<P>Only information on adverse events was extracted</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-08-29 16:41:10 -0400" MODIFIED_BY="[Empty name]">
<P>There was no extractable data on pain or function</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-08 07:41:19 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yavuz-2012">
<CHAR_METHODS MODIFIED="2015-10-08 07:41:19 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>4-arm parallel-group design</P>
<P>Trial duration: 12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-08-20 06:20:18 -0400" MODIFIED_BY="[Empty name]">
<P>120 participants with knee osteoarthritis were randomised</P>
<P>120 participants were reported at baseline</P>
<P>Number of females: 76 out of 120 (63%)</P>
<P>Mean age: 60.0 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-08 07:41:19 -0400" MODIFIED_BY="[Empty name]">
<P>
<I>Experimental intervention</I>
</P>
<P>Intervention (A): 40 mg triamsinolon acetonate (1 ml), single intra-articular injection</P>
<P>Intervention (B): 3 mg betametazone disodium phosphate (1 ml), single intra-articular injection</P>
<P>Intervention (C): 40 mg methylprednisolone acetate (1 ml), single intra-articular injection</P>
<P>
<I>Control intervention</I>
</P>
<P>1 ml 0.9% sodium chloride, single intra-articular injection</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-08-19 05:13:21 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome (A)-(C): Pain overall</P>
<P>Extracted function outcome (A)-(C): Lequesne index</P>
<P>Maximum follow-up: 12 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-08-12 05:31:48 -0400" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-08 07:41:19 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Young-2001">
<CHAR_METHODS MODIFIED="2015-10-08 07:41:19 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>2-arm parallel-group design</P>
<P>Trial duration: 4.3 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-08-20 06:20:48 -0400" MODIFIED_BY="[Empty name]">
<P>41 knees belonging to 40 participants with knee osteoarthritis were randomised</P>
<P>Unclear number of participants with knee osteoarthritis reported at baseline</P>
<P>Number of females: 16</P>
<P>Mean age: 66.5 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-08 07:41:19 -0400" MODIFIED_BY="[Empty name]">
<P>
<I>Experimental intervention</I>
</P>
<P>120 mg methylprednisolone acetate, single intra-articular injection</P>
<P>
<I>Control intervention</I>
</P>
<P>Normal saline (no dosage stated), single intra-articular injection</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-08-20 06:32:12 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: WOMAC Global</P>
<P>Extracted function outcome: Other function composite</P>
<P>Maximum follow-up: 4.3 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-08-25 04:24:19 -0400" MODIFIED_BY="[Empty name]">
<P>Funding: National Health and Medical Research Council, The Clive and Vera Ramaciotti Trust, The Rebecca L. Cooper Foundation, University of New South Wales, The Arthritis Foundation of Australia, The Royal Australasian College of Physicians<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-10-08 07:41:41 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhilyayev-2012">
<CHAR_METHODS MODIFIED="2015-10-08 07:41:41 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>4-arm parallel-group design</P>
<P>Trial duration: 12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-08-20 06:20:59 -0400" MODIFIED_BY="[Empty name]">
<P>209 knees belonging to 112 participants were randomised</P>
<P>Unclear number of participants with knee osteoarthritis reported at baseline</P>
<P>Number of females: not stated</P>
<P>Mean age: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-08 07:41:41 -0400" MODIFIED_BY="[Empty name]">
<P>
<I>Experimental intervention</I>
</P>
<P>20 mg triamcinolone acetonid plus 10 ml 0.5% procaine, single intra-articular injection</P>
<P>
<I>Control intervention</I>
</P>
<P>10 ml 0.5% procaine, single intra-articular injection</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-08-12 05:31:48 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: WOMAC Pain</P>
<P>Maximum follow-up: 12 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-08-19 05:20:52 -0400" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>IA: intra-articular<BR/>WOMAC: Western Ontario and McMaster Universities Arthritis Index<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-10-19 10:51:50 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2015-09-12 09:54:51 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Abdulla-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-12 09:54:51 -0400" MODIFIED_BY="[Empty name]">
<P>Recent systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:01:23 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anonymous-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:01:23 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:01:36 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anonymous-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:01:36 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-12 09:54:56 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Arroll-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-12 09:54:56 -0400" MODIFIED_BY="[Empty name]">
<P>Recent systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:01:57 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Arroll-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:01:57 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-12 09:54:58 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Avouac-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-12 09:54:58 -0400" MODIFIED_BY="[Empty name]">
<P>Recent systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:02:10 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baker-1969">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:02:10 -0400" MODIFIED_BY="[Empty name]">
<P>Active comparator</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-10-08 07:41:41 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bannuru-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-10-08 07:41:41 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design: Abstract to relevant systematic review, no references listed</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-10-08 07:41:41 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bannuru-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-10-08 07:41:41 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design: Abstract to relevant systematic review, no references listed</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-12 09:55:04 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bannuru-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-12 09:55:04 -0400" MODIFIED_BY="[Empty name]">
<P>Recent systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:02:39 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baratham-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:02:39 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-12 09:55:06 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bellamy-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-12 09:55:06 -0400" MODIFIED_BY="[Empty name]">
<P>Recent systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-12 09:55:08 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bellamy-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-12 09:55:08 -0400" MODIFIED_BY="[Empty name]">
<P>Recent systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:02:58 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bennell-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:02:58 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-12 09:55:15 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bjordal-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-12 09:55:15 -0400" MODIFIED_BY="[Empty name]">
<P>Recent systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:03:45 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Blanke-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:03:45 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:03:52 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bourne-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:03:52 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:03:58 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brys-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:03:58 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:04:30 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Canillas-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:04:30 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:04:48 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cats-1979b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:04:48 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:05:11 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Charalambous-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:05:11 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-12 09:55:20 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cheng-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-12 09:55:20 -0400" MODIFIED_BY="[Empty name]">
<P>Recent systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:05:31 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Courtney-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:05:31 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:06:11 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Douglas-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:06:11 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:06:49 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gait-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:06:49 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-10-08 07:41:41 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garg-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-10-08 07:41:41 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design: Abstract to relevant systematic review<BR/>, no references listed</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-10-19 10:51:50 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garg-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-10-19 10:51:50 -0400" MODIFIED_BY="[Empty name]">
<P>Reason for exclusion</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:07:34 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gerlag-2008a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:07:34 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-12 09:55:28 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Godwin-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-12 09:55:28 -0400" MODIFIED_BY="[Empty name]">
<P>Recent systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:07:45 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Habib-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:07:45 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:07:53 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Habib-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:07:53 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-10-19 10:51:49 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hepper-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-10-19 10:51:49 -0400" MODIFIED_BY="[Empty name]">
<P>Reason for exclusion</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-10-19 10:51:19 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hirsch-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-10-19 10:51:19 -0400" MODIFIED_BY="[Empty name]">
<P>Reason for exclusion</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:09:11 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ivanov-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:09:11 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong comparator</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:09:18 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jarner-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:09:18 -0400" MODIFIED_BY="[Empty name]">
<P>Active comparator</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:09:23 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jones-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:09:23 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:09:28 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jones-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:09:28 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:09:35 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Keagy-1967">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:09:35 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:09:41 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Khitrov-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:09:41 -0400" MODIFIED_BY="[Empty name]">
<P>Active comparator</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-10-08 07:41:41 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kizilkaya-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-10-08 07:41:41 -0400" MODIFIED_BY="[Empty name]">
<P>Postsurgical setting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-10-08 07:41:41 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kizilkaya-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-10-08 07:41:41 -0400" MODIFIED_BY="[Empty name]">
<P>Postsurgical setting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-10-08 07:41:41 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Koyonos-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-10-08 07:41:41 -0400" MODIFIED_BY="[Empty name]">
<P>Postsurgical setting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:10:01 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Krause-1971">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:10:01 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:10:07 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Legre_x002d_Boyer-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:10:07 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:10:13 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lequesne-1970">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:10:13 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-10-08 07:41:41 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maricar-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-10-08 07:41:41 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design: Abstract to relevant systematic review<BR/>, no references listed</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-12 09:47:38 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maricar-2013c">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-12 09:47:38 -0400" MODIFIED_BY="[Empty name]">
<P>Recent systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:10:47 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maricar-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:10:47 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:10:54 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McAlindon-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:10:54 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:11:13 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Murdoch-1959">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:11:13 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:11:18 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Murdoch-1959a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:11:18 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:11:21 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Neame-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:11:21 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:11:45 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nicol-1972">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:11:45 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:11:29 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-No-named-author">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:11:29 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:11:35 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-No-named-author-a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:11:35 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:11:37 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-No-named-author-b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:11:37 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:05:26 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-No-named-author-c">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:05:26 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-10-08 07:41:41 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Parmigiani-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-10-08 07:41:41 -0400" MODIFIED_BY="[Empty name]">
<P>Duplicate reference</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:12:09 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pendleton-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:12:09 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:12:14 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Punzi-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:12:14 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-10-08 07:41:41 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rasmussen-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-10-08 07:41:41 -0400" MODIFIED_BY="[Empty name]">
<P>Postsurgical setting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-10-08 07:41:41 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rasmussen-1998a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-10-08 07:41:41 -0400" MODIFIED_BY="[Empty name]">
<P>Postsurgical setting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-10-08 07:41:41 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rasmussen-1998b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-10-08 07:41:41 -0400" MODIFIED_BY="[Empty name]">
<P>Postsurgical setting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-08-19 02:16:23 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reshetov-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-08-19 02:16:23 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong comparator</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:12:47 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ronchetti-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:12:47 -0400" MODIFIED_BY="[Empty name]">
<P>Active comparator</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:12:54 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Roskos-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:12:54 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:13:01 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saito-1971">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:13:01 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:13:21 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shah-1967">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:13:21 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong comparator</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:13:27 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sheldon-1973">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:13:27 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:13:49 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stein-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:13:49 -0400" MODIFIED_BY="[Empty name]">
<P>Active comparator</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:14:10 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stitik-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:14:10 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:14:16 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stojanovic-1969">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:14:16 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:14:21 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Talke-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:14:21 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-10-08 07:41:42 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-Middelkoop-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-10-08 07:41:42 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design: Abstract to relevant systematic review<BR/>, no references listed</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-10-08 07:41:42 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-Middelkoop-2013a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-10-08 07:41:42 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design: Abstract to relevant systematic review<BR/>, no references listed</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:14:46 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-Middelkoop-2013b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:14:46 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-10-08 07:41:42 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-Middelkoop-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-10-08 07:41:42 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design: Abstract to relevant systematic review<BR/>, no references listed</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-10-08 07:41:42 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-Middelkoop-2014a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-10-08 07:41:42 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design: Abstract to relevant systematic review<BR/>, no references listed</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-10-08 07:41:42 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-10-08 07:41:42 -0400" MODIFIED_BY="[Empty name]">
<P>Postsurgical setting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:15:13 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:15:13 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:15:20 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wramner-1959">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:15:20 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:15:36 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yamamoto-1970">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:15:36 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:17:23 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:17:23 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:17:28 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:17:28 -0400" MODIFIED_BY="[Empty name]">
<P>Wrong study design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-17 13:17:33 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zuckner-1958">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-17 13:17:33 -0400" MODIFIED_BY="[Empty name]">
<P>Active comparator</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2015-10-08 07:41:43 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2015-10-08 07:41:42 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ellis-2011">
<CHAR_METHODS MODIFIED="2015-10-08 07:41:42 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>2-arm parallel-group design</P>
<P>Trial duration: 12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-10-08 07:41:42 -0400" MODIFIED_BY="[Empty name]">
<P>16 participants with knee osteoarthritis were randomised</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-08 07:41:42 -0400" MODIFIED_BY="[Empty name]">
<P>
<I>Experimental intervention</I>
</P>
<P>3-month exercise program plus 40 mg triamcinolone mixed with 4 ml 1% lidocaine, single intra-articular injection</P>
<P>
<I>Control intervention</I>
</P>
<P>3-month exercise program plus 1 ml normal saline mixed with 4 ml 1% lidocaine, single intra-articular injection</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-23 11:49:36 -0400" MODIFIED_BY="[Empty name]">
<P>Maximum follow-up: 12 weeks</P>
<P>Outcome data (KOOS pain and function, WOMAC pain and function) not extractable</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-23 11:48:28 -0400" MODIFIED_BY="[Empty name]"/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2015-10-08 07:41:42 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Friedman-1978">
<CHAR_METHODS MODIFIED="2015-10-08 07:41:42 -0400" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-10-08 07:41:42 -0400" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-08 07:41:42 -0400" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-23 11:48:20 -0400" MODIFIED_BY="[Empty name]">
<P>Outcome data not extractable</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-23 11:48:17 -0400" MODIFIED_BY="[Empty name]"/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2015-10-08 07:41:42 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hall-2013">
<CHAR_METHODS MODIFIED="2015-10-08 07:41:42 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>2-arm parallel-group design</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-23 11:45:41 -0400" MODIFIED_BY="[Empty name]">
<P>25 participants with knee osteoarthritis were randomised</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-08 07:41:42 -0400" MODIFIED_BY="[Empty name]">
<P>
<I>Experimental intervention</I>
</P>
<P>40 mg methylprednisolone acetate, single intra-articular injection</P>
<P>
<I>Control intervention</I>
</P>
<P>saline, single intra-articular injection</P>
<P>Cross-over design: Every participant received 1 injection each</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-10-08 07:41:42 -0400" MODIFIED_BY="[Empty name]">
<P>Maximum follow-up: 1 week</P>
<P>Outcome data (WOMAC pain, pain overall, ICOAP questionnaire, ultrasound examination) not extractable</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-23 11:47:17 -0400" MODIFIED_BY="[Empty name]"/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2015-10-08 07:41:42 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hall-2014">
<CHAR_METHODS MODIFIED="2015-10-08 07:41:42 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>2-arm parallel-group design</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-23 11:50:25 -0400" MODIFIED_BY="[Empty name]">
<P>25 participants with knee osteoarthritis were randomised</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-08 07:41:42 -0400" MODIFIED_BY="[Empty name]">
<P>
<I>Experimental intervention</I>
</P>
<P>40 mg methylprednisolone acetate, single intra-articular injection</P>
<P>
<I>Control intervention</I>
</P>
<P>saline, single intra-articular injection</P>
<P>Cross-over design: Every participant received 1 injection each</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-10-08 07:41:42 -0400" MODIFIED_BY="[Empty name]">
<P>Maximum follow-up: 1 week</P>
<P>Outcome data (WOMAC pain, pain overall, ICOAP questionnaire, ultrasound examination) not extractable</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2015-10-08 07:41:43 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Motyl-2013">
<CHAR_METHODS MODIFIED="2015-10-08 07:41:42 -0400" MODIFIED_BY="[Empty name]">
<P>Measurement reliability study on participants later taking part in a randomised controlled trial for intra-articular corticosteroid injection in knee osteoarthritis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-23 11:54:51 -0400" MODIFIED_BY="[Empty name]">
<P>15 participants with knee osteoarthritis </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-08 07:41:43 -0400" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
<P>Data for the study was collected before the intra-articular injection</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-23 11:55:24 -0400" MODIFIED_BY="[Empty name]">
<P>Outcome data not extractable</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2015-10-08 07:41:43 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Motyl-2013a">
<CHAR_METHODS MODIFIED="2015-10-08 07:41:43 -0400" MODIFIED_BY="[Empty name]">
<P>Measurement reliability study on participants later taking part in a randomised controlled trial for intra-articular corticosteroid injection in knee osteoarthritis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-23 11:56:11 -0400" MODIFIED_BY="[Empty name]">
<P>15 participants with knee osteoarthritis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-08 07:41:43 -0400" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
<P>Data for the study was collected before the intra-articular injection</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-23 11:56:20 -0400" MODIFIED_BY="[Empty name]">
<P>Outcome data not extractable</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2015-10-08 07:41:43 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-O_x0027_Neill-2014">
<CHAR_METHODS MODIFIED="2015-10-08 07:41:43 -0400" MODIFIED_BY="[Empty name]">
<P>Open-label clinical trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-23 12:02:09 -0400" MODIFIED_BY="[Empty name]">
<P>100 participants with knee osteoarthritis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-08 07:41:43 -0400" MODIFIED_BY="[Empty name]">
<P>
<I>Experimental intervention</I>
</P>
<P>Corticosteroid, single intra-articular injection, type and dosage of corticosteroid unclear.</P>
<P>The study analysed the changes in MRI scans before and after the intra-articular corticosteroid injection. All participants received the experimental intervention, there was no control group.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-23 12:01:59 -0400" MODIFIED_BY="[Empty name]">
<P>Outcome data not extractable</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2015-10-08 07:41:43 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Raynauld-1999">
<CHAR_METHODS MODIFIED="2015-10-08 07:41:43 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>2-arm parallel-group design</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-23 12:04:59 -0400" MODIFIED_BY="[Empty name]">
<P>80 participants with knee osteoarthritis were randomised</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-09-23 12:06:40 -0400" MODIFIED_BY="[Empty name]">
<P>
<I>Experimental intervention</I>
</P>
<P>40 mg triamcinolone hexacetonide, 8 intra-articular injections, 3 months interval</P>
<P>
<I>Control intervention</I>
</P>
<P>Placebo, 8 intra-articular injections, 3 months interval</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-23 12:07:05 -0400" MODIFIED_BY="[Empty name]">
<P>Outcome data (pain overall, WOMAC) not extractable</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2015-10-08 07:41:43 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rezende-2012">
<CHAR_METHODS MODIFIED="2015-10-08 07:41:43 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>2-arm parallel-group design</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-23 12:08:15 -0400" MODIFIED_BY="[Empty name]">
<P>104 participants with knee osteoarthritis were randomised</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-08 07:41:43 -0400" MODIFIED_BY="[Empty name]">
<P>
<I>Experimental intervention</I>
</P>
<P>20 mg of hexacetonide triamcinolone plus 6 ml of hylan GF-20, single intra-articular injection</P>
<P>
<I>Control intervention</I>
</P>
<P>6 ml of hylan GF-20, single intra-articular injection</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-10-08 07:41:43 -0400" MODIFIED_BY="[Empty name]">
<P>Maximum follow-up: 24 weeks</P>
<P>Outcome data (VAS, WOMAC, and Lequesne) not extractable</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2015-10-08 07:41:43 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Singh-1996">
<CHAR_METHODS MODIFIED="2015-10-08 07:41:43 -0400" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-10-08 07:41:43 -0400" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-10-08 07:41:43 -0400" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-23 12:11:05 -0400" MODIFIED_BY="[Empty name]">
<P>Outcome data not extractable</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES>
<P>ICOAP: Intermittent and Constant Osteoarthritis Pain<BR/>KOOS: Knee Injury and Osteoarthritis Outcome Score<BR/>MRI: magnetic resonance imaging<BR/>VAS: visual analogue scale<BR/>WOMAC: Western Ontario and McMaster Universities Arthritis Index</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2015-10-20 03:45:11 -0400" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2015-10-19 08:27:37 -0400" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-08 07:40:28 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Beyaz-2012">
<DESCRIPTION>
<P>Quote: "Patients were randomized by the closed-envelope technique into three groups". Because the "closed-envelope technique" was not further specified, the risk of selection bias was considered unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 10:21:30 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Campos-2013">
<DESCRIPTION>
<P>Quote: "Randomization was performed by a computer-generated program (available at: http://www.randomization.com/)."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 10:01:32 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Castro-2007">
<DESCRIPTION>
<P>Method used to generate random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-08 07:40:29 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cederlof-1966">
<DESCRIPTION>
<P>Quote: "The out-patient department nurse decided which fluid was to be injected by tossing a coin"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 10:15:32 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chao-2010">
<DESCRIPTION>
<P>Method used to generate random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-12 05:53:24 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Di-Sante-2012">
<DESCRIPTION>
<P>Quote: "(...) using a computer generated 1:1:1 allocation sequence."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 10:34:13 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dieppe-1980">
<DESCRIPTION>
<P>Method used to generate random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 10:47:46 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Friedman-1980">
<DESCRIPTION>
<P>Method used to generate random sequence of allocation was not clearly reported, so the risk of selection bias was unclear. Quote: "Half of the patients, selected according to a predetermined random schedule, were treated (...)."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 10:38:02 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fri_x0301_as-2004">
<DESCRIPTION>
<P>Method used to generate random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 10:50:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gaffney-1995">
<DESCRIPTION>
<P>Method used to generate random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 10:53:52 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grecomoro-1992">
<DESCRIPTION>
<P>Method used to generate random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-08 07:40:39 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Henriksen-2015">
<DESCRIPTION>
<P>Quote: "A computer-generated randomization sequence was produced before any patients were enrolled that allocated participants in permuted blocks of 2 to 6 to the corticosteroid or the placebo group (1:1)."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:03:36 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jones-1996">
<DESCRIPTION>
<P>Method used to generate random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:09:06 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lyons-2005">
<DESCRIPTION>
<P>Method used to generate random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:12:15 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Miller-1958">
<DESCRIPTION>
<P>Method used to generate random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:05:47 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-NCT00414427">
<DESCRIPTION>
<P>Method used to generate random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-08 07:40:40 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ozturk-2006">
<DESCRIPTION>
<P>Quote: "Patients were assigned to one of the two treatment groups based on a table of randomly assorted digits: A and B."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-12 05:58:29 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Petrella-2015">
<DESCRIPTION>
<P>Quote: "The randomization treatment was computer generated and was stratified by study center."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:23:43 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Popov-1989">
<DESCRIPTION>
<P>Method used to generate random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:25:08 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ravaud-1999">
<DESCRIPTION>
<P>Method used to generate random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-08 07:41:18 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Raynauld-2003">
<DESCRIPTION>
<P>Quote: "Patients were randomly assigned to the IA steroid or IA saline group based on a table of randomly assorted digits."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:50:51 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schue-2011">
<DESCRIPTION>
<P>Method used to generate random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-12 05:59:58 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Smith-2003">
<DESCRIPTION>
<P>Quote: "Randomization was computer-generated by a member of the hospital pharmacy department, who also prepared a blinded intra-articular injection"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-29 06:12:08 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wright-1960">
<DESCRIPTION>
<P>Quote: "The order of courses in each patient was randomized from a master sheet in which names were entered consecutively."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-12 06:00:20 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yavuz-2012">
<DESCRIPTION>
<P>Quote: "A total of 120 eligible patients with knee osteoarthritis were included (according to their admission date) and randomized into four groups."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:58:42 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Young-2001">
<DESCRIPTION>
<P>Method used to generate random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-12 06:00:51 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhilyayev-2012">
<DESCRIPTION>
<P>Quote: "joints were randomized by envelopes to one of 4 treatments"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2015-10-19 08:27:37 -0400" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-08 07:40:28 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Beyaz-2012">
<DESCRIPTION>
<P>Quote: "Patients were randomized by the closed-envelope technique into three groups". Because the "closed-envelope technique" was not further specified, the risk of selection bias was considered unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 10:24:49 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Campos-2013">
<DESCRIPTION>
<P>Method used to conceal the random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 10:01:42 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Castro-2007">
<DESCRIPTION>
<P>Method used to conceal the random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-25 04:21:22 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cederlof-1966">
<DESCRIPTION>
<P>Method used to conceal the random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 10:15:41 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chao-2010">
<DESCRIPTION>
<P>Method used to conceal the random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 10:29:44 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Di-Sante-2012">
<DESCRIPTION>
<P>Method used to conceal the random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 10:34:21 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dieppe-1980">
<DESCRIPTION>
<P>Method used to conceal the random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 10:46:28 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Friedman-1980">
<DESCRIPTION>
<P>Method used to conceal the random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 10:38:09 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fri_x0301_as-2004">
<DESCRIPTION>
<P>Method used to conceal the random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 10:50:26 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gaffney-1995">
<DESCRIPTION>
<P>Method used to conceal the random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-20 05:21:08 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grecomoro-1992">
<DESCRIPTION>
<P>Method used to conceal the random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-12 05:55:25 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Henriksen-2015">
<DESCRIPTION>
<P>Quote: "The randomization sequence was prepared by a biostatistician with no clinical involvement in the trial (R.C.). The allocation was concealed in a password-protected computer file only accessible by the biostatistician. Individual allocations were held in sealed, opaque, consecutively numbered envelopes."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:03:45 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jones-1996">
<DESCRIPTION>
<P>Method used to conceal the random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:09:12 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lyons-2005">
<DESCRIPTION>
<P>Method used to conceal the random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:12:22 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Miller-1958">
<DESCRIPTION>
<P>Method used to conceal the random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:05:54 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-NCT00414427">
<DESCRIPTION>
<P>Method used to conceal the random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:14:22 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ozturk-2006">
<DESCRIPTION>
<P>Method used to conceal the random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-31 04:00:03 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Petrella-2015">
<DESCRIPTION>
<P>Quote: "The randomization treatment was computer generated and was stratified by study center."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:23:50 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Popov-1989">
<DESCRIPTION>
<P>Method used to conceal the random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:25:14 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ravaud-1999">
<DESCRIPTION>
<P>Method used to conceal the random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:49:00 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Raynauld-2003">
<DESCRIPTION>
<P>Method used to conceal the random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:50:58 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schue-2011">
<DESCRIPTION>
<P>Method used to conceal the random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:53:23 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Smith-2003">
<DESCRIPTION>
<P>Quote: "Randomization was computer-generated by a member of the hospital pharmacy department, who also prepared a blinded intra-articular injection"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-29 04:39:14 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wright-1960">
<DESCRIPTION>
<P>Method used to conceal the random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:55:57 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yavuz-2012">
<DESCRIPTION>
<P>Method used to conceal the random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:58:58 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Young-2001">
<DESCRIPTION>
<P>Method used to conceal the random sequence of allocation was not reported, so the risk of selection bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-12 06:00:54 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhilyayev-2012">
<DESCRIPTION>
<P>Quote: "joints were randomized by envelopes to one of 4 treatments"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2015-08-12 05:43:04 -0400" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2015-08-25 04:24:45 -0400" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="GROUP" MODIFIED="2015-08-12 05:43:04 -0400" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2015-08-12 05:49:41 -0400" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-07" LEVEL="STUDY" MODIFIED="2015-08-12 05:49:41 -0400" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2015-10-19 08:27:37 -0400" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Blinding of participants?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-07 17:29:32 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Beyaz-2012">
<DESCRIPTION>
<P>Quote: "Since the solutions were in different colors, sticker was used to cover injectors to hide to ensure blinding."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 10:25:29 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Campos-2013">
<DESCRIPTION>
<P>Quote: "Patients were blinded (blocked from watching the procedures by the use of a windscreen sunshade and did not know to which group they were assigned)."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 10:04:09 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Castro-2007">
<DESCRIPTION>
<P>It was unclear if method used to blind participants was appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-25 04:22:06 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cederlof-1966">
<DESCRIPTION>
<P>It was unclear if method used to blind participants was appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 10:16:43 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chao-2010">
<DESCRIPTION>
<P>Quote: "Patients and assessors were blinded to treatment status" "Patients were then randomized to receive an injection of either (...) triamcinolone acetonide or (...) saline, which were drawn into a syringe covered with opaque tape prior to the patient encounter."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 10:30:54 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Di-Sante-2012">
<DESCRIPTION>
<P>No intra-articular sham injection in the placebo group (local therapy only)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 10:35:55 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dieppe-1980">
<DESCRIPTION>
<P>Quote: Described as "single-blind, blind-observer", implying that participants were not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 10:47:04 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Friedman-1980">
<DESCRIPTION>
<P>Quote: "During the time of [the injection] (...), the physician and patient were positioned so that neither could see the nurse's face nor the material she injected. Thus, neither had any direct information concerning what was injected and, practically speaking, had no contact with the only person who knew"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-08 07:40:39 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fri_x0301_as-2004">
<DESCRIPTION>
<P>Although the authors stated "Glucocorticoid treatment with triamcinolone acetonide was always given on a blind basis", they also stated that this was an open trial (Quote: "The study was of the longitudinal, open, prospective, controlled type").The risk of performance bias was therefore considered unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-08 07:40:39 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gaffney-1995">
<DESCRIPTION>
<P>Quote: "Although this study was not, by strict definition, double-blinded, we attempted to ensure that patients were not aware of the treatment allocated to them, by shielding the identity of the treatment received from their view at the time of injection; only the injecting physician (IL) was aware of the nature of the injection administered."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-12 05:55:12 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Grecomoro-1992">
<DESCRIPTION>
<P>Quote: "The trial design was open and randomized."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-08 07:40:39 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Henriksen-2015">
<DESCRIPTION>
<P>Quote: "To ensure blinding of the participants and the clinician performing the injections, the syringes were prepared by the study nurse in the absence of participants and blinded study staff. Because the corticosteroid liquid is milky white and the saline is clear, the syringes were masked with opaque tape to prevent disclosure of the content during the injection procedure."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-08 07:40:40 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jones-1996">
<DESCRIPTION>
<P>Quote: "Each injection was given by a second operator, thus blinding both patient and assessor." No further description of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-08 07:40:40 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lyons-2005">
<DESCRIPTION>
<P>It was unclear if method used to blind healthcare providers was appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-20 06:25:36 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Miller-1958">
<DESCRIPTION>
<P>It was unclear if method used to blind participants was appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:06:11 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-NCT00414427">
<DESCRIPTION>
<P>It was unclear if method used to blind participants was appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-08 07:40:40 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ozturk-2006">
<DESCRIPTION>
<P>It was unclear if participants were blinded (trial described as "single blind" but no description of who was blinded)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:20:30 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Petrella-2015">
<DESCRIPTION>
<P>It was unclear if method used to blind participants was appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:24:27 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Popov-1989">
<DESCRIPTION>
<P>It was unclear if method used to blind participants was appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:47:21 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ravaud-1999">
<DESCRIPTION>
<P>Quote: "The study was double-blind in relation to the IA corticosteroid and open with regard to joint lavage."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-08 07:41:18 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Raynauld-2003">
<DESCRIPTION>
<P>Study described as double-blind but no description of method of blinding provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:51:09 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schue-2011">
<DESCRIPTION>
<P>It was unclear if method used to blind participants was appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:54:01 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smith-2003">
<DESCRIPTION>
<P>It was unclear if method used to blind participants was appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-29 04:40:16 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wright-1960">
<DESCRIPTION>
<P>It was unclear if method used to blind participants was appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:56:27 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yavuz-2012">
<DESCRIPTION>
<P>It was unclear if participants were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:59:27 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Young-2001">
<DESCRIPTION>
<P>It was unclear if method used to blind participants was appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 12:01:41 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhilyayev-2012">
<DESCRIPTION>
<P>It was unclear if method used to blind participants was appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="STUDY" MODIFIED="2015-10-20 03:45:11 -0400" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of health care provider(s)</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-20 03:45:11 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Beyaz-2012">
<DESCRIPTION>
<P>Quote: "Injections were administered by another blinded investigator."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 10:26:03 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Campos-2013">
<DESCRIPTION>
<P>Physicians were not explicitly described as blinded, so the risk of performance bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 10:04:53 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Castro-2007">
<DESCRIPTION>
<P>Physicians were not explicitly described as blinded, so the risk of performance bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-25 04:22:01 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cederlof-1966">
<DESCRIPTION>
<P>Physicians were not explicitly described as blinded, so the risk of performance bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 10:17:22 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chao-2010">
<DESCRIPTION>
<P>Quote: "Injections were given (...) by a non-blinded physician"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-20 05:00:02 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Di-Sante-2012">
<DESCRIPTION>
<P>No intra-articular sham injection in the placebo group (local therapy only)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-08 07:40:29 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dieppe-1980">
<DESCRIPTION>
<P>Quote: Described as "single-blind, blind-observer", implying that healthcare providers were not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-12 05:54:33 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Friedman-1980">
<DESCRIPTION>
<P>Quote: "The physician-experimenter performed the arthrocentesis (...) a nurse-assistant entered the room and performed the injection through the intraarticular needle, and left the room. During the time of this taking place, the physician and patient were positioned so that neither could see the nurse's face nor the material she injected. Thus, neither had any direct information concerning what was injected and, practically speaking, had no contact with the only person who knew"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-08 07:40:39 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fri_x0301_as-2004">
<DESCRIPTION>
<P>Although the authors stated "Glucocorticoid treatment with triamcinolone acetonide was always given on a blind basis", they also stated that this was an open trial (Quote: "The study was of the longitudinal, open, prospective, controlled type"). The risk of performance bias was therefore considered unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 10:50:46 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gaffney-1995">
<DESCRIPTION>
<P>Quote: "Although this study was not, by strict definition, double-blinded, we attempted to ensure that patients were not aware of the treatment allocated to them, by shielding the identity of the treatment received from their view at the time of injection; only the injecting physician (IL) was aware of the nature of the injection administered."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-12 05:55:10 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Grecomoro-1992">
<DESCRIPTION>
<P>Quote: "The trial design was open and randomized."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-08 07:40:40 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Henriksen-2015">
<DESCRIPTION>
<P>Quote: "To ensure blinding of the participants and the clinician performing the injections, the syringes were prepared by the study nurse in the absence of participants and blinded study staff. Because the corticosteroid liquid is milky white and the saline is clear, the syringes were masked with opaque tape to prevent disclosure of the content during the injection procedure."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-08 07:40:40 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jones-1996">
<DESCRIPTION>
<P>Quote: "Each injection was given by a second operator, thus blinding both patient and assessor." No further description of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-12 05:57:30 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lyons-2005">
<DESCRIPTION>
<P>Quote: "(The study) was single blind, with the principal investigator administering the treatment and also measuring outcome."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-20 06:25:30 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Miller-1958">
<DESCRIPTION>
<P>Physicians were not explicitly described as blinded, so the risk of performance bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-08 07:40:40 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-NCT00414427">
<DESCRIPTION>
<P>It was unclear if method used to blind healthcare providers was appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-08 07:40:40 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ozturk-2006">
<DESCRIPTION>
<P>It was unclear if healthcare providers were blinded (trial described as "single blind" but no description of who was blinded)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-12 05:58:39 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Petrella-2015">
<DESCRIPTION>
<P>Quote: "An injecting physician delivered the randomized treatment and remained unblinded."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-08 07:40:40 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Popov-1989">
<DESCRIPTION>
<P>It was unclear if method used to blind healthcare providers was appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-12 05:59:01 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ravaud-1999">
<DESCRIPTION>
<P>Quote: "The study was double-blind in relation to the IA corticosteroid and open with regard to joint lavage. However, the procedure (joint lavage and/or IA injection) was performed by a physician other than the blinded evaluator."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-08 07:41:18 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Raynauld-2003">
<DESCRIPTION>
<P>Study described as double-blind. The following statements indicate that "double-blind" in this trial means that only patients and outcome assessors were blinded: "In order to preserve the blind, the injections were given by a rheumatologist (DC or BH) other than the evaluators." "Investigators performed these evaluations in a blinded manner using validated measures."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:51:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schue-2011">
<DESCRIPTION>
<P>Physicians were not explicitly described as blinded, so the risk of performance bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-08 07:41:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smith-2003">
<DESCRIPTION>
<P>It was unclear if method used to blind healthcare providers was appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-29 04:39:59 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wright-1960">
<DESCRIPTION>
<P>Physicians were not explicitly described as blinded, so the risk of performance bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:56:09 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yavuz-2012">
<DESCRIPTION>
<P>Physicians were not explicitly described as blinded, so the risk of performance bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:59:12 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Young-2001">
<DESCRIPTION>
<P>Physicians were not explicitly described as blinded, so the risk of performance bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 12:01:33 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhilyayev-2012">
<DESCRIPTION>
<P>Physicians were not explicitly described as blinded, so the risk of performance bias was unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2015-10-19 08:49:24 -0400" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Intention-to-treat analysis performed? Pain</NAME>
<DESCRIPTION>
<P>Pain</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 10:33:09 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Beyaz-2012">
<DESCRIPTION>
<P>9 out of 82 participants were excluded because (quote) "they did not come for follow-up"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 10:28:51 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Campos-2013">
<DESCRIPTION>
<P>5 of 52 participants excluded in experimental group, 6 of 52 participants excluded in control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 10:11:08 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Castro-2007">
<DESCRIPTION>
<P>All randomised participants included in the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-25 04:22:22 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cederlof-1966">
<DESCRIPTION>
<P>All randomised participants included in the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 10:20:00 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chao-2010">
<DESCRIPTION>
<P>9 of 40 participants excluded in experimental group, 9 of 39 participants excluded in control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 10:33:24 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Di-Sante-2012">
<DESCRIPTION>
<P>All randomised participants included in the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 10:36:42 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dieppe-1980">
<DESCRIPTION>
<P>All randomised participants included in the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-20 05:13:17 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Friedman-1980">
<DESCRIPTION>
<P>All randomised participants included in the analysis. Quote: "All patients were seen 1 wk, 4 wk, 6 wk and 8 wk post-injection except those whose pain scores at any subsequent evaluation were the same as their pre-treatment scores; they were not seen further. It was assumed that their scores would no longer improve and they were counted as remaining at their pre-treatment level throughout the experiment".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 10:44:54 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fri_x0301_as-2004">
<DESCRIPTION>
<P>82 of 299 knees were excluded at 1 month, 51 of 299 knees were excluded at 3 months</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-20 05:14:45 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gaffney-1995">
<DESCRIPTION>
<P>2 of 42 participants in control group withdrew. It was unclear whether all participants randomised were also analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 10:55:49 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grecomoro-1992">
<DESCRIPTION>
<P>All randomised participants included in the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:03:04 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Henriksen-2015">
<DESCRIPTION>
<P>All randomised participants included in the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-19 08:49:24 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jones-1996">
<DESCRIPTION>
<P>Quotes: "As some data was missing due to patient withdrawal, all analyses were performed on a last measures carried forward, intention to treat basis", but still not all participants randomised were analysed. Quote: "One patient failed to enter the study and received no injection, leaving 59 patients available for the analysis."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:11:25 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lyons-2005">
<DESCRIPTION>
<P>All randomised participants included in the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-08 07:40:40 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Miller-1958">
<DESCRIPTION>
<P>21 of 202 participants were excluded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:08:39 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-NCT00414427">
<DESCRIPTION>
<P>7 of 40 participants excluded in experimental group, 5 of 39 participants excluded in control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:17:09 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ozturk-2006">
<DESCRIPTION>
<P>7 of 23 participants excluded in experimental group, 0 of 24 participants excluded in control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:23:07 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Petrella-2015">
<DESCRIPTION>
<P>2 of 33 participants excluded in experimental group, 1 of 33 participants excluded in control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:24:54 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Popov-1989">
<DESCRIPTION>
<P>It was unclear whether all participants randomised were also analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:48:42 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ravaud-1999">
<DESCRIPTION>
<P>All randomised participants included in the analysis. Quote: "The last observation&#8211;carried-forward procedure was used to adjust for missing values."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:50:32 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Raynauld-2003">
<DESCRIPTION>
<P>1 of 34 participants excluded in experimental group, 1 of 34 participants excluded in control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:52:28 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schue-2011">
<DESCRIPTION>
<P>It was unclear whether all participants randomised were also analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-08 07:41:19 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Smith-2003">
<DESCRIPTION>
<P>Quote: "In the event of relapse as defined above, the last documented outcome variables were carried forward". Still, 6 participants were excluded (those needing surgical intervention because of the arthroscopic findings at baseline)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-31 05:22:42 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wright-1960">
<DESCRIPTION>
<P>Did not report extractable pain outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:58:21 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yavuz-2012">
<DESCRIPTION>
<P>It was unclear whether all participants randomised were also analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-20 05:31:33 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Young-2001">
<DESCRIPTION>
<P>It was unclear whether all participants randomised were also analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 12:02:22 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhilyayev-2012">
<DESCRIPTION>
<P>It was unclear whether all participants randomised were also analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="STUDY" MODIFIED="2015-10-19 08:27:37 -0400" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Intention-to-treat analysis performed? Function</NAME>
<DESCRIPTION>
<P>Function</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 10:33:07 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Beyaz-2012">
<DESCRIPTION>
<P>9 out of 82 participants were excluded because (quote) "they did not come for follow-up"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 10:29:01 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Campos-2013">
<DESCRIPTION>
<P>5 of 52 participants excluded in experimental group, 6 of 52 participants excluded in control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 10:11:13 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Castro-2007">
<DESCRIPTION>
<P>All randomised participants included in the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-31 05:21:37 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cederlof-1966">
<DESCRIPTION>
<P>Did not report extractable function outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 10:20:48 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chao-2010">
<DESCRIPTION>
<P>9 of 40 participants excluded in experimental group, 9 of 39 participants excluded in control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 10:32:30 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Di-Sante-2012">
<DESCRIPTION>
<P>All randomised participants included in the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 10:37:24 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dieppe-1980">
<DESCRIPTION>
<P>Not applicable, no function outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 10:49:45 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Friedman-1980">
<DESCRIPTION>
<P>Not applicable, no function outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 10:45:26 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fri_x0301_as-2004">
<DESCRIPTION>
<P>Not applicable, no function outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-20 05:14:49 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gaffney-1995">
<DESCRIPTION>
<P>2 of 42 participants in control group withdrew. It was unclear whether all participants randomised were also analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 10:56:00 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grecomoro-1992">
<DESCRIPTION>
<P>Not applicable, no function outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:03:14 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Henriksen-2015">
<DESCRIPTION>
<P>All randomised participants included in the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:05:29 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jones-1996">
<DESCRIPTION>
<P>Not applicable, no function outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:11:28 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lyons-2005">
<DESCRIPTION>
<P>All randomised participants included in the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-20 06:25:21 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Miller-1958">
<DESCRIPTION>
<P>Not applicable, no function outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:08:50 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-NCT00414427">
<DESCRIPTION>
<P>Not applicable, no function outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:17:21 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ozturk-2006">
<DESCRIPTION>
<P>Not applicable, no function outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:23:26 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Petrella-2015">
<DESCRIPTION>
<P>2 of 33 participants excluded in experimental group, 1 of 33 participants excluded in control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:24:55 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Popov-1989">
<DESCRIPTION>
<P>It was unclear whether all participants randomised were also analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:48:43 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ravaud-1999">
<DESCRIPTION>
<P>All randomised participants included in the analysis. Quote: "The last observation&#8211;carried-forward procedure was used to adjust for missing values."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:50:35 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Raynauld-2003">
<DESCRIPTION>
<P>1 of 34 participants excluded in experimental group, 1 of 34 participants excluded in control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:52:33 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schue-2011">
<DESCRIPTION>
<P>Not applicable, no function outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-10-08 07:41:19 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Smith-2003">
<DESCRIPTION>
<P>Quote: "In the event of relapse as defined above, the last documented outcome variables were carried forward". Still, 6 participants were excluded (those needing surgical intervention because of the arthroscopic findings at baseline)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-31 05:22:39 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wright-1960">
<DESCRIPTION>
<P>Did not report extractable function outcome data excluded in control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 11:58:25 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yavuz-2012">
<DESCRIPTION>
<P>It was unclear whether all participants randomised were also analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-20 05:31:35 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Young-2001">
<DESCRIPTION>
<P>It was unclear whether all participants randomised were also analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-19 12:02:30 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhilyayev-2012">
<DESCRIPTION>
<P>Not applicable, no function outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2015-11-02 12:53:10 -0500" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2015-11-02 12:53:10 -0500" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2015-08-28 11:07:34 -0400" MODIFIED_BY="[Empty name]">Summary of findings</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>Intra-articular corticosteroid compared with sham injection for osteoarthritis of the knee</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>participants with osteoarthritis of the knee</P>
<P>
<B>Settings: </B>various orthopaedic or rheumatology clinics</P>
<P>
<B>Intervention: </B>intra-articular corticosteroid</P>
<P>
<B>Comparison: </B>sham injection</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Sham injection</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Intra-articular corticosteroid</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Pain intensity</B>
</P>
<P>Various pain scales.</P>
<P>(median follow-up: 12 weeks)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>-1.8 cm change on 10-cm VAS<SUP>1</SUP>
</B>
<BR/>29% improvement</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>-2.8 cm change</B>
<BR/>(&#916; -1.0 cm, -1.5 to -0.6)<SUP>2</SUP>
</P>
<P>
<BR/>
<B>46% improvement</B>
<BR/>(&#916; 17%, 10% to 25%)<SUP>3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>SMD -0.40 (-0.58 to -0.22)</P>
<P/>
<P>Predictive interval (-1.20 to 0.40)</P>
</TD>
<TD VALIGN="TOP">
<P>1749</P>
<P>(26)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>9</SUP>
</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>NNTB 8 (95% CI 6 to 13)<SUP>4</SUP>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Function</B>
</P>
<P>Various function scales.</P>
<P>(median follow-up: 12 weeks)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>-1.2 units on WOMAC (range 0 to 10)<SUP>1</SUP>
</B>
<BR/>21% improvement</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>-1.9 units on WOMAC</B>
<BR/>(&#916; -0.7, -1.2 to -0.2)<SUP>5</SUP>
</P>
<P>
<BR/>
<B>34% improvement</B>
<BR/>(&#916; 13%, 4% to 22%)<SUP>6</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>SMD -0.33 (-0.56 to -0.09)</P>
<P/>
<P>Predictive interval (-1.19 to 0.54)</P>
</TD>
<TD VALIGN="TOP">
<P>1014</P>
<P>(15)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>9</SUP>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>NNTB 10 (95% CI 7 to 33)<SUP>7</SUP>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Number of participants experiencing any adverse event</B>
</P>
<P>(median follow-up: 17 weeks)</P>
</TD>
<TD VALIGN="TOP">
<P>150 per 1000 participant-years<SUP>8</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>134 per 1000 participant-years<BR/>(96 to 185)</P>
</TD>
<TD VALIGN="TOP">
<P>RR 0.89 (0.64 to 1.23)</P>
</TD>
<TD VALIGN="TOP">
<P>84</P>
<P>(2)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>10</SUP>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Little evidence of harmful effect (NNTB not statistically significant)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Number of participants who withdraw because of adverse events</B>
</P>
<P>(median follow-up: 25 weeks)</P>
</TD>
<TD VALIGN="TOP">
<P>17 per 1000 participant-years<SUP>8</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>6 per 1000 participant-years<BR/>(1 to 35)</P>
</TD>
<TD VALIGN="TOP">
<P>RR 0.33 (0.05 to 2.07)</P>
</TD>
<TD VALIGN="TOP">
<P>204</P>
<P>(2)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>10</SUP>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Little evidence of harmful effect (NNTB not statistically significant)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Number of participants experiencing any serious adverse event </B>
</P>
<P>(median follow-up: 26 weeks)</P>
</TD>
<TD VALIGN="TOP">
<P>4 per 1000 participant-years<SUP>8</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>3 per 1000 participant-years<BR/>(1 to 11)</P>
</TD>
<TD VALIGN="TOP">
<P>RR 0.63 (0.15 to 2.67)</P>
</TD>
<TD VALIGN="TOP">
<P>331</P>
<P>(5)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>10</SUP>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Little evidence of harmful effect (NNTB not statistically significant)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>CI: confidence interval; NNTB: number needed to treat for an additional beneficial outcome; RR: risk ratio; SMD: standardised mean difference; VAS: visual analogue scale; WOMAC: Western Ontario and McMaster Universities Arthritis Index</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
<P>
<SUP>1 </SUP>Median reduction as observed across placebo groups in large osteoarthritis trials (see methods section, <LINK REF="REF-N_x00fc_esch-2009" TYPE="REFERENCE">Nüesch 2009</LINK>).<BR/>
<SUP>2 </SUP>SMDs were back-transformed onto a 10-cm visual analogue scale (VAS) on the basis of a typical pooled standard deviation (SD) of 2.5 cm in large trials that assessed pain using a VAS and expressed as change based on an assumed standardised reduction of 0.72 SD units in the control group.<BR/>
<SUP>3 </SUP>Percentage of improvement was calculated based on median observed pain at baseline across control groups of large osteoarthritis trials of 6.1 cm on 10-cm VAS (<LINK REF="REF-N_x00fc_esch-2009" TYPE="REFERENCE">Nüesch 2009</LINK>).<BR/>
<SUP>4 </SUP>Absolute response risks for pain in the control groups were assumed 31% (see methods section).</P>
<P>
<SUP>5 </SUP>SMDs were back-transformed onto a standardised Western Ontario and McMaster Universities Arthritis Index (WOMAC) disability score ranging from 0 to 10 on the basis of a typical pooled SD of 2.1 in trials that assessed function using WOMAC disability scores and expressed as change based on an assumed standardised reduction of 0.58 SD units in the control group.<BR/>
<SUP>6</SUP> Percentage of improvement was calculated based on median observed WOMAC function scores at baseline across control groups of large osteoarthritis trials of 5.6 units (<LINK REF="REF-N_x00fc_esch-2009" TYPE="REFERENCE">Nüesch 2009</LINK>).<BR/>
<SUP>7 </SUP>Absolute response risks for function in the control groups were assumed 26% (see methods section).<BR/>
<SUP>8 </SUP>Median control risk across placebo groups in large osteoarthritis trials (see methods section, <LINK REF="REF-N_x00fc_esch-2009" TYPE="REFERENCE">Nüesch 2009</LINK>).</P>
<P>
<SUP>9</SUP> Downgraded (2 levels) because: Most studies that reported this outcome are of high or unclear risk of bias, and statistical heterogeneity is large.</P>
<P>
<SUP>10</SUP> Downgraded (3 levels) because: 50% or more of the studies that reported this outcome are of high or unclear risk of bias, and the confidence interval of the pooled estimate is wide and includes the null effect.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2015-10-19 09:17:20 -0400" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2015-10-19 09:17:14 -0400" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2015-08-27 04:09:37 -0400" MODIFIED_BY="[Empty name]">Stratified analyses: Pain</TITLE>
<TABLE COLS="7" ROWS="47">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Variable</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Number of studies</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>N of participants corticosteroids</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>N of participants control</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Pain intensity SMD (95% CI)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Heterogeneity I<SUP>2</SUP> (%)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>P value*</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>All trials</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>26</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>922</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>827</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.40 (-0.58 to -0.22)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>68%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="6" VALIGN="BOTTOM">
<P>Allocation concealment</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.15</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adequate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>88</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>83</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.16 (-0.46 to 0.14)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Inadequate or unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>24</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>834</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>744</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.42 (-0.62 to -0.22)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>69%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="6" VALIGN="TOP">
<P>Blinding of participants</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.64</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adequate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>220</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>218</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.34 (-0.61 to -0.06)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>49%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Inadequate or unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>20</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>702</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>609</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.42 (-0.65 to -0.19)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>72%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="6" VALIGN="TOP">
<P>Blinding of therapists</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.45</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adequate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>92</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>92</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.24 (-0.66 to 0.17)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>44%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Inadequate or unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>23</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>830</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>735</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.42 (-0.62 to -0.22)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>70%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="6" VALIGN="TOP">
<P>Intention-to-treat analysis</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.29</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>236</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>233</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.26 (-0.57 to 0.06)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>59%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No or unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>17</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>686</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>594</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.47 (-0.69 to -0.24)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>71%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="6" VALIGN="TOP">
<P>Type of control intervention</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.08</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sham injection</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>19</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>614</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>526</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.50 (-0.72 to -0.28)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>65%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No intervention</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>284</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>280</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.18 (-0.47 to 0.11)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>63%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="6" VALIGN="TOP">
<P>Funding independent of industry</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.80</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>341</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>333</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.37 (-0.55 to -0.18)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>26%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No or unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>581</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>494</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.41 (-0.70 to -0.12)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>78%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="6" VALIGN="TOP">
<P>Trial size</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.05</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8805; 50 per trial group</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>205</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>204</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.13 (-0.37 to 0.12)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>34%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&lt; 50 per trial group</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>23</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>717</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>623</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.44 (-0.65 to -0.24)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>67%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="6" VALIGN="TOP">
<P>Trial size</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.013</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8805; 100 per trial group</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>103</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>103</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.00 (-0.27 to 0.27)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&lt; 100 per trial group</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>25</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>819</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>724</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.42 (-0.61 to -0.23)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>66%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="6" VALIGN="TOP">
<P>Publication type</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.93</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Full journal article</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>22</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>785</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>706</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.40 (-0.61 to -0.20)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>70%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Other type or unpublished material</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>137</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>121</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.38 (-0.84 to -0.08)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>65%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="6" VALIGN="TOP">
<P>Ultrasound guidance of injections</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.71</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>70</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>70</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.62 (-1.83 to 0.58)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>89%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No or unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>24</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>852</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>757</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.39 (-0.57 to -0.20)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>67%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="6" VALIGN="BOTTOM">
<P>Use of local anaesthetic</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.41</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>172</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>157</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.55 (-0.93 to -0.16)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>62%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No or unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>21</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>750</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>670</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.36 (-0.57 to -0.15)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>70%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="6" VALIGN="TOP">
<P>Concomitant viscosupplementation</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.08</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>129</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>127</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.16 (-0.42 to 0.09)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No or unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>22</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>793</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>700</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.46 (-0.67 to -0.25)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>71%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="6" VALIGN="TOP">
<P>Concomitant joint lavage</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8804; 0.001</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>197</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>187</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.06 (-0.26 to 0.15)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No or unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>26</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>725</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>640</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.57 (-0.78 to -0.35)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>72%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="6" VALIGN="TOP">
<P>Use of crystalline preparation</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.82</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>18</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>623</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>562</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.47 (-0.69 to -0.24)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>72%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No or unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>299</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>265</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.52 (-0.90 to -0.14)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>76%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="6" VALIGN="TOP">
<P>Prednisolone equivalence dose</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.53</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8805; 50 mg</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>17</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>520</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>470</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.55 (-0.85 to -0.25)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>80%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&lt; 50 mg</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>13</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>402</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>357</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.43 (-0.66 to -0.20)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>56%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Number of randomised comparisons are shown in "number of studies" for stratified analyses according to use of lavage as co-intervention, crystalline preparation, prednisolone equivalence. *P value for interaction. N/A: not available.</P>
<P>CI: confidence interval<BR/>SMD: standardised mean difference</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2015-10-19 09:17:20 -0400" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2015-08-27 04:27:22 -0400" MODIFIED_BY="[Empty name]">Stratified analyses: Function</TITLE>
<TABLE COLS="7" ROWS="47">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Variable</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Number of studies</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>N of participants corticosteroids</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>N of participants control</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Function SMD (95% CI)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Heterogeneity I<SUP>2</SUP> (%)</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>P value*</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>All trials</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>546</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>468</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.33 (-0.56 to -0.09)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>69%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="6" VALIGN="TOP">
<P>Allocation concealment</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.25</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adequate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>88</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>83</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.09 (-0.49 to 0.32)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>43%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Inadequate or unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>13</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>458</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>385</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.37 (-0.64 to -0.10)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>72%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="6" VALIGN="TOP">
<P>Blinding of participants</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.97</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adequate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>201</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>199</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.32 (-0.82 to 0.18)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>83%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Inadequate or unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>345</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>269</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.33 (-0.59 to -0.07)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>58%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="6" VALIGN="TOP">
<P>Blinding of therapists</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.78</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adequate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>75</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>75</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.48 (-1.65 to 0.70)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>91%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Inadequate or unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>13</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>471</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>393</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.31 (-0.55 to -0.06)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>66%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="6" VALIGN="TOP">
<P>Intention-to-treat analysis</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.49</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>161</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>159</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.21 (-0.59 to 0.17)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>62%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No or unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>385</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>309</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.38 (-0.69 to -0.07)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>73%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="6" VALIGN="TOP">
<P>Type of control intervention</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.031</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sham injection</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>409</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>334</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.45 (-0.74 to -0.15)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>73%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No intervention</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>137</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>134</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.01 (-0.27 to 0.25)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>13%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="6" VALIGN="TOP">
<P>Funding independent of industry</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.73</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>310</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>302</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.36 (-0.66 to -0.07)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>68%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No or unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>236</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>166</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.27 (-0.71 to 0.16)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>76%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="6" VALIGN="TOP">
<P>Trial size</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.023</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8805; 50 per trial group</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>102</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>101</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.05 (-0.23 to 0.32)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&lt; 50 per trial group</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>13</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>444</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>367</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.40 (-0.67 to -0.13)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>70%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="6" VALIGN="TOP">
<P>Trial size</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8805; 100 per trial group</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&lt; 100 per trial group</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>546</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>468</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.33 (-0.56 to -0.09)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>69%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="6" VALIGN="TOP">
<P>Publication type</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.023</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Full journal article</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>14</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>514</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>438</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.37 (-0.61 to -0.13)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>68%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Other type or unpublished material</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>32</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>30</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.28 (-0.22 to 0.78)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="6" VALIGN="TOP">
<P>Ultrasound guidance of injections</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.49</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>70</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>70</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.14 (-0.70 to 0.43)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>58%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No or unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>13</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>476</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>398</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.36 (-0.62 to -0.09)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>71%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="6" VALIGN="BOTTOM">
<P>Use of local anaesthetic</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.34</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>4</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>105</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>105</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.60 (-1.25 to 0.05)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>78%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No or unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>441</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>363</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.25 (-0.51 to 0.00)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>68%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="6" VALIGN="TOP">
<P>Concomitant viscosupplementation</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.06</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>85</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>84</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.00 (-0.30 to 0.30)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No or unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>13</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>461</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>384</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.39 (-0.66 to -0.12)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>72%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="6" VALIGN="TOP">
<P>Concomitant joint lavage</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.18</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>94</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>84</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.13 (-0.55 to 0.28)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>48%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No or unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>16</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>452</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>384</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.46 (-0.71 to -0.21)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>70%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="6" VALIGN="TOP">
<P>Use of crystalline preparation</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.66</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Yes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>365</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>319</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.37 (-0.66 to -0.08)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>73%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No or unclear</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>181</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>149</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.47 (-0.83 to -0.11)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>61%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="6" VALIGN="TOP">
<P>Prednisolone equivalence dose</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0.16</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8805; 50 mg</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>328</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>277</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.52 (-0.83 to -0.20)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>74%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&lt; 50 mg</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>218</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>191</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-0.22 (-0.48 to 0.05)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>47%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Number of randomised comparisons are shown in "number of studies" for stratified analyses according to use of lavage as co-intervention, crystalline preparation, prednisolone equivalence. *P value for interaction. N/A: not available.</P>
<P>CI: confidence interval<BR/>SMD: standardised mean difference</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2015-10-19 09:56:30 -0400" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2015-10-19 09:54:31 -0400" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Pain</NAME>
<IV_OUTCOME CHI2="78.13687657560229" CI_END="-0.21694101783184763" CI_START="-0.5821874000958707" CI_STUDY="95" CI_TOTAL="95" DF="25" EFFECT_SIZE="-0.39956420896385914" ESTIMABLE="YES" I2="68.0048639059549" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2015-10-19 09:53:48 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="2.2285857936843456E-7" P_Q="1.0" P_Z="1.800971694452369E-5" Q="0.0" RANDOM="YES" SCALE="2.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="26" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.14211879965825572" TOTALS="YES" TOTAL_1="922" TOTAL_2="827" WEIGHT="99.99999999999999" Z="4.2882366375599235">
<NAME>Pain - Main</NAME>
<GROUP_LABEL_1>IA Corticosteroid</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours corticosteroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Std. Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="-0.11554433476096637" CI_START="-1.2577956652390336" EFFECT_SIZE="-0.68667" ESTIMABLE="YES" ESTIMATE="-0.68667" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 05:17:11 -0400" MODIFIED_BY="[Empty name]" ORDER="78" SE="0.291396" STUDY_ID="STD-Beyaz-2012" TOTAL_1="25" TOTAL_2="25" WEIGHT="3.8241208093333263"/>
<IV_DATA CI_END="-0.01987968948367952" CI_START="-0.8006427105163205" EFFECT_SIZE="-0.4102612" ESTIMABLE="YES" ESTIMATE="-0.4102612" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 03:23:57 -0400" MODIFIED_BY="[Empty name]" ORDER="77" SE="0.1991779" STUDY_ID="STD-Campos-2013" TOTAL_1="52" TOTAL_2="51" WEIGHT="4.775778375275158"/>
<IV_DATA CI_END="0.6527150333451347" CI_START="-0.34498503334513464" EFFECT_SIZE="0.153865" ESTIMABLE="YES" ESTIMATE="0.153865" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 05:13:21 -0400" MODIFIED_BY="[Empty name]" ORDER="87" SE="0.25452" STUDY_ID="STD-Castro-2007" TOTAL_1="32" TOTAL_2="30" WEIGHT="4.196205977353369"/>
<IV_DATA CI_END="1.2131914621373652" CI_START="-0.525841462137365" EFFECT_SIZE="0.343675" ESTIMABLE="YES" ESTIMATE="0.343675" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 03:38:51 -0400" MODIFIED_BY="[Empty name]" ORDER="201" SE="0.443639" STUDY_ID="STD-Cederlof-1966" TOTAL_1="26" TOTAL_2="25" WEIGHT="2.5615336869662086"/>
<IV_DATA CI_END="-0.3325967973937091" CI_START="-1.3323364026062907" EFFECT_SIZE="-0.8324666" ESTIMABLE="YES" ESTIMATE="-0.8324666" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 03:23:57 -0400" MODIFIED_BY="[Empty name]" ORDER="79" SE="0.2550403" STUDY_ID="STD-Chao-2010" TOTAL_1="34" TOTAL_2="33" WEIGHT="4.19083576847877"/>
<IV_DATA CI_END="-0.5870864545266703" CI_START="-1.9517815454733296" EFFECT_SIZE="-1.269434" ESTIMABLE="YES" ESTIMATE="-1.269434" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 03:23:57 -0400" MODIFIED_BY="[Empty name]" ORDER="80" SE="0.3481429" STUDY_ID="STD-Di-Sante-2012" TOTAL_1="20" TOTAL_2="20" WEIGHT="3.297069244942764"/>
<IV_DATA CI_END="-3.1123497630880514E-4" CI_START="-1.675467365023691" EFFECT_SIZE="-0.8378893" ESTIMABLE="YES" ESTIMATE="-0.8378893" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 03:23:57 -0400" MODIFIED_BY="[Empty name]" ORDER="90" SE="0.4273436" STUDY_ID="STD-Dieppe-1980" TOTAL_1="12" TOTAL_2="12" WEIGHT="2.6734870080898743"/>
<IV_DATA CI_END="0.6079679633838163" CI_START="-0.7369279633838163" EFFECT_SIZE="-0.06448" ESTIMABLE="YES" ESTIMATE="-0.06448" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 05:18:20 -0400" MODIFIED_BY="[Empty name]" ORDER="82" SE="0.343092" STUDY_ID="STD-Friedman-1980" TOTAL_1="17" TOTAL_2="17" WEIGHT="3.341372094867541"/>
<IV_DATA CI_END="0.27377972514086046" CI_START="-0.27377972514086046" EFFECT_SIZE="0.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-30 03:53:11 -0400" MODIFIED_BY="[Empty name]" ORDER="81" SE="0.1396861" STUDY_ID="STD-Fri_x0301_as-2004" TOTAL_1="103" TOTAL_2="103" WEIGHT="5.371443303717451"/>
<IV_DATA CI_END="0.376168235442188" CI_START="-0.479376035442188" EFFECT_SIZE="-0.0516039" ESTIMABLE="YES" ESTIMATE="-0.0516039" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 03:23:57 -0400" MODIFIED_BY="[Empty name]" ORDER="97" SE="0.2182551" STUDY_ID="STD-Gaffney-1995" TOTAL_1="42" TOTAL_2="42" WEIGHT="4.575352201902913"/>
<IV_DATA CI_END="0.8214240249778866" CI_START="-0.4214240249778865" EFFECT_SIZE="0.2" ESTIMABLE="YES" ESTIMATE="0.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 03:23:57 -0400" MODIFIED_BY="[Empty name]" ORDER="93" SE="0.3170589" STUDY_ID="STD-Grecomoro-1992" TOTAL_1="20" TOTAL_2="20" WEIGHT="3.5780307216835836"/>
<IV_DATA CI_END="0.3527477081985063" CI_START="-0.43131510819850627" EFFECT_SIZE="-0.0392837" ESTIMABLE="YES" ESTIMATE="-0.0392837" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-30 03:53:43 -0400" MODIFIED_BY="[Empty name]" ORDER="92" SE="0.2000197" STUDY_ID="STD-Henriksen-2015" TOTAL_1="50" TOTAL_2="50" WEIGHT="4.766966518355981"/>
<IV_DATA CI_END="-0.3923973128979198" CI_START="-1.4591284871020802" EFFECT_SIZE="-0.9257629" ESTIMABLE="YES" ESTIMATE="-0.9257629" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 03:23:57 -0400" MODIFIED_BY="[Empty name]" ORDER="83" SE="0.2721303" STUDY_ID="STD-Jones-1996" TOTAL_1="30" TOTAL_2="30" WEIGHT="4.0161767436905"/>
<IV_DATA CI_END="0.3295762146622293" CI_START="-1.4620782146622293" EFFECT_SIZE="-0.566251" ESTIMABLE="YES" ESTIMATE="-0.566251" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-30 03:54:08 -0400" MODIFIED_BY="[Empty name]" ORDER="89" SE="0.4570631" STUDY_ID="STD-Lyons-2005" TOTAL_1="10" TOTAL_2="10" WEIGHT="2.473301348954972"/>
<IV_DATA CI_END="0.43421214715972567" CI_START="-0.8645599471597257" EFFECT_SIZE="-0.2151739" ESTIMABLE="YES" ESTIMATE="-0.2151739" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 03:23:57 -0400" MODIFIED_BY="[Empty name]" ORDER="98" SE="0.3313255" STUDY_ID="STD-Miller-1958" TOTAL_1="37" TOTAL_2="36" WEIGHT="3.4466363102933713"/>
<IV_DATA CI_END="-0.37809533386559924" CI_START="-1.3826752661344008" EFFECT_SIZE="-0.8803853" ESTIMABLE="YES" ESTIMATE="-0.8803853" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 03:23:57 -0400" MODIFIED_BY="[Empty name]" ORDER="88" SE="0.2562751" STUDY_ID="STD-NCT00414427" TOTAL_1="33" TOTAL_2="34" WEIGHT="4.178102217710355"/>
<IV_DATA CI_END="0.4357325779933382" CI_START="-0.7094841779933382" EFFECT_SIZE="-0.1368758" ESTIMABLE="YES" ESTIMATE="-0.1368758" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 03:23:57 -0400" MODIFIED_BY="[Empty name]" ORDER="94" SE="0.2921525" STUDY_ID="STD-Ozturk-2006" TOTAL_1="23" TOTAL_2="24" WEIGHT="3.816699342162514"/>
<IV_DATA CI_END="0.4472706848123665" CI_START="-0.5182706848123665" EFFECT_SIZE="-0.0355" ESTIMABLE="YES" ESTIMATE="-0.0355" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 03:23:57 -0400" MODIFIED_BY="[Empty name]" ORDER="99" SE="0.2463161" STUDY_ID="STD-Petrella-2015" TOTAL_1="34" TOTAL_2="32" WEIGHT="4.281226808207978"/>
<IV_DATA CI_END="-0.26827428488284755" CI_START="-1.9083737151171527" EFFECT_SIZE="-1.088324" ESTIMABLE="YES" ESTIMATE="-1.088324" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-28 06:28:56 -0400" MODIFIED_BY="[Empty name]" ORDER="91" SE="0.4184004" STUDY_ID="STD-Popov-1989" TOTAL_1="19" TOTAL_2="11" WEIGHT="2.737240989098204"/>
<IV_DATA CI_END="-0.05791331549940093" CI_START="-0.8658880845005991" EFFECT_SIZE="-0.4619007" ESTIMABLE="YES" ESTIMATE="-0.4619007" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-29 17:00:35 -0400" MODIFIED_BY="[Empty name]" ORDER="76" SE="0.2061198" STUDY_ID="STD-Ravaud-1999" TOTAL_1="49" TOTAL_2="49" WEIGHT="4.702991152946631"/>
<IV_DATA CI_END="0.6006891096862246" CI_START="-0.3651925096862245" EFFECT_SIZE="0.1177483" ESTIMABLE="YES" ESTIMATE="0.1177483" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 03:23:57 -0400" MODIFIED_BY="[Empty name]" ORDER="100" SE="0.2464029" STUDY_ID="STD-Raynauld-2003" TOTAL_1="33" TOTAL_2="33" WEIGHT="4.2803240982096"/>
<IV_DATA CI_END="0.9964695960329798" CI_START="-1.4119415960329798" EFFECT_SIZE="-0.207736" ESTIMABLE="YES" ESTIMATE="-0.207736" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 03:23:57 -0400" MODIFIED_BY="[Empty name]" ORDER="95" SE="0.6144019" STUDY_ID="STD-Schue-2011" TOTAL_1="5" TOTAL_2="5" WEIGHT="1.670857569241775"/>
<IV_DATA CI_END="0.14336531208239228" CI_START="-0.7956985120823923" EFFECT_SIZE="-0.3261666" ESTIMABLE="YES" ESTIMATE="-0.3261666" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 03:23:57 -0400" MODIFIED_BY="[Empty name]" ORDER="96" SE="0.2395615" STUDY_ID="STD-Smith-2003" TOTAL_1="38" TOTAL_2="33" WEIGHT="4.351652856491461"/>
<IV_DATA CI_END="-1.0748383799595105" CI_START="-1.9956216200404897" EFFECT_SIZE="-1.53523" ESTIMABLE="YES" ESTIMATE="-1.53523" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-28 06:28:15 -0400" MODIFIED_BY="[Empty name]" ORDER="84" SE="0.234898" STUDY_ID="STD-Yavuz-2012" TOTAL_1="90" TOTAL_2="30" WEIGHT="4.400455952809904"/>
<IV_DATA CI_END="0.2336922105377947" CI_START="-1.0028910105377946" EFFECT_SIZE="-0.3845994" ESTIMABLE="YES" ESTIMATE="-0.3845994" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 03:23:57 -0400" MODIFIED_BY="[Empty name]" ORDER="85" SE="0.3154607" STUDY_ID="STD-Young-2001" TOTAL_1="21" TOTAL_2="20" WEIGHT="3.592999649059263"/>
<IV_DATA CI_END="-0.10137763894898583" CI_START="-0.8357165610510142" EFFECT_SIZE="-0.4685471" ESTIMABLE="YES" ESTIMATE="-0.4685471" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 03:23:57 -0400" MODIFIED_BY="[Empty name]" ORDER="86" SE="0.1873348" STUDY_ID="STD-Zhilyayev-2012" TOTAL_1="67" TOTAL_2="52" WEIGHT="4.899139250156506"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="189.76913403824835" CI_END="-0.17599594075803943" CI_START="-0.3772782645164547" CI_STUDY="95" CI_TOTAL="95" DF="62" EFFECT_SIZE="-0.27663710263724706" ESTIMABLE="YES" I2="67.32872270603092" I2_Q="71.65996407385302" ID="CMP-001.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2015-10-19 09:54:31 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="7.549516567451064E-15" P_Q="0.014190492956506762" P_Z="7.146620219493684E-8" Q="10.58573111134327" RANDOM="YES" SCALE="2.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="26" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.13271556137930154" TOTALS="SUB" TOTAL_1="2287" TOTAL_2="2042" WEIGHT="400.0" Z="5.387445333821534">
<NAME>Pain - Timepoints</NAME>
<GROUP_LABEL_1>IA Corticosteroid</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours corticosteroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Std. Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="40.308854032016136" CI_END="-0.26519385255597294" CI_START="-0.704106942099347" DF="15" EFFECT_SIZE="-0.48465039732765997" ESTIMABLE="YES" I2="62.78733206335773" ID="CMP-001.02.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2015-08-29 17:04:23 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="4.0726801047374916E-4" P_Z="1.5019148218865896E-5" STUDIES="16" TAU2="0.1172000971715072" TOTAL_1="566" TOTAL_2="475" WEIGHT="100.0" Z="4.328407361208901">
<NAME>Pain- 1-2 week</NAME>
<IV_DATA CI_END="-0.25489935781437323" CI_START="-1.4127206421856269" EFFECT_SIZE="-0.83381" ESTIMABLE="YES" ESTIMATE="-0.83381" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 05:40:13 -0400" MODIFIED_BY="[Empty name]" ORDER="103" SE="0.295368" STUDY_ID="STD-Beyaz-2012" TOTAL_1="25" TOTAL_2="25" WEIGHT="6.132393609738091"/>
<IV_DATA CI_END="-0.22180295165224884" CI_START="-1.008897048347751" EFFECT_SIZE="-0.61535" ESTIMABLE="YES" ESTIMATE="-0.61535" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:10:44 -0400" MODIFIED_BY="[Empty name]" ORDER="1" SE="0.200793" STUDY_ID="STD-Campos-2013" TOTAL_1="52" TOTAL_2="52" WEIGHT="7.959227297427015"/>
<IV_DATA CI_END="0.36069686763101017" CI_START="-1.03815686763101" EFFECT_SIZE="-0.33873" ESTIMABLE="YES" ESTIMATE="-0.33873" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:17:30 -0400" MODIFIED_BY="[Empty name]" ORDER="232" SE="0.356857" STUDY_ID="STD-Cederlof-1966" TOTAL_1="26" TOTAL_2="25" WEIGHT="5.126707326341118"/>
<IV_DATA CI_END="0.35276483633971045" CI_START="-0.8927648363397105" EFFECT_SIZE="-0.27" ESTIMABLE="YES" ESTIMATE="-0.27" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:56:47 -0400" MODIFIED_BY="[Empty name]" ORDER="2" SE="0.317743" STUDY_ID="STD-Di-Sante-2012" TOTAL_1="20" TOTAL_2="20" WEIGHT="5.746777087416553"/>
<IV_DATA CI_END="-3.111509907151033E-4" CI_START="-1.675468849009285" EFFECT_SIZE="-0.83789" ESTIMABLE="YES" ESTIMATE="-0.83789" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:57:23 -0400" MODIFIED_BY="[Empty name]" ORDER="3" SE="0.427344" STUDY_ID="STD-Dieppe-1980" TOTAL_1="12" TOTAL_2="12" WEIGHT="4.181537147344213"/>
<IV_DATA CI_END="0.22087547382303085" CI_START="-1.1424754738230307" EFFECT_SIZE="-0.4608" ESTIMABLE="YES" ESTIMATE="-0.4608" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:13:03 -0400" MODIFIED_BY="[Empty name]" ORDER="4" SE="0.3478" STUDY_ID="STD-Friedman-1980" TOTAL_1="17" TOTAL_2="17" WEIGHT="5.2640871133506995"/>
<IV_DATA CI_END="0.14072169424638736" CI_START="-0.7197416942463873" EFFECT_SIZE="-0.28951" ESTIMABLE="YES" ESTIMATE="-0.28951" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:13:38 -0400" MODIFIED_BY="[Empty name]" ORDER="5" SE="0.21951" STUDY_ID="STD-Gaffney-1995" TOTAL_1="42" TOTAL_2="42" WEIGHT="7.580632876408139"/>
<IV_DATA CI_END="1.0262849316559444" CI_START="-0.22628493165594443" EFFECT_SIZE="0.4" ESTIMABLE="YES" ESTIMATE="0.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:14:51 -0400" MODIFIED_BY="[Empty name]" ORDER="231" SE="0.319539" STUDY_ID="STD-Grecomoro-1992" TOTAL_1="20" TOTAL_2="20" WEIGHT="5.716784545918025"/>
<IV_DATA CI_END="0.3527519961877017" CI_START="-0.43131199618770166" EFFECT_SIZE="-0.03928" ESTIMABLE="YES" ESTIMATE="-0.03928" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:20:58 -0400" MODIFIED_BY="[Empty name]" ORDER="237" SE="0.20002" STUDY_ID="STD-Henriksen-2015" TOTAL_1="50" TOTAL_2="50" WEIGHT="7.974913480816384"/>
<IV_DATA CI_END="0.0875041185252099" CI_START="-0.8878641185252099" EFFECT_SIZE="-0.40018" ESTIMABLE="YES" ESTIMATE="-0.40018" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:21:25 -0400" MODIFIED_BY="[Empty name]" ORDER="238" SE="0.248823" STUDY_ID="STD-Petrella-2015" TOTAL_1="34" TOTAL_2="32" WEIGHT="6.999609738579166"/>
<IV_DATA CI_END="-0.2682710688684412" CI_START="-1.9083689311315588" EFFECT_SIZE="-1.08832" ESTIMABLE="YES" ESTIMATE="-1.08832" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-28 06:29:43 -0400" MODIFIED_BY="[Empty name]" ORDER="233" SE="0.4184" STUDY_ID="STD-Popov-1989" TOTAL_1="19" TOTAL_2="11" WEIGHT="4.289765062051813"/>
<IV_DATA CI_END="-0.25804488804288156" CI_START="-1.0826225119571184" EFFECT_SIZE="-0.6703337" ESTIMABLE="YES" ESTIMATE="-0.6703337" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-29 17:04:23 -0400" MODIFIED_BY="[Empty name]" ORDER="6" SE="0.2103553" STUDY_ID="STD-Ravaud-1999" TOTAL_1="49" TOTAL_2="49" WEIGHT="7.7654088087709745"/>
<IV_DATA CI_END="1.0772558788854918" CI_START="-1.326055878885492" EFFECT_SIZE="-0.1244" ESTIMABLE="YES" ESTIMATE="-0.1244" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:22:53 -0400" MODIFIED_BY="[Empty name]" ORDER="239" SE="0.613101" STUDY_ID="STD-Schue-2011" TOTAL_1="5" TOTAL_2="5" WEIGHT="2.5425652889439934"/>
<IV_DATA CI_END="0.25194520473040666" CI_START="-0.6835652047304066" EFFECT_SIZE="-0.21581" ESTIMABLE="YES" ESTIMATE="-0.21581" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:19:48 -0400" MODIFIED_BY="[Empty name]" ORDER="235" SE="0.238655" STUDY_ID="STD-Smith-2003" TOTAL_1="38" TOTAL_2="33" WEIGHT="7.1988261809014755"/>
<IV_DATA CI_END="-1.0492042090108105" CI_START="-1.9687957909891893" EFFECT_SIZE="-1.509" ESTIMABLE="YES" ESTIMATE="-1.509" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-28 06:29:35 -0400" MODIFIED_BY="[Empty name]" ORDER="7" SE="0.234594" STUDY_ID="STD-Yavuz-2012" TOTAL_1="90" TOTAL_2="30" WEIGHT="7.279153704703638"/>
<IV_DATA CI_END="-0.056719570245015505" CI_START="-0.7892404297549845" EFFECT_SIZE="-0.42298" ESTIMABLE="YES" ESTIMATE="-0.42298" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:19:01 -0400" MODIFIED_BY="[Empty name]" ORDER="234" SE="0.186871" STUDY_ID="STD-Zhilyayev-2012" TOTAL_1="67" TOTAL_2="52" WEIGHT="8.241610731288704"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="67.23775262784413" CI_END="-0.21175854084662107" CI_START="-0.6085680495140589" DF="21" EFFECT_SIZE="-0.41016329518033995" ESTIMABLE="YES" I2="68.76754623814777" ID="CMP-001.02.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2015-08-30 03:55:11 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="9.673425276357506E-7" P_Z="5.0815354405216444E-5" STUDIES="22" TAU2="0.14417666247128874" TOTAL_1="808" TOTAL_2="721" WEIGHT="100.00000000000001" Z="4.051844871527425">
<NAME>Pain- 4-6 week</NAME>
<IV_DATA CI_END="-0.1175413347609664" CI_START="-1.2597926652390337" EFFECT_SIZE="-0.688667" ESTIMABLE="YES" ESTIMATE="-0.688667" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:24:29 -0400" MODIFIED_BY="[Empty name]" ORDER="19" SE="0.291396" STUDY_ID="STD-Beyaz-2012" TOTAL_1="25" TOTAL_2="25" WEIGHT="4.473063615613318"/>
<IV_DATA CI_END="-0.019878293487281096" CI_START="-0.8006417065127189" EFFECT_SIZE="-0.41026" ESTIMABLE="YES" ESTIMATE="-0.41026" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:25:56 -0400" MODIFIED_BY="[Empty name]" ORDER="11" SE="0.199178" STUDY_ID="STD-Campos-2013" TOTAL_1="52" TOTAL_2="51" WEIGHT="5.573753867189609"/>
<IV_DATA CI_END="0.6527150333451347" CI_START="-0.34498503334513464" EFFECT_SIZE="0.153865" ESTIMABLE="YES" ESTIMATE="0.153865" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:34:36 -0400" MODIFIED_BY="[Empty name]" ORDER="249" SE="0.25452" STUDY_ID="STD-Castro-2007" TOTAL_1="32" TOTAL_2="30" WEIGHT="4.904004388840715"/>
<IV_DATA CI_END="1.2131914621373652" CI_START="-0.525841462137365" EFFECT_SIZE="0.343675" ESTIMABLE="YES" ESTIMATE="0.343675" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:31:49 -0400" MODIFIED_BY="[Empty name]" ORDER="244" SE="0.443639" STUDY_ID="STD-Cederlof-1966" TOTAL_1="26" TOTAL_2="25" WEIGHT="3.0051315719717553"/>
<IV_DATA CI_END="-0.3325967973937091" CI_START="-1.3323364026062907" EFFECT_SIZE="-0.8324666" ESTIMABLE="YES" ESTIMATE="-0.8324666" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 03:23:57 -0400" MODIFIED_BY="[Empty name]" ORDER="10" SE="0.2550403" STUDY_ID="STD-Chao-2010" TOTAL_1="34" TOTAL_2="33" WEIGHT="4.897790085328518"/>
<IV_DATA CI_END="-0.5870864545266703" CI_START="-1.9517815454733296" EFFECT_SIZE="-1.269434" ESTIMABLE="YES" ESTIMATE="-1.269434" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 03:23:57 -0400" MODIFIED_BY="[Empty name]" ORDER="12" SE="0.3481429" STUDY_ID="STD-Di-Sante-2012" TOTAL_1="20" TOTAL_2="20" WEIGHT="3.8613533610031694"/>
<IV_DATA CI_END="0.6079679633838163" CI_START="-0.7369279633838163" EFFECT_SIZE="-0.06448" ESTIMABLE="YES" ESTIMATE="-0.06448" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:27:42 -0400" MODIFIED_BY="[Empty name]" ORDER="20" SE="0.343092" STUDY_ID="STD-Friedman-1980" TOTAL_1="17" TOTAL_2="17" WEIGHT="3.9128308170930755"/>
<IV_DATA CI_END="0.27377972514086046" CI_START="-0.27377972514086046" EFFECT_SIZE="0.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-30 03:55:11 -0400" MODIFIED_BY="[Empty name]" ORDER="13" SE="0.1396861" STUDY_ID="STD-Fri_x0301_as-2004" TOTAL_1="103" TOTAL_2="103" WEIGHT="6.260208814149934"/>
<IV_DATA CI_END="0.3702202711144473" CI_START="-0.4853596711144473" EFFECT_SIZE="-0.0575697" ESTIMABLE="YES" ESTIMATE="-0.0575697" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:23:03 -0400" MODIFIED_BY="[Empty name]" ORDER="21" SE="0.2182642" STUDY_ID="STD-Gaffney-1995" TOTAL_1="42" TOTAL_2="42" WEIGHT="5.342238965185901"/>
<IV_DATA CI_END="0.821424220974285" CI_START="-0.42142422097428506" EFFECT_SIZE="0.2" ESTIMABLE="YES" ESTIMATE="0.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:32:09 -0400" MODIFIED_BY="[Empty name]" ORDER="245" SE="0.317059" STUDY_ID="STD-Grecomoro-1992" TOTAL_1="20" TOTAL_2="20" WEIGHT="4.1876323510969"/>
<IV_DATA CI_END="-0.3923973128979198" CI_START="-1.4591284871020802" EFFECT_SIZE="-0.9257629" ESTIMABLE="YES" ESTIMATE="-0.9257629" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 03:23:57 -0400" MODIFIED_BY="[Empty name]" ORDER="15" SE="0.2721303" STUDY_ID="STD-Jones-1996" TOTAL_1="30" TOTAL_2="30" WEIGHT="4.695592553523394"/>
<IV_DATA CI_END="0.3295770186658308" CI_START="-1.462077018665831" EFFECT_SIZE="-0.56625" ESTIMABLE="YES" ESTIMATE="-0.56625" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:35:33 -0400" MODIFIED_BY="[Empty name]" ORDER="251" SE="0.457063" STUDY_ID="STD-Lyons-2005" TOTAL_1="10" TOTAL_2="10" WEIGHT="2.9022234984152537"/>
<IV_DATA CI_END="0.43421702714171806" CI_START="-0.864557027141718" EFFECT_SIZE="-0.21517" ESTIMABLE="YES" ESTIMATE="-0.21517" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:36:36 -0400" MODIFIED_BY="[Empty name]" ORDER="253" SE="0.331326" STUDY_ID="STD-Miller-1958" TOTAL_1="37" TOTAL_2="36" WEIGHT="4.035093726596871"/>
<IV_DATA CI_END="-0.37810022986199765" CI_START="-1.3826797701380023" EFFECT_SIZE="-0.88039" ESTIMABLE="YES" ESTIMATE="-0.88039" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:35:07 -0400" MODIFIED_BY="[Empty name]" ORDER="250" SE="0.256275" STUDY_ID="STD-NCT00414427" TOTAL_1="33" TOTAL_2="34" WEIGHT="4.8830556292551694"/>
<IV_DATA CI_END="0.4357293579753304" CI_START="-0.7094893579753304" EFFECT_SIZE="-0.13688" ESTIMABLE="YES" ESTIMATE="-0.13688" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:32:56 -0400" MODIFIED_BY="[Empty name]" ORDER="246" SE="0.292153" STUDY_ID="STD-Ozturk-2006" TOTAL_1="23" TOTAL_2="24" WEIGHT="4.464454892194294"/>
<IV_DATA CI_END="0.44727048881596804" CI_START="-0.518270488815968" EFFECT_SIZE="-0.0355" ESTIMABLE="YES" ESTIMATE="-0.0355" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:38:24 -0400" MODIFIED_BY="[Empty name]" ORDER="254" SE="0.246316" STUDY_ID="STD-Petrella-2015" TOTAL_1="34" TOTAL_2="32" WEIGHT="5.002369211945355"/>
<IV_DATA CI_END="-0.05791331549940093" CI_START="-0.8658880845005991" EFFECT_SIZE="-0.4619007" ESTIMABLE="YES" ESTIMATE="-0.4619007" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-29 17:08:24 -0400" MODIFIED_BY="[Empty name]" ORDER="16" SE="0.2061198" STUDY_ID="STD-Ravaud-1999" TOTAL_1="49" TOTAL_2="49" WEIGHT="5.48974248398167"/>
<IV_DATA CI_END="0.9964657920293785" CI_START="-1.4119457920293785" EFFECT_SIZE="-0.20774" ESTIMABLE="YES" ESTIMATE="-0.20774" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:36:02 -0400" MODIFIED_BY="[Empty name]" ORDER="252" SE="0.614402" STUDY_ID="STD-Schue-2011" TOTAL_1="5" TOTAL_2="5" WEIGHT="1.9643326524876672"/>
<IV_DATA CI_END="0.14336289206438446" CI_START="-0.7957028920643845" EFFECT_SIZE="-0.32617" ESTIMABLE="YES" ESTIMATE="-0.32617" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:33:30 -0400" MODIFIED_BY="[Empty name]" ORDER="247" SE="0.239562" STUDY_ID="STD-Smith-2003" TOTAL_1="38" TOTAL_2="33" WEIGHT="5.083810649899236"/>
<IV_DATA CI_END="-1.0748383799595105" CI_START="-1.9956216200404897" EFFECT_SIZE="-1.53523" ESTIMABLE="YES" ESTIMATE="-1.53523" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-28 06:30:10 -0400" MODIFIED_BY="[Empty name]" ORDER="22" SE="0.234898" STUDY_ID="STD-Yavuz-2012" TOTAL_1="90" TOTAL_2="30" WEIGHT="5.140242350822911"/>
<IV_DATA CI_END="0.23369219852699002" CI_START="-1.00289219852699" EFFECT_SIZE="-0.3846" ESTIMABLE="YES" ESTIMATE="-0.3846" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:30:31 -0400" MODIFIED_BY="[Empty name]" ORDER="18" SE="0.315461" STUDY_ID="STD-Young-2001" TOTAL_1="21" TOTAL_2="20" WEIGHT="4.205001469179024"/>
<IV_DATA CI_END="-0.10138014695618897" CI_START="-0.835719853043811" EFFECT_SIZE="-0.46855" ESTIMABLE="YES" ESTIMATE="-0.46855" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:34:12 -0400" MODIFIED_BY="[Empty name]" ORDER="248" SE="0.187335" STUDY_ID="STD-Zhilyayev-2012" TOTAL_1="67" TOTAL_2="52" WEIGHT="5.7160730442262535"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="54.06007757440579" CI_END="4.1244079309388226E-5" CI_START="-0.4370990267586334" DF="17" EFFECT_SIZE="-0.218528891339662" ESTIMABLE="YES" I2="68.55350424423274" ID="CMP-001.02.03" LOG_CI_END="-4.384638386697398" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2015-08-30 03:57:03 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="9.689717384686602E-6" P_Z="0.05004324682064122" STUDIES="18" TAU2="0.1415038722384689" TOTAL_1="646" TOTAL_2="587" WEIGHT="100.00000000000001" Z="1.959594140279918">
<NAME>Pain- 3 months</NAME>
<IV_DATA CI_END="-0.11554433476096637" CI_START="-1.2577956652390336" EFFECT_SIZE="-0.68667" ESTIMABLE="YES" ESTIMATE="-0.68667" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:39:01 -0400" MODIFIED_BY="[Empty name]" ORDER="23" SE="0.291396" STUDY_ID="STD-Beyaz-2012" TOTAL_1="25" TOTAL_2="25" WEIGHT="5.492616839739913"/>
<IV_DATA CI_END="0.2518656788326446" CI_START="-0.5623856788326447" EFFECT_SIZE="-0.15526" ESTIMABLE="YES" ESTIMATE="-0.15526" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:39:52 -0400" MODIFIED_BY="[Empty name]" ORDER="25" SE="0.207721" STUDY_ID="STD-Campos-2013" TOTAL_1="47" TOTAL_2="46" WEIGHT="6.734908699143804"/>
<IV_DATA CI_END="0.7696790445687822" CI_START="-0.23115304456878222" EFFECT_SIZE="0.269263" ESTIMABLE="YES" ESTIMATE="0.269263" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:46:10 -0400" MODIFIED_BY="[Empty name]" ORDER="259" SE="0.255319" STUDY_ID="STD-Castro-2007" TOTAL_1="32" TOTAL_2="30" WEIGHT="6.016757375726199"/>
<IV_DATA CI_END="1.1870631593659149" CI_START="-0.367243159365915" EFFECT_SIZE="0.40991" ESTIMABLE="YES" ESTIMATE="0.40991" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:44:16 -0400" MODIFIED_BY="[Empty name]" ORDER="255" SE="0.396514" STUDY_ID="STD-Cederlof-1966" TOTAL_1="26" TOTAL_2="25" WEIGHT="4.163040701175646"/>
<IV_DATA CI_END="0.1966490442435035" CI_START="-0.8307754442435035" EFFECT_SIZE="-0.3170632" ESTIMABLE="YES" ESTIMATE="-0.3170632" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 03:23:57 -0400" MODIFIED_BY="[Empty name]" ORDER="24" SE="0.2621029" STUDY_ID="STD-Chao-2010" TOTAL_1="30" TOTAL_2="29" WEIGHT="5.91628415889788"/>
<IV_DATA CI_END="0.7369309633838163" CI_START="-0.6079649633838163" EFFECT_SIZE="0.064483" ESTIMABLE="YES" ESTIMATE="0.064483" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:41:19 -0400" MODIFIED_BY="[Empty name]" ORDER="27" SE="0.343092" STUDY_ID="STD-Friedman-1980" TOTAL_1="17" TOTAL_2="17" WEIGHT="4.797595938832987"/>
<IV_DATA CI_END="0.4346204409689527" CI_START="-0.11382844096895264" EFFECT_SIZE="0.160396" ESTIMABLE="YES" ESTIMATE="0.160396" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-30 03:57:03 -0400" MODIFIED_BY="[Empty name]" ORDER="26" SE="0.139913" STUDY_ID="STD-Fri_x0301_as-2004" TOTAL_1="103" TOTAL_2="103" WEIGHT="7.720494792611508"/>
<IV_DATA CI_END="0.7202031634119166" CI_START="-0.5202031634119166" EFFECT_SIZE="0.1" ESTIMABLE="YES" ESTIMATE="0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:44:36 -0400" MODIFIED_BY="[Empty name]" ORDER="256" SE="0.316436" STUDY_ID="STD-Grecomoro-1992" TOTAL_1="20" TOTAL_2="20" WEIGHT="5.146648590255126"/>
<IV_DATA CI_END="0.48649527283826394" CI_START="-0.29793327283826393" EFFECT_SIZE="0.094281" ESTIMABLE="YES" ESTIMATE="0.094281" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:46:31 -0400" MODIFIED_BY="[Empty name]" ORDER="260" SE="0.200113" STUDY_ID="STD-Henriksen-2015" TOTAL_1="50" TOTAL_2="50" WEIGHT="6.850013007880287"/>
<IV_DATA CI_END="-0.5698325971264875" CI_START="-2.6070074028735126" EFFECT_SIZE="-1.58842" ESTIMABLE="YES" ESTIMATE="-1.58842" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:46:52 -0400" MODIFIED_BY="[Empty name]" ORDER="261" SE="0.519697" STUDY_ID="STD-Lyons-2005" TOTAL_1="10" TOTAL_2="10" WEIGHT="3.0214949016608887"/>
<IV_DATA CI_END="0.21186051985779786" CI_START="-0.9418605198577978" EFFECT_SIZE="-0.365" ESTIMABLE="YES" ESTIMATE="-0.365" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:45:04 -0400" MODIFIED_BY="[Empty name]" ORDER="257" SE="0.294322" STUDY_ID="STD-Ozturk-2006" TOTAL_1="23" TOTAL_2="24" WEIGHT="5.451353810651808"/>
<IV_DATA CI_END="0.5021070493201845" CI_START="-0.4633790493201844" EFFECT_SIZE="0.019364" ESTIMABLE="YES" ESTIMATE="0.019364" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:47:29 -0400" MODIFIED_BY="[Empty name]" ORDER="262" SE="0.246302" STUDY_ID="STD-Petrella-2015" TOTAL_1="34" TOTAL_2="32" WEIGHT="6.151370277930206"/>
<IV_DATA CI_END="0.12707420138868847" CI_START="-0.6908172013886884" EFFECT_SIZE="-0.2818715" ESTIMABLE="YES" ESTIMATE="-0.2818715" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-29 17:08:51 -0400" MODIFIED_BY="[Empty name]" ORDER="28" SE="0.2086496" STUDY_ID="STD-Ravaud-1999" TOTAL_1="49" TOTAL_2="49" WEIGHT="6.720835971462609"/>
<IV_DATA CI_END="0.6006891096862246" CI_START="-0.3651925096862245" EFFECT_SIZE="0.1177483" ESTIMABLE="YES" ESTIMATE="0.1177483" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 03:23:57 -0400" MODIFIED_BY="[Empty name]" ORDER="29" SE="0.2464029" STUDY_ID="STD-Raynauld-2003" TOTAL_1="33" TOTAL_2="33" WEIGHT="6.149858007203774"/>
<IV_DATA CI_END="0.1572216833241986" CI_START="-2.480701683324199" EFFECT_SIZE="-1.16174" ESTIMABLE="YES" ESTIMATE="-1.16174" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:48:25 -0400" MODIFIED_BY="[Empty name]" ORDER="263" SE="0.672952" STUDY_ID="STD-Schue-2011" TOTAL_1="5" TOTAL_2="5" WEIGHT="2.0923283827116412"/>
<IV_DATA CI_END="0.4712745101933368" CI_START="-0.46146451019333684" EFFECT_SIZE="0.004905" ESTIMABLE="YES" ESTIMATE="0.004905" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:45:46 -0400" MODIFIED_BY="[Empty name]" ORDER="258" SE="0.237948" STUDY_ID="STD-Smith-2003" TOTAL_1="38" TOTAL_2="33" WEIGHT="6.2769735071814265"/>
<IV_DATA CI_END="-0.8049411782105671" CI_START="-1.695058821789433" EFFECT_SIZE="-1.25" ESTIMABLE="YES" ESTIMATE="-1.25" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-28 06:30:27 -0400" MODIFIED_BY="[Empty name]" ORDER="30" SE="0.227075" STUDY_ID="STD-Yavuz-2012" TOTAL_1="90" TOTAL_2="30" WEIGHT="6.4413600383664456"/>
<IV_DATA CI_END="0.06575328829860738" CI_START="-1.2611932882986074" EFFECT_SIZE="-0.59772" ESTIMABLE="YES" ESTIMATE="-0.59772" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:43:02 -0400" MODIFIED_BY="[Empty name]" ORDER="31" SE="0.338513" STUDY_ID="STD-Zhilyayev-2012" TOTAL_1="14" TOTAL_2="26" WEIGHT="4.856064998567857"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="5.41877511494967" CI_END="0.10650504079801043" CI_START="-0.24910860166642018" DF="6" EFFECT_SIZE="-0.07130178043420488" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.04" LOG_CI_END="-0.9726298369299085" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2015-08-29 17:13:07 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.49132787224942076" P_Z="0.4318913486306838" STUDIES="7" TAU2="0.0" TOTAL_1="267" TOTAL_2="259" WEIGHT="99.99999999999997" Z="0.7859592827550328">
<NAME>Pain- 6 months</NAME>
<IV_DATA CI_END="0.2189035933582947" CI_START="-0.5959435933582947" EFFECT_SIZE="-0.18852" ESTIMABLE="YES" ESTIMATE="-0.18852" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:48:41 -0400" MODIFIED_BY="[Empty name]" ORDER="32" SE="0.207873" STUDY_ID="STD-Campos-2013" TOTAL_1="47" TOTAL_2="46" WEIGHT="19.046030966858524"/>
<IV_DATA CI_END="0.4600654347830987" CI_START="-0.3241514347830987" EFFECT_SIZE="0.067957" ESTIMABLE="YES" ESTIMATE="0.067957" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:52:31 -0400" MODIFIED_BY="[Empty name]" ORDER="268" SE="0.200059" STUDY_ID="STD-Henriksen-2015" TOTAL_1="50" TOTAL_2="50" WEIGHT="20.562904872527405"/>
<IV_DATA CI_END="1.3959313611790216" CI_START="-0.5587093611790217" EFFECT_SIZE="0.418611" ESTIMABLE="YES" ESTIMATE="0.418611" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:50:01 -0400" MODIFIED_BY="[Empty name]" ORDER="264" SE="0.498642" STUDY_ID="STD-Miller-1958" TOTAL_1="26" TOTAL_2="25" WEIGHT="3.3099614985550407"/>
<IV_DATA CI_END="0.12337602903998396" CI_START="-1.035876029039984" EFFECT_SIZE="-0.45625" ESTIMABLE="YES" ESTIMATE="-0.45625" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:51:06 -0400" MODIFIED_BY="[Empty name]" ORDER="265" SE="0.295733" STUDY_ID="STD-Ozturk-2006" TOTAL_1="23" TOTAL_2="24" WEIGHT="9.410248147044989"/>
<IV_DATA CI_END="0.3934702049623138" CI_START="-0.5724902049623138" EFFECT_SIZE="-0.08951" ESTIMABLE="YES" ESTIMATE="-0.08951" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:53:29 -0400" MODIFIED_BY="[Empty name]" ORDER="269" SE="0.246423" STUDY_ID="STD-Petrella-2015" TOTAL_1="34" TOTAL_2="32" WEIGHT="13.553085334260835"/>
<IV_DATA CI_END="0.1955511858047974" CI_START="-0.6061865858047975" EFFECT_SIZE="-0.2053177" ESTIMABLE="YES" ESTIMATE="-0.2053177" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-29 17:13:07 -0400" MODIFIED_BY="[Empty name]" ORDER="33" SE="0.2045287" STUDY_ID="STD-Ravaud-1999" TOTAL_1="49" TOTAL_2="49" WEIGHT="19.673976023518396"/>
<IV_DATA CI_END="0.6910182429656491" CI_START="-0.2446842429656491" EFFECT_SIZE="0.223167" ESTIMABLE="YES" ESTIMATE="0.223167" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:52:04 -0400" MODIFIED_BY="[Empty name]" ORDER="267" SE="0.238704" STUDY_ID="STD-Smith-2003" TOTAL_1="38" TOTAL_2="33" WEIGHT="14.443793157234802"/>
</IV_SUBGROUP>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2015-10-19 09:54:57 -0400" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Function</NAME>
<IV_OUTCOME CHI2="45.87650285125289" CI_END="-0.08965639442882259" CI_START="-0.563320529347197" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_SIZE="-0.3264884618880098" ESTIMABLE="YES" I2="69.4832885466603" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2015-10-19 09:54:47 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="2.937039937767061E-5" P_Q="1.0" P_Z="0.006893655978809046" Q="0.0" RANDOM="YES" SCALE="2.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.1457812348476609" TOTALS="YES" TOTAL_1="546" TOTAL_2="468" WEIGHT="99.99999999999999" Z="2.701938270156979">
<NAME>Function - Main</NAME>
<GROUP_LABEL_1>IA Corticosteroid</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours corticosteroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Std. Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="-0.5025176383159513" CI_START="-1.6952223616840487" EFFECT_SIZE="-1.09887" ESTIMABLE="YES" ESTIMATE="-1.09887" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 05:54:58 -0400" MODIFIED_BY="[Empty name]" ORDER="69" SE="0.304267" STUDY_ID="STD-Beyaz-2012" TOTAL_1="25" TOTAL_2="25" WEIGHT="6.125648966403647"/>
<IV_DATA CI_END="0.38209848623882503" CI_START="-0.39042288623882504" EFFECT_SIZE="-0.0041622" ESTIMABLE="YES" ESTIMATE="-0.0041622" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 03:24:35 -0400" MODIFIED_BY="[Empty name]" ORDER="68" SE="0.1970754" STUDY_ID="STD-Campos-2013" TOTAL_1="52" TOTAL_2="51" WEIGHT="7.908720104483707"/>
<IV_DATA CI_END="0.7764007224798855" CI_START="-0.2246587224798855" EFFECT_SIZE="0.275871" ESTIMABLE="YES" ESTIMATE="0.275871" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 07:13:02 -0400" MODIFIED_BY="[Empty name]" ORDER="74" SE="0.255377" STUDY_ID="STD-Castro-2007" TOTAL_1="32" TOTAL_2="30" WEIGHT="6.91998511084427"/>
<IV_DATA CI_END="-0.449287042172166" CI_START="-1.495694957827834" EFFECT_SIZE="-0.972491" ESTIMABLE="YES" ESTIMATE="-0.972491" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 03:24:35 -0400" MODIFIED_BY="[Empty name]" ORDER="70" SE="0.2669457" STUDY_ID="STD-Chao-2010" TOTAL_1="32" TOTAL_2="31" WEIGHT="6.727327418277513"/>
<IV_DATA CI_END="0.14263647475151764" CI_START="-1.1161268747515176" EFFECT_SIZE="-0.4867452" ESTIMABLE="YES" ESTIMATE="-0.4867452" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 03:24:35 -0400" MODIFIED_BY="[Empty name]" ORDER="71" SE="0.321119" STUDY_ID="STD-Di-Sante-2012" TOTAL_1="20" TOTAL_2="20" WEIGHT="5.866273332678955"/>
<IV_DATA CI_END="0.6375840788809619" CI_START="-0.2201980788809619" EFFECT_SIZE="0.208693" ESTIMABLE="YES" ESTIMATE="0.208693" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 06:00:23 -0400" MODIFIED_BY="[Empty name]" ORDER="208" SE="0.218826" STUDY_ID="STD-Gaffney-1995" TOTAL_1="42" TOTAL_2="42" WEIGHT="7.539305272847496"/>
<IV_DATA CI_END="0.4920687123340474" CI_START="-0.2924147123340474" EFFECT_SIZE="0.099827" ESTIMABLE="YES" ESTIMATE="0.099827" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 06:03:46 -0400" MODIFIED_BY="[Empty name]" ORDER="212" SE="0.200127" STUDY_ID="STD-Henriksen-2015" TOTAL_1="50" TOTAL_2="50" WEIGHT="7.857134911943464"/>
<IV_DATA CI_END="-0.17940056584171382" CI_START="-2.0816914341582864" EFFECT_SIZE="-1.130546" ESTIMABLE="YES" ESTIMATE="-1.130546" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 03:24:35 -0400" MODIFIED_BY="[Empty name]" ORDER="75" SE="0.4852872" STUDY_ID="STD-Lyons-2005" TOTAL_1="10" TOTAL_2="10" WEIGHT="3.8294395880557497"/>
<IV_DATA CI_END="0.4887787735700087" CI_START="-0.47624477357000866" EFFECT_SIZE="0.006267" ESTIMABLE="YES" ESTIMATE="0.006267" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 06:01:27 -0400" MODIFIED_BY="[Empty name]" ORDER="210" SE="0.246184" STUDY_ID="STD-Petrella-2015" TOTAL_1="33" TOTAL_2="33" WEIGHT="7.074582503457098"/>
<IV_DATA CI_END="-0.26827428488284755" CI_START="-1.9083737151171527" EFFECT_SIZE="-1.088324" ESTIMABLE="YES" ESTIMATE="-1.088324" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-28 08:37:21 -0400" MODIFIED_BY="[Empty name]" ORDER="213" SE="0.4184004" STUDY_ID="STD-Popov-1989" TOTAL_1="19" TOTAL_2="11" WEIGHT="4.550887999744853"/>
<IV_DATA CI_END="0.056443009526863264" CI_START="-0.7431482095268633" EFFECT_SIZE="-0.3433526" ESTIMABLE="YES" ESTIMATE="-0.3433526" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-30 04:00:20 -0400" MODIFIED_BY="[Empty name]" ORDER="67" SE="0.2039811" STUDY_ID="STD-Ravaud-1999" TOTAL_1="49" TOTAL_2="49" WEIGHT="7.791830964087547"/>
<IV_DATA CI_END="0.5485950511209574" CI_START="-0.41669505112095745" EFFECT_SIZE="0.06595" ESTIMABLE="YES" ESTIMATE="0.06595" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 06:03:03 -0400" MODIFIED_BY="[Empty name]" ORDER="211" SE="0.246252" STUDY_ID="STD-Raynauld-2003" TOTAL_1="33" TOTAL_2="33" WEIGHT="7.0734348651091565"/>
<IV_DATA CI_END="0.15715633696248704" CI_START="-0.7813763369624871" EFFECT_SIZE="-0.31211" ESTIMABLE="YES" ESTIMATE="-0.31211" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 05:59:40 -0400" MODIFIED_BY="[Empty name]" ORDER="207" SE="0.239426" STUDY_ID="STD-Smith-2003" TOTAL_1="38" TOTAL_2="33" WEIGHT="7.18889238549699"/>
<IV_DATA CI_END="-0.38262329864503986" CI_START="-1.23665330135496" EFFECT_SIZE="-0.8096383" ESTIMABLE="YES" ESTIMATE="-0.8096383" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-28 08:38:47 -0400" MODIFIED_BY="[Empty name]" ORDER="72" SE="0.2178688" STUDY_ID="STD-Yavuz-2012" TOTAL_1="90" TOTAL_2="30" WEIGHT="7.55561313085364"/>
<IV_DATA CI_END="0.4554657649041852" CI_START="-0.7712819649041852" EFFECT_SIZE="-0.1579081" ESTIMABLE="YES" ESTIMATE="-0.1579081" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 03:24:35 -0400" MODIFIED_BY="[Empty name]" ORDER="73" SE="0.3129516" STUDY_ID="STD-Young-2001" TOTAL_1="21" TOTAL_2="20" WEIGHT="5.9909234457159055"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="112.01171967590092" CI_END="-0.05133976011044028" CI_START="-0.29827040432072804" CI_STUDY="95" CI_TOTAL="95" DF="36" EFFECT_SIZE="-0.17480508221558416" ESTIMABLE="YES" I2="67.8605059326258" I2_Q="68.65694712849063" ID="CMP-002.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2015-10-19 09:54:57 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="9.96454696533533E-10" P_Q="0.02258285449134312" P_Z="0.005520803668123373" Q="9.571499024994408" RANDOM="YES" SCALE="2.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.1234062926662607" TOTALS="SUB" TOTAL_1="1464" TOTAL_2="1245" WEIGHT="400.0" Z="2.774962715160924">
<NAME>Function - Timepoints</NAME>
<GROUP_LABEL_1>IA Corticosteroid</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours corticosteroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Std. Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="32.018892085095445" CI_END="-0.1448121443637279" CI_START="-0.7177104480780817" DF="9" EFFECT_SIZE="-0.4312612962209048" ESTIMABLE="YES" I2="71.89159457459981" ID="CMP-002.02.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2015-08-29 17:27:53 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.9763721682164448E-4" P_Z="0.0031694329665795952" STUDIES="10" TAU2="0.14846238913153145" TOTAL_1="419" TOTAL_2="344" WEIGHT="99.99999999999999" Z="2.9508085572565315">
<NAME>Function - 1-2 weeks</NAME>
<IV_DATA CI_END="-0.7493056953985195" CI_START="-1.9856643046014806" EFFECT_SIZE="-1.367485" ESTIMABLE="YES" ESTIMATE="-1.367485" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 07:18:11 -0400" MODIFIED_BY="[Empty name]" ORDER="39" SE="0.3154034" STUDY_ID="STD-Beyaz-2012" TOTAL_1="25" TOTAL_2="25" WEIGHT="8.614882045646679"/>
<IV_DATA CI_END="-0.2533788495519325" CI_START="-1.0424211504480676" EFFECT_SIZE="-0.6479" ESTIMABLE="YES" ESTIMATE="-0.6479" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 03:24:35 -0400" MODIFIED_BY="[Empty name]" ORDER="34" SE="0.20129" STUDY_ID="STD-Campos-2013" TOTAL_1="52" TOTAL_2="52" WEIGHT="11.302719045228743"/>
<IV_DATA CI_END="0.7570988809507431" CI_START="-0.4840106809507431" EFFECT_SIZE="0.1365441" ESTIMABLE="YES" ESTIMATE="0.1365441" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 03:24:35 -0400" MODIFIED_BY="[Empty name]" ORDER="37" SE="0.3166154" STUDY_ID="STD-Di-Sante-2012" TOTAL_1="20" TOTAL_2="20" WEIGHT="8.588348656906014"/>
<IV_DATA CI_END="0.42769937077836157" CI_START="-0.4276994707783615" EFFECT_SIZE="-5.0E-8" ESTIMABLE="YES" ESTIMATE="-5.0E-8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 07:28:53 -0400" MODIFIED_BY="[Empty name]" ORDER="218" SE="0.218218" STUDY_ID="STD-Gaffney-1995" TOTAL_1="42" TOTAL_2="42" WEIGHT="10.893371450041785"/>
<IV_DATA CI_END="0.4920687083304459" CI_START="-0.2924151083304459" EFFECT_SIZE="0.0998268" ESTIMABLE="YES" ESTIMATE="0.0998268" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 07:18:11 -0400" MODIFIED_BY="[Empty name]" ORDER="40" SE="0.2001271" STUDY_ID="STD-Henriksen-2015" TOTAL_1="50" TOTAL_2="50" WEIGHT="11.330707524494915"/>
<IV_DATA CI_END="0.11332619410778189" CI_START="-0.8607813941077819" EFFECT_SIZE="-0.3737276" ESTIMABLE="YES" ESTIMATE="-0.3737276" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 07:18:11 -0400" MODIFIED_BY="[Empty name]" ORDER="41" SE="0.2485014" STUDY_ID="STD-Petrella-2015" TOTAL_1="34" TOTAL_2="32" WEIGHT="10.160954468446189"/>
<IV_DATA CI_END="-0.26827428488284755" CI_START="-1.9083737151171527" EFFECT_SIZE="-1.088324" ESTIMABLE="YES" ESTIMATE="-1.088324" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-28 08:39:58 -0400" MODIFIED_BY="[Empty name]" ORDER="38" SE="0.4184004" STUDY_ID="STD-Popov-1989" TOTAL_1="19" TOTAL_2="11" WEIGHT="6.602311975887039"/>
<IV_DATA CI_END="0.053821449424702406" CI_START="-0.7462162494247024" EFFECT_SIZE="-0.3461974" ESTIMABLE="YES" ESTIMATE="-0.3461974" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-29 17:26:11 -0400" MODIFIED_BY="[Empty name]" ORDER="35" SE="0.204095" STUDY_ID="STD-Ravaud-1999" TOTAL_1="49" TOTAL_2="49" WEIGHT="11.235116638287446"/>
<IV_DATA CI_END="0.29404325377028706" CI_START="-0.6404832537702871" EFFECT_SIZE="-0.17322" ESTIMABLE="YES" ESTIMATE="-0.17322" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 07:29:32 -0400" MODIFIED_BY="[Empty name]" ORDER="219" SE="0.238404" STUDY_ID="STD-Smith-2003" TOTAL_1="38" TOTAL_2="33" WEIGHT="10.4042880940971"/>
<IV_DATA CI_END="-0.458315325945461" CI_START="-1.3179288740545392" EFFECT_SIZE="-0.8881221" ESTIMABLE="YES" ESTIMATE="-0.8881221" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-28 08:41:32 -0400" MODIFIED_BY="[Empty name]" ORDER="36" SE="0.2192932" STUDY_ID="STD-Yavuz-2012" TOTAL_1="90" TOTAL_2="30" WEIGHT="10.867300100964076"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="36.55068012685858" CI_END="-0.09436392549729505" CI_START="-0.6259023269514765" DF="11" EFFECT_SIZE="-0.36013312622438576" ESTIMABLE="YES" I2="69.90480078121212" ID="CMP-002.02.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2015-08-29 17:28:34 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.370035909875611E-4" P_Z="0.00791045349237509" STUDIES="12" TAU2="0.14874322262960382" TOTAL_1="444" TOTAL_2="374" WEIGHT="100.0" Z="2.6558681559358885">
<NAME>Function - 4-6 weeks</NAME>
<IV_DATA CI_END="-0.5025196383159514" CI_START="-1.6952243616840488" EFFECT_SIZE="-1.098872" ESTIMABLE="YES" ESTIMATE="-1.098872" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 07:32:28 -0400" MODIFIED_BY="[Empty name]" ORDER="51" SE="0.304267" STUDY_ID="STD-Beyaz-2012" TOTAL_1="25" TOTAL_2="25" WEIGHT="7.619331490941265"/>
<IV_DATA CI_END="0.38209848623882503" CI_START="-0.39042288623882504" EFFECT_SIZE="-0.0041622" ESTIMABLE="YES" ESTIMATE="-0.0041622" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 03:24:35 -0400" MODIFIED_BY="[Empty name]" ORDER="43" SE="0.1970754" STUDY_ID="STD-Campos-2013" TOTAL_1="52" TOTAL_2="51" WEIGHT="9.802167172000996"/>
<IV_DATA CI_END="0.7764007224798855" CI_START="-0.2246587224798855" EFFECT_SIZE="0.275871" ESTIMABLE="YES" ESTIMATE="0.275871" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 07:39:40 -0400" MODIFIED_BY="[Empty name]" ORDER="49" SE="0.255377" STUDY_ID="STD-Castro-2007" TOTAL_1="32" TOTAL_2="30" WEIGHT="8.593681245891675"/>
<IV_DATA CI_END="-0.45170604217216603" CI_START="-1.498113957827834" EFFECT_SIZE="-0.97491" ESTIMABLE="YES" ESTIMATE="-0.97491" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 03:24:35 -0400" MODIFIED_BY="[Empty name]" ORDER="44" SE="0.2669457" STUDY_ID="STD-Chao-2010" TOTAL_1="32" TOTAL_2="31" WEIGHT="8.357647746725196"/>
<IV_DATA CI_END="0.1426316747515176" CI_START="-1.1161316747515175" EFFECT_SIZE="-0.48675" ESTIMABLE="YES" ESTIMATE="-0.48675" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 07:42:32 -0400" MODIFIED_BY="[Empty name]" ORDER="46" SE="0.321119" STUDY_ID="STD-Di-Sante-2012" TOTAL_1="20" TOTAL_2="20" WEIGHT="7.300503692499583"/>
<IV_DATA CI_END="0.6375840788809619" CI_START="-0.2201980788809619" EFFECT_SIZE="0.208693" ESTIMABLE="YES" ESTIMATE="0.208693" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 07:54:09 -0400" MODIFIED_BY="[Empty name]" ORDER="225" SE="0.218826" STUDY_ID="STD-Gaffney-1995" TOTAL_1="42" TOTAL_2="42" WEIGHT="9.351206907293607"/>
<IV_DATA CI_END="-0.17940056584171382" CI_START="-2.0816914341582864" EFFECT_SIZE="-1.130546" ESTIMABLE="YES" ESTIMATE="-1.130546" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 03:24:35 -0400" MODIFIED_BY="[Empty name]" ORDER="50" SE="0.4852872" STUDY_ID="STD-Lyons-2005" TOTAL_1="10" TOTAL_2="10" WEIGHT="4.785229357422951"/>
<IV_DATA CI_END="0.48877798958441493" CI_START="-0.4762439895844149" EFFECT_SIZE="0.006267" ESTIMABLE="YES" ESTIMATE="0.006267" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 07:47:36 -0400" MODIFIED_BY="[Empty name]" ORDER="53" SE="0.2461836" STUDY_ID="STD-Petrella-2015" TOTAL_1="33" TOTAL_2="33" WEIGHT="8.782962106124941"/>
<IV_DATA CI_END="0.056443009526863264" CI_START="-0.7431482095268633" EFFECT_SIZE="-0.3433526" ESTIMABLE="YES" ESTIMATE="-0.3433526" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-29 17:27:28 -0400" MODIFIED_BY="[Empty name]" ORDER="42" SE="0.2039811" STUDY_ID="STD-Ravaud-1999" TOTAL_1="49" TOTAL_2="49" WEIGHT="9.659547628617599"/>
<IV_DATA CI_END="0.15715633696248704" CI_START="-0.7813763369624871" EFFECT_SIZE="-0.31211" ESTIMABLE="YES" ESTIMATE="-0.31211" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 09:19:53 -0400" MODIFIED_BY="[Empty name]" ORDER="224" SE="0.239426" STUDY_ID="STD-Smith-2003" TOTAL_1="38" TOTAL_2="33" WEIGHT="8.922827454099274"/>
<IV_DATA CI_END="-0.38262329864503986" CI_START="-1.23665330135496" EFFECT_SIZE="-0.8096383" ESTIMABLE="YES" ESTIMATE="-0.8096383" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-28 08:42:47 -0400" MODIFIED_BY="[Empty name]" ORDER="47" SE="0.2178688" STUDY_ID="STD-Yavuz-2012" TOTAL_1="90" TOTAL_2="30" WEIGHT="9.371128642257862"/>
<IV_DATA CI_END="0.4554657649041852" CI_START="-0.7712819649041852" EFFECT_SIZE="-0.1579081" ESTIMABLE="YES" ESTIMATE="-0.1579081" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 03:24:35 -0400" MODIFIED_BY="[Empty name]" ORDER="48" SE="0.3129516" STUDY_ID="STD-Young-2001" TOTAL_1="21" TOTAL_2="20" WEIGHT="7.45376655612506"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="26.102830832408035" CI_END="0.10297142291409228" CI_START="-0.3677922046044848" DF="10" EFFECT_SIZE="-0.13241039084519626" ESTIMABLE="YES" I2="61.68997889844011" ID="CMP-002.02.03" LOG_CI_END="-0.9872832859037525" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2015-08-29 17:32:10 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0036043232217725096" P_Z="0.2702237984689775" STUDIES="11" TAU2="0.09490934765241621" TOTAL_1="433" TOTAL_2="367" WEIGHT="100.00000000000001" Z="1.1025473595035364">
<NAME>Function - 3 months</NAME>
<IV_DATA CI_END="-0.4465769985777228" CI_START="-1.630603001422277" EFFECT_SIZE="-1.03859" ESTIMABLE="YES" ESTIMATE="-1.03859" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 07:56:25 -0400" MODIFIED_BY="[Empty name]" ORDER="57" SE="0.302053" STUDY_ID="STD-Beyaz-2012" TOTAL_1="25" TOTAL_2="25" WEIGHT="7.7481390689804615"/>
<IV_DATA CI_END="0.40480123430717013" CI_START="-0.4082012343071701" EFFECT_SIZE="-0.0017" ESTIMABLE="YES" ESTIMATE="-0.0017" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 07:58:01 -0400" MODIFIED_BY="[Empty name]" ORDER="56" SE="0.2074024" STUDY_ID="STD-Campos-2013" TOTAL_1="47" TOTAL_2="46" WEIGHT="10.456980797278383"/>
<IV_DATA CI_END="0.8851480013502302" CI_START="-0.12038800135023014" EFFECT_SIZE="0.38238" ESTIMABLE="YES" ESTIMATE="0.38238" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 07:56:58 -0400" MODIFIED_BY="[Empty name]" ORDER="60" SE="0.256519" STUDY_ID="STD-Castro-2007" TOTAL_1="32" TOTAL_2="30" WEIGHT="8.97435184352683"/>
<IV_DATA CI_END="0.16132896033389804" CI_START="-0.918328960333898" EFFECT_SIZE="-0.3785" ESTIMABLE="YES" ESTIMATE="-0.3785" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 07:57:45 -0400" MODIFIED_BY="[Empty name]" ORDER="58" SE="0.275428" STUDY_ID="STD-Chao-2010" TOTAL_1="25" TOTAL_2="29" WEIGHT="8.445750070475906"/>
<IV_DATA CI_END="0.400313460875597" CI_START="-0.38367566087559696" EFFECT_SIZE="0.0083189" ESTIMABLE="YES" ESTIMATE="0.0083189" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 03:24:35 -0400" MODIFIED_BY="[Empty name]" ORDER="61" SE="0.2000009" STUDY_ID="STD-Henriksen-2015" TOTAL_1="50" TOTAL_2="50" WEIGHT="10.69070699570475"/>
<IV_DATA CI_END="0.5888524137394403" CI_START="-1.1746040137394402" EFFECT_SIZE="-0.2928758" ESTIMABLE="YES" ESTIMATE="-0.2928758" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 03:24:35 -0400" MODIFIED_BY="[Empty name]" ORDER="62" SE="0.4498696" STUDY_ID="STD-Lyons-2005" TOTAL_1="10" TOTAL_2="10" WEIGHT="4.851392344247238"/>
<IV_DATA CI_END="0.5425130234978022" CI_START="-0.4231714234978022" EFFECT_SIZE="0.0596708" ESTIMABLE="YES" ESTIMATE="0.0596708" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 03:24:35 -0400" MODIFIED_BY="[Empty name]" ORDER="63" SE="0.2463526" STUDY_ID="STD-Petrella-2015" TOTAL_1="34" TOTAL_2="32" WEIGHT="9.269215148731982"/>
<IV_DATA CI_END="0.45191811487656414" CI_START="-0.3418665148765641" EFFECT_SIZE="0.0550258" ESTIMABLE="YES" ESTIMATE="0.0550258" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-29 17:32:10 -0400" MODIFIED_BY="[Empty name]" ORDER="55" SE="0.2024998" STUDY_ID="STD-Ravaud-1999" TOTAL_1="49" TOTAL_2="49" WEIGHT="10.611593075754708"/>
<IV_DATA CI_END="0.5485953511209575" CI_START="-0.41669475112095744" EFFECT_SIZE="0.0659503" ESTIMABLE="YES" ESTIMATE="0.0659503" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 07:59:38 -0400" MODIFIED_BY="[Empty name]" ORDER="54" SE="0.246252" STUDY_ID="STD-Raynauld-2003" TOTAL_1="33" TOTAL_2="33" WEIGHT="9.272168200631771"/>
<IV_DATA CI_END="0.6358622146346582" CI_START="-0.29857021463465816" EFFECT_SIZE="0.168646" ESTIMABLE="YES" ESTIMATE="0.168646" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:01:50 -0400" MODIFIED_BY="[Empty name]" ORDER="228" SE="0.23838" STUDY_ID="STD-Smith-2003" TOTAL_1="38" TOTAL_2="33" WEIGHT="9.50529623504552"/>
<IV_DATA CI_END="-0.3061120031933537" CI_START="-1.1545419968066462" EFFECT_SIZE="-0.730327" ESTIMABLE="YES" ESTIMATE="-0.730327" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-28 08:43:07 -0400" MODIFIED_BY="[Empty name]" ORDER="59" SE="0.2164402" STUDY_ID="STD-Yavuz-2012" TOTAL_1="90" TOTAL_2="30" WEIGHT="10.174406219622455"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="2.2366254415364493" CI_END="0.2773668396629284" CI_START="-0.15693343295637327" DF="3" EFFECT_SIZE="0.06021670335327758" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.04" LOG_CI_END="-0.5569454618360724" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.2202830242246252" MODIFIED="2015-08-29 17:33:52 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.5247704738078343" P_Z="0.5867809312117411" STUDIES="4" TAU2="0.0" TOTAL_1="168" TOTAL_2="160" WEIGHT="100.0" Z="0.543506772990734">
<NAME>Function - 6 months</NAME>
<IV_DATA CI_END="0.34088484424708587" CI_START="-0.4723418442470858" EFFECT_SIZE="-0.0657285" ESTIMABLE="YES" ESTIMATE="-0.0657285" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 03:24:35 -0400" MODIFIED_BY="[Empty name]" ORDER="65" SE="0.2074596" STUDY_ID="STD-Campos-2013" TOTAL_1="47" TOTAL_2="46" WEIGHT="28.520488390048293"/>
<IV_DATA CI_END="0.4671793333958169" CI_START="-0.4982985333958169" EFFECT_SIZE="-0.0155596" ESTIMABLE="YES" ESTIMATE="-0.0155596" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 03:24:35 -0400" MODIFIED_BY="[Empty name]" ORDER="66" SE="0.2462999" STUDY_ID="STD-Petrella-2015" TOTAL_1="34" TOTAL_2="32" WEIGHT="20.234643607139812"/>
<IV_DATA CI_END="0.405067076281167" CI_START="-0.388564676281167" EFFECT_SIZE="0.0082512" ESTIMABLE="YES" ESTIMATE="0.0082512" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-29 17:33:52 -0400" MODIFIED_BY="[Empty name]" ORDER="64" SE="0.2024608" STUDY_ID="STD-Ravaud-1999" TOTAL_1="49" TOTAL_2="49" WEIGHT="29.946228455224563"/>
<IV_DATA CI_END="0.8444485938045463" CI_START="-0.09660459380454633" EFFECT_SIZE="0.373922" ESTIMABLE="YES" ESTIMATE="0.373922" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-27 08:04:25 -0400" MODIFIED_BY="[Empty name]" ORDER="230" SE="0.240069" STUDY_ID="STD-Smith-2003" TOTAL_1="38" TOTAL_2="33" WEIGHT="21.298639547587335"/>
</IV_SUBGROUP>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2015-10-19 09:55:07 -0400" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Quality of life</NAME>
<IV_OUTCOME CHI2="0.0028167458064216108" CI_END="0.28044541556681635" CI_START="-0.29752127649906546" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="-0.008537930466124577" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-0.5521516549959071" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2015-10-19 09:55:07 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9576737477828986" P_Q="1.0" P_Z="0.9538230446737102" Q="0.0" RANDOM="YES" SCALE="2.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="92" TOTAL_2="92" WEIGHT="99.99999999999999" Z="0.05790657643712089">
<NAME>Quality of life - Main</NAME>
<GROUP_LABEL_1>IA Corticosteroid</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours corticosteroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Std. Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="0.42769942077836154" CI_START="-0.42769942077836154" EFFECT_SIZE="0.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-28 07:21:24 -0400" MODIFIED_BY="[Empty name]" ORDER="169" SE="0.218218" STUDY_ID="STD-Gaffney-1995" TOTAL_1="42" TOTAL_2="42" WEIGHT="45.65289327737378"/>
<IV_DATA CI_END="0.37628867679996447" CI_START="-0.4077086767999645" EFFECT_SIZE="-0.01571" ESTIMABLE="YES" ESTIMATE="-0.01571" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-28 07:27:53 -0400" MODIFIED_BY="[Empty name]" ORDER="168" SE="0.200003" STUDY_ID="STD-Henriksen-2015" TOTAL_1="50" TOTAL_2="50" WEIGHT="54.34710672262621"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2015-10-19 09:55:18 -0400" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Number of participants experiencing any adverse event</NAME>
<DICH_OUTCOME CHI2="0.6084037469951897" CI_END="1.2344657041787708" CI_START="0.6380246574194908" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8874793282126466" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.09147902890318077" LOG_CI_START="-0.19516253699310795" LOG_EFFECT_SIZE="-0.05184175404496362" METHOD="IV" MODIFIED="2015-10-19 09:55:18 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4353896409362509" P_Q="1.0" P_Z="0.47835247194080155" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="42" TOTAL_2="42" WEIGHT="100.0" Z="0.7089548963758847">
<NAME>Number of participants experiencing any adverse event - Main</NAME>
<GROUP_LABEL_1>IA Corticosteroid</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours corticosteroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2194376939880056" CI_START="0.6278508559925905" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="24" LOG_CI_END="0.08615961535211286" LOG_CI_START="-0.2021435093074864" LOG_EFFECT_SIZE="-0.057991946977686754" MODIFIED="2015-08-28 06:05:52 -0400" MODIFIED_BY="[Empty name]" ORDER="157" O_E="0.0" SE="0.16935068254853203" STUDY_ID="STD-Petrella-2015" TOTAL_1="33" TOTAL_2="33" VAR="0.028679653679653666" WEIGHT="98.85067441557878"/>
<DICH_DATA CI_END="65.16081469815073" CI_START="0.1381198200435548" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8139865056042341" LOG_CI_START="-0.8597439961649093" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2015-08-29 17:36:53 -0400" MODIFIED_BY="[Empty name]" ORDER="160" O_E="0.0" SE="1.5705625319186327" STUDY_ID="STD-Wright-1960" TOTAL_1="9" TOTAL_2="9" VAR="2.4666666666666663" WEIGHT="1.1493255844212167"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2015-10-19 09:55:27 -0400" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Number of participants who withdraw because of adverse events</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.0672648917079823" CI_START="0.05374788279759865" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.31539612908800346" LOG_CI_START="-1.2696386385273284" LOG_EFFECT_SIZE="-0.47712125471966244" METHOD="IV" MODIFIED="2015-10-19 09:55:27 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.2380153104434316" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="102" TOTAL_2="102" WEIGHT="100.0" Z="1.1799620987696173">
<NAME>Number of participants who with draw because of adverse events -Main</NAME>
<GROUP_LABEL_1>IA Corticosteroid</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours corticosteroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.998619777376188" CI_START="0.013891285522207827" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9030150526439626" LOG_CI_START="-1.8572575620832878" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2015-08-28 06:08:27 -0400" MODIFIED_BY="[Empty name]" ORDER="159" O_E="0.0" SE="1.621397797460593" STUDY_ID="STD-Campos-2013" TOTAL_1="52" TOTAL_2="52" VAR="2.6289308176100623" WEIGHT="32.97415175421718"/>
<DICH_DATA CI_END="3.0967497955252377" CI_START="0.035879912310534466" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4909061175904471" LOG_CI_START="-1.4451486270297722" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2015-08-28 06:08:05 -0400" MODIFIED_BY="[Empty name]" ORDER="158" O_E="0.0" SE="1.1372481406154653" STUDY_ID="STD-Henriksen-2015" TOTAL_1="50" TOTAL_2="50" VAR="1.2933333333333332" WEIGHT="67.02584824578283"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2015-10-19 09:56:30 -0400" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Number of participants experiencing any serious adverse event</NAME>
<DICH_OUTCOME CHI2="0.5405716029698047" CI_END="2.674000090032367" CI_START="0.1483720798609544" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6298785239286077" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.4271614175484635" LOG_CI_START="-0.828647815385313" LOG_EFFECT_SIZE="-0.20074319891842476" METHOD="IV" MODIFIED="2015-10-19 09:56:30 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4621960179098549" P_Q="1.0" P_Z="0.5309168697271931" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="165" TOTAL_2="166" WEIGHT="100.0" Z="0.6266070191287096">
<NAME>Number of participants experiencing any serious adverse event - Main</NAME>
<GROUP_LABEL_1>IA Corticosteroid</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours corticosteroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.0967497955252377" CI_START="0.035879912310534466" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4909061175904471" LOG_CI_START="-1.4451486270297722" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2015-08-28 06:13:09 -0400" MODIFIED_BY="[Empty name]" ORDER="160" O_E="0.0" SE="1.1372481406154653" STUDY_ID="STD-Henriksen-2015" TOTAL_1="50" TOTAL_2="50" VAR="1.2933333333333332" WEIGHT="42.073832790445174"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-28 06:13:43 -0400" MODIFIED_BY="[Empty name]" ORDER="162" O_E="0.0" SE="0.0" STUDY_ID="STD-Lyons-2005" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-28 06:14:07 -0400" MODIFIED_BY="[Empty name]" ORDER="163" O_E="0.0" SE="0.0" STUDY_ID="STD-Ozturk-2006" TOTAL_1="23" TOTAL_2="24" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.683507312873237" CI_START="0.1496220402233839" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.825004427578788" LOG_CI_START="-0.825004427578788" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-28 06:13:24 -0400" MODIFIED_BY="[Empty name]" ORDER="161" O_E="0.0" SE="0.9692233691951198" STUDY_ID="STD-Petrella-2015" TOTAL_1="33" TOTAL_2="33" VAR="0.9393939393939394" WEIGHT="57.92616720955483"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-30 05:20:16 -0400" MODIFIED_BY="[Empty name]" ORDER="164" O_E="0.0" SE="0.0" STUDY_ID="STD-Ravaud-1999" TOTAL_1="49" TOTAL_2="49" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2015-10-19 09:55:39 -0400" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Joint space narrowing</NAME>
<IV_OUTCOME CHI2="0.0" CI_END="0.4569716247743293" CI_START="-0.49377162477432934" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="-0.0184" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="-0.340110766202628" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2015-10-19 09:55:39 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.9395277259497161" Q="0.0" RANDOM="YES" SCALE="2.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="34" TOTAL_2="34" WEIGHT="100.0" Z="0.07586346225998902">
<NAME>Joint space narrowing - Main</NAME>
<GROUP_LABEL_1>IA Corticosteroid</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours corticosteroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Std. Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="0.4569716247743293" CI_START="-0.49377162477432934" EFFECT_SIZE="-0.0184" ESTIMABLE="YES" ESTIMATE="-0.0184" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-08-30 05:18:03 -0400" MODIFIED_BY="[Empty name]" ORDER="161" SE="0.242541" STUDY_ID="STD-Raynauld-2003" TOTAL_1="34" TOTAL_2="34" WEIGHT="100.0"/>
</IV_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2015-10-20 03:45:13 -0400" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="flowchart.jpg" FILE_TYPE="JPG" ID="FIG-01" MODIFIED="2015-10-19 09:30:06 -0400" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow chart. *records with the exact same bibliographic information of another already-screened record.</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2015-10-20 03:45:12 -0400" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAASoAAARDCAIAAABQm/tNAAA3/UlEQVR42u2dv24jR/a2CRgwNmCg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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2015-10-20 03:45:12 -0400" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-001.01" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Pain, outcome: 1.1 Pain - Main.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA8gAAAIQCAMAAABqlrfGAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="funnel_plot_pain.jpg" FILE_TYPE="JPG" ID="FIG-04" MODIFIED="2015-08-31 11:29:02 -0400" MODIFIED_BY="[Empty name]" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Contour-enhanced funnel plot for effects on knee pain. Numbers on x axis refer to standardised mean differences (SMDs), on y axis to standard errors of SMDs</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2015-10-20 03:45:13 -0400" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.02" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Pain, outcome: 1.2 Pain - Time points. P for trend = 0.001</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA8gAAAWACAMAAACyV58LAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2015-10-20 03:45:13 -0400" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-002.01" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Function, outcome: 2.1 Function - Main.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA8gAAAFgCAMAAABQXKCaAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="funnel_plot_function.jpg" FILE_TYPE="JPG" ID="FIG-07" MODIFIED="2015-08-31 11:30:16 -0400" MODIFIED_BY="[Empty name]" NO="7" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Contour-enhanced funnel plot for effects on knee function. Numbers on x axis refer to standardised mean differences (SMDs), on y axis to standard errors of SMDs</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2015-10-20 03:45:13 -0400" MODIFIED_BY="[Empty name]" NO="8" REF_ID="CMP-002.02" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Function, outcome: 2.2 Function - Time points. P for trend = 0.011</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA8gAAAPgCAMAAADZc6VrAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-09" MODIFIED="2015-10-20 03:45:13 -0400" MODIFIED_BY="[Empty name]" NO="9" REF_ID="CMP-003.01" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Quality of life, outcome: 3.1 Quality of life - Main.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA8EAAACQCAMAAAAfrJn9AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-10" MODIFIED="2015-10-20 03:45:13 -0400" MODIFIED_BY="[Empty name]" NO="10" REF_ID="CMP-007.01" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 7 Joint space narrowing, outcome: 7.1 Joint space narrowing - Main.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA8MAAACACAMAAAAYj0tbAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAAAexklEQVR42u1dC3Abx3n+SfDucABF8kDSFmXJJkXG6eThNBRFia84
hvyoonQ803EymbhRnHTGbidO0qQa59FmHCdN7DhNUzfxS9NEk0mTJq3jsd3IsWsLsU2CFiGZdl5u
LQOk/BIdk7wjKYIgcCDR3b03cCABgg9Q+j8JvL3bf//9/939d/+9ux+okACBQGxiVGITIBBowwgE
Am0YgUCgDW8EgkGASDAYVLXT/v38vuqIg6JB1KjcQPPyMIXsUg2iwGfULMp+v2vJlSOS2ccJfhUa
fFkMiY4RaAguUQHJ471HWBFJEHz0U1ZdpdbwPF/daLaZXTUV+pdVTdJU83J+ycv7y0cvj4hmWBJa
YBQeaAKYmadnY+2vnfnyrn90WNreHaMwOupemua5QCenvK0RmOHe2P/KZJYRv7J9NEeckvDTvp/c
OXvFW+m927NkaAH49vwj/ZC/ghYIjd81eXaOSL/QG/n8N8nnW+XUVbW7/xeeenkk/YqLarOJh5qW
Ue27u1/kiGqLPSc+f3tPOamG6/AqQIYIKCy1tccXkENzADUCX0unbb/IkQOdv+VDAi+SFToj8DVk
UfVxgk/laZ5MaA/JhMTns8qBLO53PjKo6/UG+kJxgEOCUENJjoheSdCY05Ia39IXK3gHiKF5TTKn
DIMy7Buk6tbwQg3R2cdzvgSpPeATjugkAS/MkSt8H1x3IfkETN38oqUno5eJvP5Gg9e6IAUN0BdK
sDZTfYJdNSEFKYGpxmRs9PO8t19vY0M1PylOVOuF67b2UtUO8UKGqlNNVDPSjJ7q5FMNXrgOb4p1
+NPjL1x69XP0zHtxP5ufazvue6hdmW+BH9x+O5nDKdV9FfLLka+na3rve2iXnLy86cThXeNJmndf
xw8fzHyBJH8zeadZbnRb/OTCNvvCUGmwrph8KCYT8iNix2hSY/4b1aPzLXkd5nc0vfnrI7BAGRMZ
FrdZi9Wpm57zzu8kmnRM8u23JP9drky+fyLdAm+8fOK+tN4Ur//nK6RolJRepBzu7bjvYabbD26/
09ST0d/bOzl1+Uha57UuXSVs3/Zm3ZymWuX7Jhdsqj27kPa8fhGM6vJmJitfP/GNBa2NLdVO66ox
DqQ/ue5biDovyN8i6UdfvUXvk/S9HZPirrfSur64Dm+KZfjFAXEgypzcHgiwS0moiUGCJN5Zb1DN
Q7QplIDd0B4j6WNw0cIDCZ3WGwXqiSfqrXLwCMROO2qxWMdqgI6M0XFY1PMSnMG3ZDw9CF23+rUd
/S0Qs88IgWhjj8Q0iUWJOImTh2pggQrSZApCZMw4l74aTbd31lt6MvrdEONIc+i81gXTAnRdVq1t
RgRn83JdajdnyZvYUfNJpoitjYlqFXZupD9jhJ40foCm38XSjJ700Hho3tJ3rVGB73iUeE8LQokD
kdnqzo99gq5ivQ8wS+P6QhAMJ0kmo6AflqYU5GwgFYj3QNin0ItcH7k8kGL5Vjm9lG0V6dFYCz0k
o1+1cWVkOl9HkZXNSC3Jbng2YTA2GQbh8WuO7Xv8GggJPUzgJ7855Hu3XVD6V77OIT3TTW8Hm572
5mAX12my3ZnogaG4i2o/uX5oz0+uh5Aur/TeiPeyZVRjkmv9YE9bqun64jq8GXAhdAY74QY2JOHt
2hYFZNk5bUMYZK3BWY489kJ7z5xO+0AopHe1VS5MU3ZUwaXGUJThSpeOzKlxZQhMnxnWF58sGbgw
P8ixFBP4ALz2Uk7pS4kK9q0aJU1Cjp5kc601R4Xj4hojMDU2DCk31ZrCarjJkncWXj2VU3oL6QL7
6kdJ1dy02dOe9VINbbh0LMALoaPAHjZ4w/8gB4I+YsvDreDVstu0LvVC21hQNHJ811XeDh9neeRK
Y1B/VGGV46C1xVGLb2BeThA6L7QOw2DWeAFHjaXg5mAi8N9ktA4QxkSGZrA9g6nq82iatFJNiFvf
mrPSjcPjjt21UzczTc9aVcJEMHitA0SiWhWpmLaZkKUa18vZZPTA24dzVJNgwn7OWsGXmzbbx6kv
2nBZb4dT8Ecy6NPUmCamvrQ1HnkKTp88ED85peU/MLCDHkZPzjYPzZCc2+PPTcN0ZMb/7N0s7/Sx
A9NDOq1VLvTsnHNVHT+Wbqo9NkX4xA+cnDYtO7zdKMn4loyDkQ9yV0Z+DfcPbKcyOMbHPwMb6KPt
8UuOPw3+tuaF7I3FVvFjffYLDt1saSpv3B8hzaHxWhfMvKuWn2mfYm02Kcx5nF5OlU1GX3j6sRzV
+p53zDWkH5qHnrKlzcbX28epL+6HEQgErsMIBNowAoFAG0YgEGjDCAQCbRiBQBtGIBDlZcNytcDv
80eyY1qXiKqMZPbxNNZ0ecplsVqxnbyfxneuUWMZ+gYZVpe3k6etD/JX5CzS78tXJBgBmQ/yMkSC
3hwKPdXvz1uJyGKjB4w3MUiVAu9rcCXNq53sF/gaFVRNYomvA6hOGHJzQnUEVrs9l2hob7CRNnHw
Jmv88OJAcQqpGX5fhrSrplAdUyhg9B2L8143hexxS9tmp86+eMXX0lkxrUtEwmixpn/23PKUy0KL
7bw4WmpsZ+Tzt/ecWKvYTkNfUuPo6Ojq8h4dpVyNM1sf5G9VZxFbJHFWkZZvz3/1Srj449wDTTc/
ZhTNos2OQ7a17lvbppMAD2x7K2k094K0ayTtRpq3Te7e87uG9qlk6tLIS6TqTPwTz9G4Szbi/81z
5itXfD1dcsBVoWiB8abXiSpV256cNxWaDX6jOIUq903d9cYdycNNQ6doW57+TlrlzurWrcV5r5tC
9nX4FkjTyFEj3pV+VD9d4EQyb6naFG7ErlYz09diTQ8b1MQS94sqRHzeumAwOx4W2KUjNLDSDVps
568Kje1s2JDYTkPftQSNpwUWvavH5xZQhLYxK6LHveasgtAEA+Qjw216vC7rW6GOdVqD6A2wds+D
J1iUVIocTUzAQlY/GH1m9Lfk4+vqBKHfbDkxSlhcqL3oleF+BPWCljPfMxUQQwlYR4yzaKIkOZoQ
YTErHtqInWb9QS+KQm2dsD9gDEqYaCcKLQKbihaaFqFKXw3NOO+N8KUroV3sp81thb5U7fHJ9CVS
FX4MtM1rh31HO2ppM7zBFnF4r+gYMZnjXffA7r2/1Oa0ydegtuOof1edRfBZ/94qVzmqYBcZEHS0
hKBqr8/+El9/GhZoLS0dT1QPt8CskHqlm055f1vdbXb9S3A9G2dAXzIPQctw9RP7mjU5SdrH0oy+
pcNfs7cGmjuOUl7FOi3Z+q4+6jr8YkctU+LyydTc3gJeo9PamBWZnSBtkxsPIZKW+Tb5fBo8RH9/
R7PWt/7btCE9051IQv54p86h7n5o6D7eaesS0l/OftD7zOzvxVhv++LpnquMgUFf686QIT93o38S
biCT6EdGtJyPwtn13j9yx3v6IdFznLMr5LHaeyHW8zfw467jC2Z/kER6pmfX4mxyTi9QQRU6SFa9
OE9MpFKtVMWYlpOGUxu3H56xRY6as030BMCbpPtvZhPOvBG7mmDz0dPZJU7H4BHwQo32pRaOeFid
IAqCqxzTAnTni+3s1mI79XjMRKVrbOeP7NzMeE4ttjNmxXbO09jOhBXXWhQsfVd/P6wjAbER6NCS
RnzuMrC1sRn36kC4W00PdA2k1RcHxq14XdK3XSxb4ZaphYNe0la8bZt465A/qx/0PjNlGSW7n0kr
rpiHh+lSlwnXdO25DXb5xZaf7+TZ3B6FwLrfBLqbKPQV+K5doeNPZ8VD6/HbZn88ybHPgrnmtIl0
zIUH/Ht3gOj3Ngo7+ftpTs+6K2SzYe7M8CDsudye2wsBMvuK4fRYenCcTafkfIHZDJuhzzznLBEI
kBltETo53bAIbadDo0AgT3wc95Pnw9BZZ9RqL/Qi1JEP5fXF64gE0mWLJ6BXY99reYsOZOC66ww5
7eleo4UZr6Jh6RsiWKMeYW1I8eSt91ZD3/IFbG1stk2WDVb18p18L43ZYa1xTK+p0+im3iUrGBkQ
ZXVgxDwPHR1YeCmrH/Q+M2UJsHpNxkrkpsaBSognx6+F++Cm1EhqYv4VNoeGQV53G7524Cb5e+FP
Wgrd1g9tVnszhTLGINT7o1P7GP3x2lA8EAaiUGeMrLxTqZH50Q/HP7MxCtmfLQWmzjyvTzRh5lPT
ADQqENf7tl42Dd+QFbuqx5oOGEbEQlg9IKuW98ku9RsEkbz6BZSCYjtTEF+12M7ivybFFlu7ZiC6
a53iGp/rgiutyGHXuFfSNAL5eIiD5LHF61ZkByjn15rvbu7hbNOqKHY3Z/WD3meePFHM3GxqtsJj
dAhA2xzX3bSoTTBb1t2GA1z04p4qmyvdV723Oau9zUFo9oeTRTyZyNjGXCsfiHIZrbUv3Tgb9gYD
gUeokwC0G8YamGvURvdOj5IZiKn3c0fsKimhxZreAA3N2o28VtInCRg2ldOjWj3QqBFc2ZbHly48
trMStpQQ28niVb0rjO009F1DEGl3Eum0mOPc+Fw3hLU2pi3nFveq+cLjpIF6SMqK1xWg7ceOIbuU
M93B7pmZ24fpwfkxZz/ofZYbxawVEoWxQM8kiHzj79kASKQh3MjG3svhOvmZ4Dp/ia1ABrRgV0h5
NqE621uP39b7I0ch342qRNY1opfI9E2+BGH1Bpajx3lviA2fHYrzX408xWJalfAnqd2kj8/eRRUZ
gMEm9kjCEbsKz7BY0ynoCs9qanrmBkOkPb4jgf64TY+HVQbPPqpVNzs06SqHM7YznvVlEM7YTn9h
sZ3TtvRT5oacxnY+s8LYTkPfNdwPj7bHd52cYX3gEp/rCtrGz02Bf+Ait7hXetMqDAIH3CCET9ni
dSePx71gPhU145DdEBuAgZjmnRlTTe/bnP2gx+Pa46Z1sCr8Fc1zpIuquemrTpJtZn8lB+I0m82b
nly88LZjr6+vDUcrIBw1ZNMWm746Z3vr8dt6f+Qo9Phr/sSwAjOe5tqTowAN0ASibxdrbT3Oe/1Q
SPywDNu6fztRMEveNxL94pDbzfXSv+wJsXprkXd0yzXPFvNQp/HsCr7hrSGeKNsmWJFsK2qFDbdh
IVPpK2Kf3n/1AnC+cTfrhhTaTrkgMJ8Gz9OdRZTwixPFV+OfKN9vP16RbD7/+Ca0YQQCUb6owCZA
IAo1jkxZionrMALhjtwbU3XlKCbGHiIQmxtowwgE2jACgUAbRiAQK4P9xUEt2qiQm1yK5DhohVwP
GwdLACOliWteV6Rl6DUKSx8HF2m9xC+8prxFHIrn6KnQv0Xo48LAqBekLApnG8ISuQrg3dVVsGFY
2ehUtCHgethAE5bs5sY+zuvKcvQahXkm2Sc6Zd3EV0ovorh0k+OCIhVjwi4MjK6Wsiiy23CJXElB
Y1wNG3ZOlVrbkn+2ydbWAebE6dr95TepKoWOEsntzDnIlTUfcdLqFVlrYaUy4bFS5H/x/cEiaENl
ZsPZ86bbukqvbarZSip2ZDspDL9RUtZ1yK3AALOLSIUU2RDxjdyN9aNDa0S7MTas6F2uO0aaiyXl
HQhW/7iNgTLd4EiFbNSzV10AWPe9wQrab0VNTv0spcTeWr5lljbljd12nWv7YfP2RzGdkGfd26iO
WdJKbZu4YsaltMYLVp72K64+aUXmIBVsRstPf1kUxjZZAbf1WJHKdd+1uffDkvMOkHPor7srtoab
K2UJsc2JTJGytVPWWdsV1Fd8kUIddmnZ/pfcZZFWTTlEgfthfdnNulupZC/IylKedJn3jbSsCUsO
E7ZuvK6PZiuob71FLKCvJVjqAYWEJrw2NkwN18X30S9ZOVZK0TwofaPpPGz4vleRskTJJ5hFrzif
YDq0K69te1FFnB1jbxe9x1fasEq2B21RuF3Il4tYKZaMW8JZErE6C3IB2WU42M6BuCU0YUTRW/EN
KIrrMLYBArGZ1+Eq7CkEwh2WxQbL+cscMW4JgdjcQBtGINCGEQgE2jACgUAbRiDQhhEIBNowAoFA
G0YgEGjDCATaMAKBQBtGIBBowwgEAm0YgUAbRiAQaMMIxCaDeiTj93DJGilStiLidwAgEHnMN93w
vifGoX5SO33POFf1WCfaMAKxOcz38BdTEy4ZF3p47lSgbH3pIINx1uCzZbBDwAtqNS9kZIholLVC
HUAmodOLPH9IpbRenBZKRqNP4H0NdDDtCxZaxM8LvkaSkPncIn5ySa4W+IwKaoYXqmU2UA/xfHUE
6rj7CUF/QZXoPAgi1ftof/f7ed4f0YePNvxN/iQt0Hr9Al+jGsah1amlmW6Sl9/fD7aRt9HmG/Dv
r5qdP3jGzYThj2dOv1wh+Or6y2iweEQzOTraAqFR42zvdjPZAjQpn/m/pLT7yAPdN1X8Yuu1946O
QkXNXFr1V2gjaIZ74ytbJlVC60u+9S20whLdo4Ut8vtjaTJxNsFogbOxWiO/P7oAcO/e7CKNlXvI
pW2zE0L3VFLqneQ6DqWo9VTID418qeLg4LGFsX85XFAld/QxHiR1uO/LD8FU8mfp+NjQN1Q2SrTv
q7H4E+m1en/X0D6d1BjodWq5VLfAeyemXv8PdbSlUD3Xcub03vFUZkqZ+Z2oL0z17sdZ/sw989J3
hqrnym0dNnBIEGqAp7/xpooCLxqOw86oB+ahLwYfgAX4Kr2yOL4A9V4tN9HrDYihOE0e7W5FIywR
8eTEhUBGeiRZcJHZ1MRx+vVoYz05We9O07+PwUgUUuRfLAZ99EIKou0gwo+4DPyJUFglH9B4EIjQ
HiOpRIoTQLWTWPxBZdLfAmIUkmYuq5Ot5Oxasl/hUvGNN9/AXd6qU7HPjU1APcBkPTXYpY9jnxt5
udJbLTWWoQ3XDvuOdtSm6G+81cjJeJcx16gQJaOKOEnH4GvwIcEnQ+VYpZwaMXJPGQzeAUk0wpJx
458OvgGw21dEEe+tz74KsPV4TsbQGfp3BwQCkCH/yOEYvcBSB0nf3SAnRwqr4pjGg+CgmRqGG+wk
Fn+4x6ddkEGjtNVJnW+We32lj46lDTZfz6nYwbFxYpxQ1Gdy7LWRUx7vXZJaXjachFiNboWJHTU3
w6JpwwHgoO1hkvz78N2+vTvA2yzu5P+LZ9/+1wPmRr+CrNOIUnHHcPcOsi0uZnSfeb7rEoj4cr+p
Oc76JqrZkLVMs9SPQPTv2im0CAV97WqvxsPiBtD/Aeiyk1j8Gx5j0vPwsGiOIr1OajoLLDfaM+nf
e/FGtvSZzGuZilIYZGKZbeVlw2Sm7NStsO6yrz+odRszTYBXr41/KkzctiQXgzTZDY0kTn8m/mGa
GwZztAXMSRexcgRGSAvPFbVABWJk7r3Cny97QOvFsHkhrHX3VOpD8xPJmvlCqhgwRoKZ6r+y9/lP
2Eks/vNfZgclclPDQKWzTrpAGLolorChyxin/FMyXb3zkq2NoLvKBX8avrCjpXoh+a9T42W2HwZZ
hitZYg4+9pLNtmUIfDY5l+GMc+JGCYEejs2qHFxqFocKNMHVwZ4DwaV+ez4XHthzWb4i+0BWSddU
0P7dp/U9SdEB0FbFdY8v6zzRW8f7aJEKrSaZGqF6FfxWcZBY/DtvZaJws6l4hcccb3JEG3Sdmm6W
UcPGGvIMMeSauq2NdK/LXOWlj/We7c1vWzg8O8WV4X7YC63DMEjmWZnscy61bk/x5OPj1Wd6BRCF
BpHdmPhzAdq0OVRsm5cTQbYGbMEvni8ZXmGsjfREKBQq+LfnRb7x9yAsUSQMwxeQXiRdNgyP0oeA
PLS2wnfpSijC4Niyb+xRzoRHKylHCnPQ2gbzUH9wdsJJYvHXRRGFsUDPpP6EkhS7Br5lyxVg5x/K
5QYKN1VBDLm27ivsPpX+akfusb7xoua3Tajx6YnyEDu350ZPxg+cnIb7B7ZDV/g9ljNH9sLwuMd3
+/MyPO2ZqW0fJa5E5Tjs8rO7jOMPLmytPcl+3CIN30cjLBFnPc2zpBOKQTU3fdWSRU5HDsSPTcLE
sdkDEbZ0TrTH45FdxB32jNN7G4VUovMgeDISn21PQzJ6TdajXYu/Dn9F89zzou59T9I67fvnmZO7
9rWny6jpOaXi++nq1m9sc73h3PDRS1qT6bnpiTJ6z6Pw97TkJm9hg6omdSaAVnjeIbiMw9B4dr6U
4hsA9cJJMc12uux1yw8+l6j/I1eGLV/Eu5b9VycKovN5ZRzR5x+4ykxqyWHhX+rGDw8ZtSzVUi/4
q++lMxUiVzVeri2P70sjEMs7GfibaQgEAm0YgUCgDSMQaMMIBAJtGIFYGkqZ8YFflJtmdkZowwjE
ubMOK1kGXvScoWSXKYKjkpurrPLUhUCgL70MpNJcB3xUjUAUj6p8i6JE/iiSliIJM0kO9MTK0C8a
Z4pJz8xSP9o4QlZZgwWAxtZiZ5zZLiBwQ7zR288yYbSMDTNjkpjdSsaZ7aCYJOYV/YzarOK2ploc
c8oaB4Mut1arBOI8wSr19aqNmTJklMeGlcLaVFKWamzJXIQdC7ELM8mVhZRDgEAgClyHDUe3kLtQ
SoEegpsRL+tPKOvggSAQ5/J+WFreqZFW7vvo2+liCHBFRiDyoHL5pTDvophnKc5aeSUlH3f3Z0dK
DgEuxbgd3lg+5c2oyt3/1W9BS5J1Q1hP0rvIikXiLGBt2pWsTJMjmCxAvyFt3pc201kE2bUhzg+s
Rqevzj0kpazusmVLs6L44WUEKVDOXGtHILJ2VFKpw10qE0lWT54caapWMAnAqpgwArHWbqcildcO
bFXkyWmXqtVvWak4TmjxiHLfV5e3PBjzgChvdxqxXLvgV0EjynCMlr5knUd3QdGGEWXrA5eyDJ/L
BpzVLuhLI9CT3tztUuXwPlwmMOMJUFETmz2MwSiexcEKc3CtFbIilmyukX5zT8rvPZmpHDkQm8mh
Lhd/uLxeT8hplyqH95F3wJdoCUvZkuTC3noE5oxvMq4UVEZ/DoZGvLkd6jJgsooGLK0BCzdfWlEU
86DoMRCKcVkxXoZUFDM+wpajl3XyIjn2TIOvgk4TAlEyqtzXXHPpk4ywYHtQLzhfFsmNB87iJTnC
gtl/einXfy5gosr20Zcoo0i4ECPOSxteZuWXHBsFR6xwwa6C5GaWUuE7EvNlsby+P/Ys4nxBfl9a
ynaLl1gbLUpXXzpfZuGeNFm4Hd88QLCUwSsSeuiILMgryFlPKVZ1HbZegizQDCSn75x3xV3mPesV
bPrdy1i3p9GOzx2wXzku4bfLLsr702fXu1YXsh9WR4Sculblt9iq8u46Cxr+kpLzOF5Zcp21dtM5
2SsxN2mJLTN+B9c5hhLHe1coH4dkwbWVbnLJdfGlqRMtmQfTJo3z3DNbWlKyvwDAdsFirPHV4/wV
JcfH1imVHGHyfKWAa5kiXHXE5kG/j/fWgVeFiAhqNe9XteWRfIJ1AiR4bn8/o2vcLyQAVD/HKGq9
QaD/QPUKAYCIjxcjAAGBFxPsOqGr1uiMPEIri4Lr4GnwCoTJfhXU/ZTGJ1sikPL9PO9tYHSq12vV
FZS8fIDVReXU5VoDG5aM3aZ1kMx7R/q5tSU1S9hyJEm/tSXZySQ7BzD4GmVddrcWR4cwS67YOWUw
JupcxNWPp4jdCU/D1TxUcamHbZ7kI2NQ96j64FXsJPF3NZ8FqH9Y5evJmeeMvgrfI56eA9jtTXl3
A8R9KVkCmlP/qkFn5BH8XBxbcBNh9onk1HUQvgAuGIQfe5Pei60sUn5fdeqJWdDq2rLHrAsWz1TH
WV1UTkOutbqnVd4oMgQTl+FzZ0McpKtdog+UHnjzEUj/ErwxqBEsgncFoOqxRGKenaTaxw8DzLdD
jJ5HA4adx5rIuTcKMS/ZSaoG9UfqQU5qdHoeweeigUk3Eeb7QIzC0RSoHOEH0T0WASnPJY+8U2N6
S2z8V2ZdMBqQe0w5DblWAxU4xBGbxIS1zWjkqoV0d0huSnrn2SUhyQ7kQw/y9oVM7bhFnkNhXeaI
O375Isxy7DK5GDbpaB458Knse1raidqoLnZREagjTi4ROpsIap1acbrJKYLGzyaCTa7zcB1GnN94
XwV/luxkudqbAQZkkDPsqvHIJjA3dv8MSw2wS2GTQkfYvEyGfmdizFetXQ6FQkmTQtbMolJ2fxRU
u/jYDBWh7g6NusIhAhd/82hLbl1O5MiFNow4b5DhonQL/NCuHwIk22CYWF5/Qm7Wc8VA4CNXsBTf
qt5I3N7fQ6vmGOtGXdU6tp/YmQitxJUVEwFqf/0yCJMg+XQb/APLo257KzS7ifCXk++ke1mu/TaA
O0Vou5PYZMAU4eb+QM8i6HV57fwo2jRTt8mFNow4z+Dv2Er2uVAzEAVIJ/lr0wCh2g8Z4/h/9vC1
Ee1GSOJTHyMU+/mUvqf96630768TzUOkRL2QVAivv+DiU8Sp3QqTl/AJ3YaVa1gewYmU4GofXVua
6PW3wkSErnp+votwim/16Lk/u0qonQa9Lp+dH8VPmRR2uXA/jECc58B1GIFAG0YgEGjDCAQCbRiB
QBtGIBBowwgEAm0YgUCgDSMQaMMIBAJtGIFArC3+Hw6zocOc0y0WAAAAAElFTkSuQmCC
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-11" MODIFIED="2015-10-20 03:45:13 -0400" MODIFIED_BY="[Empty name]" NO="11" REF_ID="CMP-004.01" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 4 Number of participants experiencing any adverse event, outcome: 4.1 Number of participants experiencing any adverse event - Main.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAyQAAACgCAMAAADKHVhlAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-12" MODIFIED="2015-10-20 03:45:13 -0400" MODIFIED_BY="[Empty name]" NO="12" REF_ID="CMP-005.01" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 5 Number of participants who withdraw because of adverse events, outcome: 5.1 Number of participants who withdraw because of adverse events -Main.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAyQAAACgCAMAAADKHVhlAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-13" MODIFIED="2015-10-20 03:45:13 -0400" MODIFIED_BY="[Empty name]" NO="13" REF_ID="CMP-006.01" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 6 Number of participants experiencing any serious adverse event, outcome: 6.1 Number of participants experiencing any serious adverse event - Main.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAyQAAADQCAMAAADBP1WkAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2015-10-19 08:06:53 -0400" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2015-10-05 22:43:12 -0400" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2015-09-01 03:49:56 -0400" MODIFIED_BY="[Empty name]">MEDLINE and PubMed search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2015-10-05 22:43:12 -0400" MODIFIED_BY="[Empty name]">
<TABLE COLS="6" ROWS="22">
<TR>
<TD VALIGN="TOP">
<P>
<B>MEDLINE*</B>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>
<B>PubMed&#8224;</B>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Search line</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Search Terms</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>No. citations</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Search line</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Search Terms</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>No. citations</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>*Adrenal Cortex Hormones/ or *17-Hydroxycorticosteroids/ or *11-Hydroxycorticosteroids/ or *Hydroxycorticosteroids/ or *Ketosteroids/ or *17-Ketosteroids/ or *Androstenedione/ or *Prednisolone/ or *Glucocorticoids/ or *Triamcinolone Acetonide/ or *Hydrocortisone/ or *cortisone/</P>
</TD>
<TD VALIGN="TOP">
<P>104853</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD ROWSPAN="20" VALIGN="TOP">
<P>((((((osteoarthritis*[tw] OR osteoarthro*[tw] OR gonarthriti*[tw] OR gonarthro*[tw] OR coxarthriti*[tw] OR coxarthro*[tw] OR arthros*[tw] OR arthrot*[tw] OR ((knee*[tw] OR hip[tw] OR hips[tw] OR joint*[tw]) near/3 (pain*[tw] OR ache[tw] OR aches[tw] OR aching[tw] OR achy[tw] OR discomfort*[tw])) OR ((knee*[tw] OR hip[tw] OR hips[tw] OR joint*[tw]) near/3 stiff*[tw])))) AND ((adrenal cortex hormone*[tw] OR adrenal cortical hormone*[tw] OR adrenal steroid*[tw] OR adrenocortical hormone*[tw] OR adrenocortical steroid*[tw] OR adrenocorticalsteroid*[tw] OR adrenocorticosteroid*[tw] OR cortical steroid*[tw] OR cortico-steroid*[tw] OR corticoid*[tw] OR corticosteroid*[tw] OR dermocortico-steroid*[tw] OR dermocorticosteroid*[tw] OR glucocortic*[tw] OR hydroxycorticosteroid*[tw] OR ketosteroid*[tw] OR androstenedion*[tw] OR steroid[tw] OR triamcinolone hexacetonide[tw] OR hydrocortison*[tw] OR prednisolone[tw] OR Prednison*[tw] OR cortison*[tw] OR Pregnadiene*[tw]))) AND ((intraartic*[tw] OR intra-artic*[tw] OR inject*[tw] OR infiltration*[tw] OR infiltrating[tw]))) AND (((clinical[Title/Abstract] AND trial[Title/Abstract]) OR &#8220;clinical trial&#8221;[tw] OR &#8220;clinical trials&#8221;[tw] OR random*[tw] OR "therapeutic use"[tw] OR placebo[tw] OR sham[tw]))) AND publisher[sb]</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>(adrenal cortex hormone* or adrenal cortical hormone* or adrenal steroid* or adrenocortical hormone* or adrenocortical steroid* or adrenocorticalsteroid* or adrenocorticosteroid* or cortical steroid* or cortico-steroid* or corticoid* or corticosteroid* or dermocortico-steroid* or dermocorticosteroid* or glucocortic* or hydroxycorticosteroid* or ketosteroid* or androstenedion* or steroid or triamcinolone hexacetonide or hydrocortison* or prednisolone or Prednison* or cortison* or Pregnadiene*).mp.</P>
</TD>
<TD VALIGN="TOP">
<P>429888</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>or/1-2</P>
</TD>
<TD VALIGN="TOP">
<P>430785</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>(intraartic* or intra-artic* or inject* or infiltration* or infiltrating).mp.</P>
</TD>
<TD VALIGN="TOP">
<P>831275</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>exp osteoarthritis/</P>
</TD>
<TD VALIGN="TOP">
<P>44274</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>(osteoarthriti$ or osteoarthro$ or gonarthriti$ or gonarthro$ or coxarthriti$ or coxarthro$).ti,ab,sh.</P>
</TD>
<TD VALIGN="TOP">
<P>62668</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>(arthros$ or arthrot$).ti,ab.</P>
</TD>
<TD VALIGN="TOP">
<P>26671</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>((knee$ or hip$ or joint$) adj3 (pain$ or ach$ or discomfort$)).ti,ab.</P>
</TD>
<TD VALIGN="TOP">
<P>20156</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>((knee$ or hip$ or joint$) adj3 stiff$).ti,ab.</P>
</TD>
<TD VALIGN="TOP">
<P>2914</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>or/5-9</P>
</TD>
<TD VALIGN="TOP">
<P>101715</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>(randomized controlled trial or controlled clinical trial).pt.</P>
</TD>
<TD VALIGN="TOP">
<P>465958</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>(randomized or placebo or randomly or groups or trial).ab.</P>
</TD>
<TD VALIGN="TOP">
<P>1916245</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>13</P>
</TD>
<TD VALIGN="TOP">
<P>drug therapy.fs.</P>
</TD>
<TD VALIGN="TOP">
<P>1728855</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>14</P>
</TD>
<TD VALIGN="TOP">
<P>or/11-13</P>
</TD>
<TD VALIGN="TOP">
<P>3430383</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>random*.ti,ab.</P>
</TD>
<TD VALIGN="TOP">
<P>739136</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>or/14-15</P>
</TD>
<TD VALIGN="TOP">
<P>3575985</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P>and/3-4,10,16</P>
</TD>
<TD VALIGN="TOP">
<P>766</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>18</P>
</TD>
<TD VALIGN="TOP">
<P>exp animals/ not humans.sh.</P>
</TD>
<TD VALIGN="TOP">
<P>3974624</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>19</P>
</TD>
<TD VALIGN="TOP">
<P>17 not 18</P>
</TD>
<TD VALIGN="TOP">
<P>719</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>remove duplicates from 19</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>713</B>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>
<B>6</B>
</P>
</TD>
</TR>
</TABLE>
<P>* Search performed at 02<SUP>nd</SUP> of February 2015, using the following database in OvidSP: Ovid MEDLINE(R) In-Process &amp; Other Non-Indexed Citations and Ovid MEDLINE(R) 1946 to Present<BR/>&#8224; Top-up search in PubMed (http://www.ncbi.nlm.nih.gov/pubmed) at 03<SUP>rd</SUP> Februari 2015, to retrieve citations not yet indexed in OvidSP MEDLINE databases</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2015-10-19 08:06:53 -0400" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2015-09-01 03:53:20 -0400" MODIFIED_BY="[Empty name]">EMBASE and CENTRAL search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2015-10-19 08:06:53 -0400" MODIFIED_BY="[Empty name]">
<TABLE COLS="7" ROWS="24">
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>EMBASE*</B>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>CENTRAL&#8224;</B>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Search line</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Search Terms</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>No. citations</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Search line</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Search Terms</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>No. citations</B>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>*Adrenal Cortex Hormones/ or *17-Hydroxycorticosteroids/ or *11-Hydroxycorticosteroids/ or *Hydroxycorticosteroids/ or *Ketosteroids/ or *17-Ketosteroids/ or *Androstenedione/ or *Prednisolone/ or *Glucocorticoids/ or *Triamcinolone Acetonide/ or *Hydrocortisone/ or *cortisone/</P>
</TD>
<TD VALIGN="TOP">
<P>191907</P>
</TD>
<TD VALIGN="TOP">
<P>#1</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Adrenal Cortex Hormones] explode all trees</P>
</TD>
<TD VALIGN="TOP">
<P>11438</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>#2</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Prednisolone] explode all trees</P>
</TD>
<TD VALIGN="TOP">
<P>3470</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>#3</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Hydrocortisone] explode all trees</P>
</TD>
<TD VALIGN="TOP">
<P>4565</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>2</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>(adrenal cortex hormone* or adrenal cortical hormone* or adrenal steroid* or adrenocortical hormone* or adrenocortical steroid* or adrenocorticalsteroid* or adrenocorticosteroid* or cortical steroid* or cortico-steroid* or corticoid* or corticosteroid* or dermocortico-steroid* or dermocorticosteroid* or glucocortic* or hydroxycorticosteroid* or ketosteroid* or androstenedion* or steroid or triamcinolone hexacetonide or hydrocortison* or prednisolone or Prednison* or cortison* or Pregnadiene*).mp.</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>871195</P>
</TD>
<TD VALIGN="TOP">
<P>#4</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Triamcinolone Acetonide] explode all trees</P>
</TD>
<TD VALIGN="TOP">
<P>603</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#5</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Ketosteroids] explode all trees</P>
</TD>
<TD VALIGN="TOP">
<P>962</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>#6</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>"adrenal cortex hormone*" or "adrenal cortical hormone*" or "adrenal steroid*" or "adrenocortical hormone*" or "adrenocortical steroid*" or "adrenocorticalsteroid*" or "adrenocorticosteroid*" or "cortical steroid*" or "cortico-steroid*" or corticoid* or corticosteroid* or "dermocortico-steroid*" or dermocorticosteroid* or glucocortic* or hydroxycorticosteroid* or ketosteroid* or androstenedion* or steroid or "triamcinolone hexacetonide" or hydrocortison* or prednisolone or Prednison* or cortison* or Pregnadiene*</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>33629</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>or/1,2</P>
</TD>
<TD VALIGN="TOP">
<P>874556</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>(intraartic* or intra-artic* or inject* or infiltration* or infiltrating).mp.</P>
</TD>
<TD VALIGN="TOP">
<P>1069778</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>exp osteoarthritis/</P>
</TD>
<TD VALIGN="TOP">
<P>92440</P>
</TD>
<TD VALIGN="TOP">
<P>#7</P>
</TD>
<TD VALIGN="TOP">
<P>#1 or #2 or #3 or #4 or #5 or #6</P>
</TD>
<TD VALIGN="TOP">
<P>35680</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>(osteoarthriti$ or osteoarthro$ or gonarthriti$ or gonarthro$ or coxarthriti$ or coxarthro$).ti,ab,sh.</P>
</TD>
<TD VALIGN="TOP">
<P>96428</P>
</TD>
<TD VALIGN="TOP">
<P>#8</P>
</TD>
<TD VALIGN="TOP">
<P>intraartic* or intra-artic* or inject* or infiltration* or infiltrating</P>
</TD>
<TD VALIGN="TOP">
<P>52930</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>(arthros$ or arthrot$).ti,ab.</P>
</TD>
<TD VALIGN="TOP">
<P>36551</P>
</TD>
<TD VALIGN="TOP">
<P>#9</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Osteoarthritis] explode all trees</P>
</TD>
<TD VALIGN="TOP">
<P>3605</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>((knee$ or hip$ or joint$) adj3 (pain$ or ach$ or discomfort$)).ti,ab.</P>
</TD>
<TD VALIGN="TOP">
<P>29955</P>
</TD>
<TD VALIGN="TOP">
<P>#10</P>
</TD>
<TD VALIGN="TOP">
<P>(osteoarthritis* or osteoarthro* or gonarthriti* or gonarthro* or coxarthriti* or coxarthro* or arthros* or arthrot* or ((knee* or hip* or joint*) near/3 (pain* or ach* or discomfort*)) or ((knee* or hip* or joint*) near/3 stiff*))</P>
</TD>
<TD VALIGN="TOP">
<P>12050</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>((knee$ or hip$ or joint$) adj3 stiff$).ti,ab.</P>
</TD>
<TD VALIGN="TOP">
<P>4364</P>
</TD>
<TD VALIGN="TOP">
<P>#11</P>
</TD>
<TD VALIGN="TOP">
<P>#9 or #10</P>
</TD>
<TD VALIGN="TOP">
<P>12050</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>or/5-9</P>
</TD>
<TD VALIGN="TOP">
<P>160749</P>
</TD>
<TD VALIGN="TOP">
<P>#12</P>
</TD>
<TD VALIGN="TOP">
<P>#7 and #8 and #11</P>
</TD>
<TD VALIGN="TOP">
<P>481</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>exp clinical trial/ or exp evaluation studies/</P>
</TD>
<TD VALIGN="TOP">
<P>1017697</P>
</TD>
<TD VALIGN="TOP">
<P>#13</P>
</TD>
<TD VALIGN="TOP">
<P>#7 and #8 and #11 [in trials]</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>264</B>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>(clin$ adj25 trial$).ti,ab. or ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab. or (placebo$ or random$ or control$ or prospectiv$ or volunteer$).ti,ab.</P>
</TD>
<TD VALIGN="TOP">
<P>4813156</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>13</P>
</TD>
<TD VALIGN="TOP">
<P>(randomized controlled trial or randomization or double blind procedure or single blind procedure or methodology or follow up or prospective study or comparative study or placebo).sh.</P>
</TD>
<TD VALIGN="TOP">
<P>3749360</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>14</P>
</TD>
<TD VALIGN="TOP">
<P>or/11-13</P>
</TD>
<TD VALIGN="TOP">
<P>7670295</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>and/3-4,10,14</P>
</TD>
<TD VALIGN="TOP">
<P>1364</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>animals/ not humans/</P>
</TD>
<TD VALIGN="TOP">
<P>1206540</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P>15 not 16</P>
</TD>
<TD VALIGN="TOP">
<P>1356</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>18</P>
</TD>
<TD VALIGN="TOP">
<P>remove duplicates from 17</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>1341</B>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<P>* Search performed at 03<SUP>rd</SUP> of February 2015, using the following database in OvidSP: Embase Weekly Alerts 2014/07/28-Present, Embase Classic+Embase 1947 to Present<BR/>&#8224; Search performed at 03<SUP>rd</SUP> of February 2015, using the Cochrane Library of the publisher Wiley at http://onlinelibrary.wiley.com/cochranelibrary/search.</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="AFF_55AAB96B82E26AA2000F11BC5E70C1F3_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="55AAB96B82E26AA2000F11BC5E70C1F3">
<ADDRESS>
<DEPARTMENT>Institute of Social and Preventive Medicine (ISPM)</DEPARTMENT>
<ORGANISATION>University of Bern</ORGANISATION>
<ADDRESS_1>Finkenhubelweg 11</ADDRESS_1>
<ADDRESS_2/>
<CITY>Bern</CITY>
<ZIP>3012</ZIP>
<REGION>Bern</REGION>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1>+39 0871 355 67 20</PHONE_1>
<PHONE_2>+39 389 999 36 50</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>